Tisagenlecleucel in Adult Relapsed or Refractory Diffus

New England Journal of Medicine
380, 45-56
DOI: 10.1056/nejmoa1804980

Citation Report

#	Article	IF	Citations
1	Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report. International Journal of Molecular Sciences, 2018, 19, 4118.	1.8	7
2	CAR-T â€“ and a side order of IgG, to go? â€“ Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Reviews, 2019, 38, 100596.	2.8	109
3	SOHO State of the Art Updates and Next Questions: T-Cellâ€“Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptorâ€“Modified T Cells and Bispecific T-Cellâ€“Engaging Agents. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 537-544.	0.2	18
5	Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. British Journal of Haematology, 2019, 187, e35-e38.	1.2	35
8	Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Advances, 2019, 3, 1661-1669.	2.5	21
9	Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products. Expert Opinion on Biological Therapy, 2019, 19, 1157-1164.	1.4	14
10	Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory nonâ€“germinal center B-cellâ€“like DLBCL. Blood, 2019, 134, 1024-1036.	0.6	100
13	Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date . OncoTargets and Therapy, 2019, Volume 12, 4543-4554.	1.0	6
14	Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1012-1021.	0.4	105
15	Targeting Biology in Non-Hodgkin Lymphoma. Hematology/Oncology Clinics of North America, 2019, 33, 727-738.	0.9	1
16	Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. Frontiers in Immunology, 2019, 10, 1613.	2.2	70
17	Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e344-e351.	2.0	59
18	Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. Immunotherapy, 2019, 11, 851-857.	1.0	48
19	Hitting back at lymphoma: How do modern diagnostics identify highâ€risk diffuse large Bâ€cell lymphoma subsets and alter treatment?. Cancer, 2019, 125, 3111-3120.	2.0	17
20	Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells. Antibodies, 2019, 8, 41.	1.2	90
21	Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes. Journal of Thoracic Oncology, 2019, 14, 1970-1981.	0.5	52
22	Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood, 2019, 134, 860-866.	0.6	178
23	Novel and emerging therapies for B cell lymphoma. Journal of Hematology and Oncology, 2019, 12, 82.	6.9	37

#	Article	IF	Citations
24	Cellular therapy: Immuneâ€related complications. Immunological Reviews, 2019, 290, 114-126.	2.8	55
25	T cell receptorâ€based cancer immunotherapy: Emerging efficacy and pathways of resistance. Immunological Reviews, 2019, 290, 127-147.	2.8	180
26	CAR T cells for brain tumors: Lessons learned and road ahead. Immunological Reviews, 2019, 290, 60-84.	2.8	151
27	Updates on CAR Tâ€cell therapy in Bâ€cell malignancies. Immunological Reviews, 2019, 290, 39-59.	2.8	61
28	Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma. Current Hematologic Malignancy Reports, 2019, 14, 207-218.	1.2	17
29	CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood, 2019, 134, 626-635.	0.6	59
30	Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma. Hematology/Oncology Clinics of North America, 2019, 33, 687-705.	0.9	6
31	High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood, 2019, 134, 636-640.	0.6	127
32	Cost burden of diffuse large B-cell lymphoma. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 645-661.	0.7	14
33	Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma. Current Oncology, 2019, 26, 253-265.	0.9	26
34	Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System Manufacturing. Human Gene Therapy, 2019, 30, 1477-1493.	1.4	24
35	Utilization of Chimeric Antigen Receptor T-cell Therapy in Adults. Seminars in Oncology Nursing, 2019, 35, 150930.	0.7	4
36	Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy. , 2019, 7, 271.		45
37	Successful antiâ€CD19 CAR Tâ€cell therapy in HIVâ€infected patients with refractory highâ€grade Bâ€cell lymphoma. Cancer, 2019, 125, 3692-3698.	2.0	42
38	Driving the CAR to the Bone Marrow Transplant Program. Current Hematologic Malignancy Reports, 2019, 14, 561-569.	1.2	10
39	Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies. International Journal of Molecular Sciences, 2019, 20, 5010.	1.8	35
40	Imaging of T-cells and their responses during anti-cancer immunotherapy. Theranostics, 2019, 9, 7924-7947.	4.6	77
41	Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 751-757.	0.2	19

#	Article	IF	Citations
42	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia, 2019, 33, 2767-2778.	3.3	47
43	Recent updates on CAR T clinical trials for multiple myeloma. Molecular Cancer, 2019, 18, 154.	7.9	71
44	Evolution of platelet function in adult patients with chronic immune thrombocytopenia on romiplostim treatment. British Journal of Haematology, 2019, 187, e38-e42.	1.2	11
45	Transgenic Tumor Models for Evaluating CAR Tâ€Cell Immunotherapies. Current Protocols in Pharmacology, 2019, 86, e66.	4.0	0
46	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2305-2321.	2.0	132
47	Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma. Clinical Cancer Research, 2019, 25, 6995-7003.	3.2	70
48	Management Principles Associated With Cytokine Release Syndrome. Seminars in Oncology Nursing, 2019, 35, 150931.	0.7	6
49	Clinical lessons learned from the first leg of the CAR T cell journey. Nature Medicine, 2019, 25, 1341-1355.	15.2	400
50	Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. Frontiers in Immunology, 2019, 10, 2109.	2.2	32
52	The Future of Cellular Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S102-S105.	0.2	0
53	Glypican 3-Targeted Therapy in Hepatocellular Carcinoma. Cancers, 2019, 11, 1339.	1.7	80
54	CAR T cell viability release testing and clinical outcomes: is there a lower limit?. Blood, 2019, 134, 1873-1875.	0.6	24
55	Defining precision cellular immunotherapyâ€"seeking biomarkers to predict and optimize outcomes of T cell therapies in cancer. Precision Cancer Medicine, 2019, 2, 25-25.	1.8	1
56	Current Perspectives in Cancer Immunotherapy. Cancers, 2019, 11, 1472.	1.7	149
57	On the mark: genetically engineered immunotherapies for autoimmunity. Current Opinion in Immunology, 2019, 61, 69-73.	2.4	9
59	Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 791-798.	0.2	11
60	What is new in the treatment of Waldenstrom macroglobulinemia?. Leukemia, 2019, 33, 2555-2562.	3.3	19
61	Eligibility for CAR Tâ€cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL. American Journal of Hematology, 2019, 94, E117-E116.	2.0	19

#	Article	IF	Citations
62	Modelling CAR-T therapy in humanized mice. EBioMedicine, 2019, 40, 25-26.	2.7	13
63	CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia. International Journal of Molecular Sciences, 2019, 20, 2764.	1.8	20
64	DLL3: an emerging target in small cell lung cancer. Journal of Hematology and Oncology, 2019, 12, 61.	6.9	115
65	Advances in cancer immunotherapy 2019 â€“ latest trends. Journal of Experimental and Clinical Cancer Research, 2019, 38, 268.	3.5	401
66	Clinical Approach to the Patient in Critical State Following Immunotherapy and/or Stem Cell Transplantation: Guideline for the On-Call Physician. Journal of Clinical Medicine, 2019, 8, 884.	1.0	14
67	Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells. American Journal of Hematology, 2019, 94, E245-E247.	2.0	1
68	DÃ©jÃ Vu But New: Using T Cells to Deplete B Cells to Treat Lupus. American Journal of Kidney Diseases, 2019, 74, 708-710.	2.1	0
69	Gene editing for immune cell therapies. Nature Biotechnology, 2019, 37, 1425-1434.	9.4	147
70	Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. Journal of Clinical Oncology, 2019, 37, 2105-2119.	0.8	155
71	A review of chimeric antigen receptor T-cells in lymphoma. Expert Review of Hematology, 2019, 12, 551-561.	1.0	11
72	Is It Time to Revisit the Role of Allogeneic Transplantation in Lymphoma?. Current Oncology Reports, 2019, 21, 65.	1.8	2
73	An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT. Current Research in Translational Medicine, 2019, 67, 79-88.	1.2	30
74	Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. Journal of Hematology and Oncology, 2019, 12, 59.	6.9	127
75	CAR Tâ€cell therapy: Full speed ahead. Hematological Oncology, 2019, 37, 95-100.	0.8	131
76	Managing the toxicities of CAR Tâ€cell therapy. Hematological Oncology, 2019, 37, 48-52.	0.8	214
77	T cell immunotherapy enhanced by designer biomaterials. Biomaterials, 2019, 217, 119265.	5.7	40
78	Newer biological agents: CAR T cells, PARP inhibitors, and ALK inhibitors. Journal of Onco-Nephrology, 2019, 3, 92-97.	0.3	0
79	Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma. Blood Advances, 2019, 3, 1230-1243.	2.5	43

#	Article	IF	Citations
80	Doubleâ€hit lymphoma: So what?. Hematological Oncology, 2019, 37, 19-23.	0.8	18
81	Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma. Leukemia, 2019, 33, 2540-2544.	3.3	26
82	Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. International Journal of Molecular Sciences, 2019, 20, 2469.	1.8	14
83	Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood, 2019, 133, 2800-2802.	0.6	49
84	The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 433-444.	1.8	200
85	Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 446-453.	1.8	20
86	Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clinical and Translational Immunology, 2019, 8, e1049.	1.7	205
87	A safe and potent anti-CD19 CAR T cell therapy. Nature Medicine, 2019, 25, 947-953.	15.2	314
88	Outcomes of patients with large Bâ€cell lymphomas and progressive disease following CD19â€specific CAR Tâ€cell therapy. American Journal of Hematology, 2019, 94, E209-E213.	2.0	92
89	Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel . Cancer Management and Research, 2019, Volume 11, 2393-2404.	0.9	14
90	Novel approaches to promote CAR T-cell function in solid tumors. Expert Opinion on Biological Therapy, 2019, 19, 789-799.	1.4	5
91	Tisagenlecleucel in Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 2019, 380, 1585-1586.	13.9	13
92	CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Therapeutic Advances in Hematology, 2019, 10, 204062071984158.	1.1	160
93	CAR-T efficacy: is conditioning the key?. Blood, 2019, 133, 1799-1800.	0.6	79
94	EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells. Molecular Therapy, 2019, 27, 933-946.	3.7	69
95	Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma. Expert Review of Hematology, 2019, 12, 255-264.	1.0	3
96	Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma. Expert Review of Hematology, 2019, 12, 407-418.	1.0	4
97	Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets. Frontiers in Oncology, 2019, 9, 107.	1.3	34

#	Article	IF	Citations
98	Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. Frontiers in Oncology, 2019, 9, 146.	1.3	123
99	Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and longâ€term survival followâ€up from the randomized, phase 3 INOâ€VATE study. Cancer, 2019, 125, 2474-2487.	2.0	210
100	Checking in on Lenalidomide in Diffuse Large B Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e307-e311.	0.2	5
101	Diffuse large Bâ€cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. American Journal of Hematology, 2019, 94, 604-616.	2.0	307
102	Wishing on a CAR: Understanding the Scope of Intrinsic T-cell Deficits in Patients with Cancer. Cancer Discovery, 2019, 9, 466-468.	7.7	8
103	The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma. Current Oncology Reports, 2019, 21, 44.	1.8	6
105	CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions. Journal of the National Cancer Institute, 2019, 111, 646-654.	3.0	126
106	Anti-CD19 CAR T cell therapy for lymphoma â€" off to the races!. Nature Reviews Clinical Oncology, 2019, 16, 279-280.	12.5	9
107	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood, 2019, 133, 1876-1887.	0.6	230
108	Toxicities of CD19 CARâ€T cell immunotherapy. American Journal of Hematology, 2019, 94, S42-S49.	2.0	102
110	Precision medicine for human cancers with Notch signaling dysregulation (Review). International Journal of Molecular Medicine, 2020, 45, 279-297.	1.8	105
111	The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy. HemaSphere, 2019, 3, e295.	1.2	17
112	Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. Blood Advances, 2019, 3, 2230-2236.	2.5	59
113	The CNS can be a safe space for CARs. Blood, 2019, 134, 845-846.	0.6	3
114	Beat pediatric ALL MRD: CD28 CAR T and transplant. Blood, 2019, 134, 2333-2335.	0.6	5
115	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. Blood Advances, 2019, 3, 3062-3069.	2.5	74
116	Teaming up for CAR-T cell therapy. Haematologica, 2019, 104, 2335-2336.	1.7	7
117	The case for CAR T-cell therapy in follicular lymphomas. Blood, 2019, 134, 577-578.	0.6	16

#	Article	IF	Citations
118	New drugs for the management of relapsed or refractory diffuse large B-cell lymphoma. Annals of Lymphoma, 0, 3, 10-10.	4.5	11
120	Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care. Blood, 2019, 134, 2013-2021.	0.6	7
121	Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement. Mayo Clinic Proceedings, 2019, 94, 2361-2364.	1.4	12
122	Cardiotoxicity of Immune Therapy. Cardiology Clinics, 2019, 37, 385-397.	0.9	54
123	B cell targeted therapies in autoimmune disease. Current Opinion in Immunology, 2019, 61, 92-99.	2.4	75
124	CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma. Frontiers in Oncology, 2019, 9, 1350.	1.3	47
125	Unexpected neurologic complications following a novel lymphoma treatment â€˜expectedâ€™ to give rise to neurologic toxicity. BMJ Case Reports, 2019, 12, e229946.	0.2	6
126	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2019, 629, xxi-xl.	0.4	1
127	Introducing the HemaSphere Controversies Series. HemaSphere, 2019, 3, e296.	1.2	1
128	Impact of Increasing Wait Times on Overall Mortality of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma: A Discrete Event Simulation Model. JCO Clinical Cancer Informatics, 2019, 3, 1-9.	1.0	15
130	Hematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: it's not quite time to scrap the old vehicle for the new car. Current Opinion in Hematology, 2019, 26, 288-293.	1.2	0
131	Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). Journal of the American College of Cardiology, 2019, 74, 3099-3108.	1.2	225
132	Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart. Journal of the American College of Cardiology, 2019, 74, 3153-3163.	1.2	78
133	CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entitiesâ€“Merits and Challenges. International Journal of Molecular Sciences, 2019, 20, 5942.	1.8	38
134	Cytokine Release Syndrome: Current Perspectives . ImmunoTargets and Therapy, 2019, Volume 8, 43-52.	2.7	116
135	Don't Get Stuck on the Shoulder: Radiation Oncologists Should Get Into the CAR With T-Cell Therapies. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1022-1024.	0.4	2
136	Management of T-Cell Engaging Immunotherapy Complications. Cancer Journal (Sudbury, Mass), 2019, 25, 223-230.	1.0	15
138	Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptorâ€“T cell manufacture. Cytotherapy, 2019, 21, 1198-1205.	0.3	23

#	Article	IF	Citations
139	Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. Current Opinion in Neurology, 2019, 32, 500-510.	1.8	57
140	Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 6223.	1.8	88
141	Current landscape for chimeric antigen receptor T cells in lymphomas. Current Opinion in Hematology, 2019, 26, 421-426.	1.2	1
142	Current status and hurdles for CAR-T cell immune therapy. Blood Science, 2019, 1, 148-155.	0.4	5
143	CARâ€T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope. HemaSphere, 2019, 3, e185.	1.2	33
144	CAR T Cell Toxicity: Current Management and Future Directions. HemaSphere, 2019, 3, e186.	1.2	121
145	In the Eye of the Storm: Immuneâ€mediated Toxicities Associated With CARâ€T Cell Therapy. HemaSphere, 2019, 3, e191.	1.2	80
146	Are We Ready to Treat Diffuse Large Bâ€cell and Highâ€Grade Lymphoma According to Major Genetic Subtypes?. HemaSphere, 2019, 3, e284.	1.2	9
147	Mechanisms of failure of chimeric antigen receptor T-cell therapy. Current Opinion in Hematology, 2019, 26, 427-433.	1.2	30
148	Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies. Frontiers in Oncology, 2019, 9, 1237.	1.3	106
149	Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges. Drugs in Context, 2019, 8, 1-14.	1.0	29
150	Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical Trials. JCO Precision Oncology, 2019, 3, 1-10.	1.5	11
151	Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e123-e127.	2.0	220
152	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation, 2019, 25, 625-638.	2.0	1,741
153	NaÃ¯ve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers. Cancer Discovery, 2019, 9, 492-499.	7.7	167
154	Chimeric antigen receptor modified T cell therapy in B cell nonâ€Hodgkin lymphomas. American Journal of Hematology, 2019, 94, S18-S23.	2.0	19
155	Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading models. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 1-6.	0.6	12
156	Chimeric antigen receptor T cells for treatment of transformed WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 465-468.	0.6	13

#	Article	IF	Citations
157	Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2020, 55, 393-399.	1.3	29
158	Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma. Transfusion Medicine Reviews, 2020, 34, 29-33.	0.9	81
159	Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy. Biology of Blood and Marrow Transplantation, 2020, 26, 34-43.	2.0	93
160	Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions. , 2020, 205, 107419.		81
161	CAR Tâ€Cell Therapy in Hematologic Malignancies: A Voyage in Progress. Clinical Pharmacology and Therapeutics, 2020, 107, 112-122.	2.3	111
162	CAR-T Cell Therapy for Lymphoma: How Does Radiation Therapy Fit In?. Practical Radiation Oncology, 2020, 10, e155-e158.	1.1	8
163	Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. Practical Radiation Oncology, 2020, 10, 44-52.	1.1	10
164	Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. Biology of Blood and Marrow Transplantation, 2020, 26, 26-33.	2.0	222
165	Future prospects of chimeric antigen receptor Tâ€cell therapy for multiple myeloma. Advances in Cell and Gene Therapy, 2020, 3, e72.	0.6	0
166	Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy. Blood Reviews, 2020, 40, 100640.	2.8	32
167	Noncoding RNAs as potential mediators of resistance to cancer immunotherapy. Seminars in Cancer Biology, 2020, 65, 65-79.	4.3	55
168	Determinants of response and resistance to CAR T cell therapy. Seminars in Cancer Biology, 2020, 65, 80-90.	4.3	59
169	Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma. JAMA Oncology, 2020, 6, 281.	3.4	36
170	Another disappointment in treating relapsed, refractory highâ€risk aggressive Bâ€cell lymphomas. British Journal of Haematology, 2020, 188, 202-204.	1.2	2
171	Innovation and Access at the Mercy of Payment Policy: The Future of Chimeric Antigen Receptor Therapies. Journal of Clinical Oncology, 2020, 38, 384-387.	0.8	17
172	Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma â€“ a LWPâ€EBMT study. British Journal of Haematology, 2020, 188, 745-756.	1.2	20
173	Transposon-mediated generation of CAR-T cells shows efficient anti B-cell leukemia response after ex vivo expansion. Gene Therapy, 2020, 27, 85-95.	2.3	27
174	Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science, 2020, 27, 1.	2.6	1,277

#	Article	IF	Citations
175	Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis. Journal of Hematology and Oncology, 2020, 13, 1.	6.9	244
176	Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade. Hematological Oncology, 2020, 38, 213-222.	0.8	13
177	The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnology Advances, 2020, 40, 107502.	6.0	216
178	Current challenges and emerging opportunities of CAR-T cell therapies. Journal of Controlled Release, 2020, 319, 246-261.	4.8	78
179	Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. MAbs, 2020, 12, 1688616.	2.6	71
180	Late Psychiatric and Neurocognitive Effects of Chimeric Antigen Receptor T Cell Therapy Warrant Further Investigation. Biology of Blood and Marrow Transplantation, 2020, 26, e3-e4.	2.0	2
181	Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?. Biology of Blood and Marrow Transplantation, 2020, 26, e77-e85.	2.0	41
183	Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials. Molecular Therapy - Methods and Clinical Development, 2020, 16, 136-144.	1.8	89
185	Mechanisms of resistance to CAR T cell therapies. Seminars in Cancer Biology, 2020, 65, 91-98.	4.3	31
186	Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications. Journal of Clinical Oncology, 2020, 38, 359-366.	0.8	17
187	Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist. Oncologist, 2020, 25, e138-e146.	1.9	23
188	Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?. Leukemia, 2020, 34, 21-34.	3.3	117
189	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica, 2020, 105, 297-316.	1.7	230
190	Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma. Leukemia and Lymphoma, 2020, 61, 799-807.	0.6	10
191	What a headache! Double-hit lymphoma with CNS recurrence â€“ Role of chimeric antigen receptor (CAR) T-cell therapy. Leukemia and Lymphoma, 2020, 61, 757-762.	0.6	4
192	Response Assessment and Postâ€“CAR T-Cell Therapy Management. , 2020, , 113-127.		0
193	CAR 2.0: The Next Generation of Synthetic Receptorâ€“Based Cellular Therapy for Cancer. , 2020, , 199-208.		0
194	Advances in chimeric antigen receptor T cells. Current Opinion in Hematology, 2020, 27, 368-377.	1.2	24

#	Article	IF	Citations
195	Treatment of postâ€transplant lymphoproliferative disorder (PTLD) in a heart transplant recipient with chimeric antigen receptor Tâ€cell therapy. Pediatric Transplantation, 2021, 25, e13861.	0.5	18
196	Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites. , 2020, 8, 251513552094435.	1.4	2
197	Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Advances, 2020, 4, 4669-4678.	2.5	64
198	Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. Journal of Clinical Oncology, 2020, 38, 3805-3815.	0.8	129
199	Longâ€term outcomes of relapsed/refractory doubleâ€hit lymphoma (r/r DHL) treated with CD19/22 CAR Tâ€cell cocktail therapy. Clinical and Translational Medicine, 2020, 10, e176.	1.7	14
200	Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas. Biology of Blood and Marrow Transplantation, 2020, 26, 2299-2305.	2.0	4
201	Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice. Current Opinion in Oncology, 2020, 32, 603-612.	1.1	5
202	Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2. , 2020, 8, e001114.		12
203	Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study. Annals of Translational Medicine, 2020, 8, 1048-1048.	0.7	5
204	Antibody and antibody fragments for cancer immunotherapy. Journal of Controlled Release, 2020, 328, 395-406.	4.8	63
205	Improving CAR T cell therapy by optimizing critical quality attributes. Seminars in Hematology, 2020, 57, 33-38.	1.8	22
206	Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy. Clinical Cancer Research, 2020, 26, 6299-6309.	3.2	49
207	Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase. Molecular Cancer Therapeutics, 2020, 19, 2502-2515.	1.9	17
208	US costâ€“effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma. Journal of Comparative Effectiveness Research, 2020, 9, 1003-1015.	0.6	7
209	Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials. Current Research in Translational Medicine, 2020, 68, 159-170.	1.2	24
210	Abrogation of HLA surface expression using CRISPR/Cas9 genome editing: a step toward universal T cell therapy. Scientific Reports, 2020, 10, 17753.	1.6	29
211	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. , 2020, 8, e000810.		5
212	Colorectal Cancer Immunotherapy: Options and Strategies. Frontiers in Immunology, 2020, 11, 1624.	2.2	207

#	Article	IF	Citations
213	Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 2211-2216.	2.0	40
214	Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 957-970.	0.9	6
215	Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 2020, 4, 4898-4911.	2.5	238
216	Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy. Blood Advances, 2020, 4, 4869-4872.	2.5	12
217	Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer. Tumori, 2021, 107, 341-352.	0.6	9
218	Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3â€“5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial. Annals of Oncology, 2020, 31, 1251-1259.	0.6	41
219	Key Clinical and Translational Research Questions to Address Unmet Needs in Mantle Cell Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 983-996.	0.9	0
220	Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nature Medicine, 2020, 26, 1878-1887.	15.2	321
221	Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nature Medicine, 2020, 26, 1569-1575.	15.2	266
222	Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma. Haematologica, 2020, 106, 255-258.	1.7	38
223	CCND2 mRNA Expression Is Correlated With R-CHOP Treatment Efficacy and Prognosis in Patients With ABC-DLBCL. Frontiers in Oncology, 2020, 10, 1180.	1.3	9
224	Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center. Annals of Palliative Medicine, 2020, 9, 1442-1452.	0.5	4
225	Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital setting. Current Opinion in Biotechnology, 2020, 65, 233-241.	3.3	28
226	A multicenter evaluation of heterogeneity in cellular therapy processing laboratory procedure times to assess workload capacity. Transfusion, 2020, 60, 1811-1820.	0.8	3
227	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. Journal of Clinical Oncology, 2020, 38, 3095-3106.	0.8	216
228	Early Off-Study Experience of Chimeric Antigen Receptor T Cells in Aggressive Lymphoma: Closer to a Real-World Setting. Journal of Clinical Oncology, 2020, 38, 3085-3087.	0.8	4
229	Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy. Contemporary Clinical Trials, 2020, 96, 106083.	0.8	9
230	Selective inhibitors of nuclear export in aggressive B-cell lymphomas. Lancet Haematology,the, 2020, 7, e500-e501.	2.2	1

#	Article	IF	Citations
231	Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clinical Cancer Research, 2020, 26, 4823-4831.	3.2	47
233	Chimeric Antigen Receptor T Cell Therapy Delivers Response in Lymphoma Progressing after Allogeneic Transplantation, but is the Sequence Optimal?. Biology of Blood and Marrow Transplantation, 2020, 26, e211-e212.	2.0	0
234	Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome. Experimental Hematology, 2020, 88, 7-14.e3.	0.2	21
235	Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2020, 61, 2767-2770.	0.6	14
236	Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma. Frontiers of Medicine, 2020, 14, 811-815.	1.5	2
237	How to Combine the Two Landmark Treatment Methodsâ€"Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?. Frontiers in Immunology, 2020, 11, 611710.	2.2	14
239	The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions. Pharmaceuticals, 2020, 13, 389.	1.7	36
240	Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. International Journal of Molecular Sciences, 2020, 21, 8553.	1.8	22
241	Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9. Nature Communications, 2020, 11, 5902.	5.8	55
242	Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies. International Journal of Molecular Sciences, 2020, 21, 8655.	1.8	13
243	Next-generation cell therapies: the emerging role of CAR-NK cells. Blood Advances, 2020, 4, 5868-5876.	2.5	85
244	Complications after CD19+ CAR T-Cell Therapy. Cancers, 2020, 12, 3445.	1.7	32
245	Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies. , 2020, 8, e001626.		6
246	Adoptive T cell therapy: Boosting the immune system to fight cancer. Seminars in Immunology, 2020, 49, 101437.	2.7	22
247	Current Immunotherapy Approaches in Non-Hodgkin Lymphomas. Vaccines, 2020, 8, 708.	2.1	13
248	Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas. Frontiers in Immunology, 2020, 11, 564099.	2.2	32
249	A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma. Frontiers of Medicine, 2020, 14, 711-725.	1.5	8
250	Non-Coding RNAs in Diffuse Large B-Cell Lymphoma . OncoTargets and Therapy, 2020, Volume 13, 12097-12112.	1.0	7

#	Article	IF	Citations
251	Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance. Cancers, 2020, 12, 3553.	1.7	22
252	Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. Blood Advances, 2020, 4, 4648-4652.	2.5	53
253	C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas. Blood Advances, 2020, 4, 5858-5862.	2.5	12
254	Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas. Hematology American Society of Hematology Education Program, 2020, 2020, 148-153.	0.9	11
255	Transformed lymphoma: what should I do now?. Hematology American Society of Hematology Education Program, 2020, 2020, 306-311.	0.9	13
256	Immunotherapy with cells (article not eligible for CME credit). Hematology American Society of Hematology Education Program, 2020, 2020, 590-597.	0.9	1
257	Next-generation cell therapies: the emerging role of CAR-NK cells. Hematology American Society of Hematology Education Program, 2020, 2020, 570-578.	0.9	27
258	Cardiotoxicity of Contemporary Anticancer Immunotherapy. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 62.	0.4	34
259	Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Advances, 2020, 4, 5607-5615.	2.5	222
260	Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers. Frontiers in Immunology, 2020, 11, 565236.	2.2	9
261	Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing. Biomarker Research, 2020, 8, 56.	2.8	17
262	Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer Journal, 2020, 10, 79.	2.8	137
263	A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq. Molecular Therapy, 2020, 28, 2577-2592.	3.7	58
264	Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 903-921.	0.9	17
265	Evolution of the role of haploidentical stem cell transplantation: past, present, and future. Expert Review of Hematology, 2020, 13, 835-850.	1.0	11
266	Hematopoietic stem cell transplantation and chimeric antigen receptor TÂcell for relapsed or refractory diffuse large B-cell lymphoma. Immunotherapy, 2020, 12, 997-1006.	1.0	17
267	Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR. Cancers, 2020, 12, 1970.	1.7	23
268	B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. International Journal of Molecular Sciences, 2020, 21, 5192.	1.8	24

#	Article	IF	Citations
269	Advances in gene therapy for hematologic disease and considerations for transfusion medicine. Seminars in Hematology, 2020, 57, 83-91.	1.8	5
270	The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduction and Targeted Therapy, 2020, 5, 134.	7.1	84
271	A Head Start: CAR-T Cell Therapy for Primary Malignant Brain Tumors. Current Treatment Options in Oncology, 2020, 21, 73.	1.3	1
272	VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma. Pediatric Blood and Cancer, 2020, 67, e28313.	0.8	24
273	G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma. Bone Marrow Transplantation, 2020, 55, 2347-2349.	1.3	40
274	Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica, 2021, 106, 2667-2672.	1.7	92
275	Commercial <scp>antiâ€CD19 CAR</scp> T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. American Journal of Hematology, 2020, 95, 1324-1333.	2.0	89
276	CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain. Frontiers in Oncology, 2020, 10, 1306.	1.3	32
277	Non-signaling Chimeric Antigen Receptors Enhance Antigen-Directed Killing by Î³Î´ T Cells in Contrast to Î±Î² T Cells. Molecular Therapy - Oncolytics, 2020, 18, 149-160.	2.0	15
278	Quality risk management of the chimeric antigen receptor T cell pharmaceutical circuit in one of the first qualified European centers. Cytotherapy, 2020, 22, 792-801.	0.3	2
279	Improving CAR T-cells: The next generation. Seminars in Hematology, 2020, 57, 115-121.	1.8	13
280	Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma. Expert Opinion on Investigational Drugs, 2020, 29, 1079-1088.	1.9	16
281	An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma. Expert Review of Hematology, 2020, 13, 933-942.	1.0	1
282	Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Advances, 2020, 4, 3776-3787.	2.5	162
283	Targeting immune checkpoints in hematological malignancies. Journal of Hematology and Oncology, 2020, 13, 111.	6.9	66
284	Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system. Frontiers of Medicine, 2020, 14, 726-745.	1.5	9
285	Current Status of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 371-377.	0.6	8
286	Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches. International Journal of Molecular Sciences, 2020, 21, 8000.	1.8	25

#	Article	IF	Citations
287	Chimeric antigen receptor Tâ€cell therapy for haematological malignancies. Medical Journal of Australia, 2020, 213, 404.	0.8	1
289	Letter to the Editor Regarding â€œComparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphomaâ€• Biology of Blood and Marrow Transplantation, 2020, 26, e333-e334.	2.0	9
291	Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy. Cancers, 2020, 12, 3052.	1.7	13
292	Tailoring precision immunotherapy: coming to a clinic soon?. ESMO Open, 2020, 5, e000631.	2.0	8
293	Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet, The, 2020, 396, 839-852.	6.3	1,224
294	Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments. International Journal of Molecular Sciences, 2020, 21, 6324.	1.8	58
295	Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. Journal of Allergy and Clinical Immunology, 2020, 146, 940-948.	1.5	78
296	Beyond CAR T cells: Engineered Vî³9Vî´2 T cells to fight solid tumors. Immunological Reviews, 2020, 298, 117-133.	2.8	9
297	Targeting signalling pathways and the immune microenvironment of cancer stem cells â€” a clinical update. Nature Reviews Clinical Oncology, 2020, 17, 204-232.	12.5	431
298	Synergistic effect of ibrutinib and CD19 CARâ€T cells on Raji cells in vivo and in vitro. Cancer Science, 2020, 111, 4051-4060.	1.7	19
299	Emerging immunotherapies in multiple myeloma. BMJ, The, 2020, 370, m3176.	3.0	62
300	Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 2020, 4, 3943-3951.	2.5	69
301	Advances in CAR T-Cell Therapy for Aggressive B-NHL. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S94-S97.	0.2	1
302	Therapeutic vaccines for aggressive B-cell lymphoma. Leukemia and Lymphoma, 2020, 61, 3038-3051.	0.6	6
303	Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Annals of Hematology, 2020, 99, 2215-2229.	0.8	29
304	Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. Frontiers in Immunology, 2020, 11, 1973.	2.2	148
305	Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo. Nature Medicine, 2020, 26, 1776-1787.	15.2	63
306	CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens. Frontiers in Immunology, 2020, 11, 1568.	2.2	20

#	Article	IF	Citations
307	Immuneâ€based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies. HemaSphere, 2020, 4, e423.	1.2	4
308	Neurological adverse events following CAR T-cell therapy: a real-world analysis. Immunotherapy, 2020, 12, 1077-1082.	1.0	10
309	The Landscape of CAR-T Cell Clinical Trials against Solid Tumorsâ€"A Comprehensive Overview. Cancers, 2020, 12, 2567.	1.7	70
310	Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells. Frontiers in Immunology, 2020, 11, 1787.	2.2	45
311	Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma. Blood Advances, 2020, 4, 3742-3753.	2.5	19
312	Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions. Current Opinion in Oncology, 2020, 32, 434-441.	1.1	3
313	CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Advances, 2020, 4, 3850-3852.	2.5	46
314	CD19-directed CAR T-cell therapy in B-cell NHL. Current Opinion in Oncology, 2020, 32, 408-417.	1.1	26
315	Diffuse Large B-Cell Lymphoma in the Elderly: Current Approaches. Current Oncology Reports, 2020, 22, 114.	1.8	7
316	Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singaporeâ€™s healthcare system perspective. Journal of Medical Economics, 2020, 23, 1321-1329.	1.0	20
317	New agents and regimens for diffuse large B cell lymphoma. Journal of Hematology and Oncology, 2020, 13, 175.	6.9	79
318	Immunotherapy Advances for Epithelial Ovarian Cancer. Cancers, 2020, 12, 3733.	1.7	24
319	Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers, 2020, 12, 3837.	1.7	9
320	CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison. Blood Advances, 2020, 4, 6157-6168.	2.5	26
321	Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies. Frontiers in Cell and Developmental Biology, 2020, 8, 547653.	1.8	44
322	Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells. Frontiers in Immunology, 2020, 11, 608167.	2.2	23
323	Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?. Frontiers in Oncology, 2020, 10, 608916.	1.3	13
324	An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity. Cell Chemical Biology, 2021, 28, 802-812.e6.	2.5	25

#	Article	IF	Citations
325	Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies. Frontiers in Immunology, 2020, 11, 620312.	2.2	21
326	4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells. Frontiers in Immunology, 2020, 11, 539654.	2.2	18
327	Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. Frontiers in Oncology, 2020, 10, 599933.	1.3	15
328	Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML). Cancers, 2020, 12, 3617.	1.7	7
329	Recent Advancements in Hematology: Knowledge, Methods and Dissemination. Hemato, 2020, 1, 5-6.	0.2	0
330	The Application of CAR-T Cells in Haematological Malignancies. Archivum Immunologiae Et Therapiae Experimentalis, 2020, 68, 34.	1.0	19
331	Immunotherapeutic approaches for fungal infections. Current Opinion in Microbiology, 2020, 58, 130-137.	2.3	15
332	Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Advances, 2020, 4, 5414-5424.	2.5	263
333	Biomarkers in individualized management of chimeric antigen receptor T cell therapy. Biomarker Research, 2020, 8, 13.	2.8	23
334	ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 302-313.	1.8	19
335	Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL. Cells, 2020, 9, 1225.	1.8	40
336	Treatment of Aggressive B Cell Lymphomas: Updates in 2019. Current Hematologic Malignancy Reports, 2020, 15, 225-234.	1.2	7
337	Advances in CAR T Therapy for Hematologic Malignancies. Pharmacotherapy, 2020, 40, 741-755.	1.2	11
338	Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress. Annals of Hematology, 2020, 99, 1681-1699.	0.8	5
339	CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome. , 2020, 8, e000364.		14
340	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. Journal of Clinical Oncology, 2020, 38, 3119-3128.	0.8	481
341	Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers. Journal of Emergency Medicine, 2020, 59, 61-74.	0.3	5
342	The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL. Blood Advances, 2020, 4, 2011-2017.	2.5	12

#	Article	IF	Citations
343	CRISPR screen in mechanism and target discovery for cancer immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188378.	3.3	25
344	Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series. Blood Advances, 2020, 4, 1859-1866.	2.5	7
345	Updates in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Lymphoma and Leukemia from the Annual Meeting of American Society of Hematology 2019. Critical Reviews in Oncology/Hematology, 2020, 152, 103007.	2.0	0
346	Value and affordability of CAR T-cell therapy in the United States. Bone Marrow Transplantation, 2020, 55, 1706-1715.	1.3	66
347	Immunotherapy and Response Assessment in Malignant Glioma. Topics in Magnetic Resonance Imaging, 2020, 29, 95-102.	0.7	5
348	Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e275-e291.	1.8	32
349	Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma. International Journal of Clinical Oncology, 2020, 25, 1736-1743.	1.0	16
350	The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Research, 2020, 30, 507-519.	5.7	480
351	Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?. Blood, 2020, 136, 137-139.	0.6	51
352	Chimeric Antigen Receptor T Cell Therapy Comes to Clinical Practice. Current Oncology, 2020, 27, 115-123.	0.9	26
353	Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection. Leukemia, 2020, 34, 3055-3059.	3.3	23
354	Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: from basic to practice. Leukemia and Lymphoma, 2020, 61, 2324-2334.	0.6	6
355	ICU Resource Use in Critically Ill Patients following Chimeric Antigen Receptor T-Cell Therapy. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1184-1187.	2.5	19
356	CAR T-cell immunotherapy of B-cell malignancy: the story so far. , 2020, 8, 251513552092716.	1.4	30
357	Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. Blood, 2020, 135, 996-1007.	0.6	49
358	Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome. Blood, 2020, 136, 1980-1983.	0.6	19
359	Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives. Cancers, 2020, 12, 1497.	1.7	15
360	Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma. Current Hematologic Malignancy Reports, 2020, 15, 316-332.	1.2	11

#	Article	IF	Citations
361	The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL). Annals of Hematology, 2020, 99, 1583-1594.	0.8	0
362	A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?. Advances in Therapy, 2020, 37, 3040-3058.	1.3	34
363	Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 152, 103010.	2.0	34
364	Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nature Reviews Clinical Oncology, 2020, 17, 595-610.	12.5	124
365	The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. Frontiers in Immunology, 2020, 11, 888.	2.2	45
366	A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity. International Journal of Molecular Sciences, 2020, 21, 3886.	1.8	23
367	CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas. International Journal of Molecular Sciences, 2020, 21, 3906.	1.8	50
368	Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas. Targeted Oncology, 2020, 15, 365-375.	1.7	14
369	CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. Frontiers in Oncology, 2020, 10, 849.	1.3	62
370	Neurotoxicityâ€"CAR T-cell therapy: what the neurologist needs to know. Practical Neurology, 2020, 20, 285-293.	0.5	30
371	Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncology, The, 2020, 21, 978-988.	5.1	320
372	Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematology/Oncology Clinics of North America, 2020, 34, 575-587.	0.9	19
373	Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematology/Oncology Clinics of North America, 2020, 34, 621-629.	0.9	12
374	Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. Expert Opinion on Biological Therapy, 2021, 21, 831-839.	1.4	9
375	The benefit of CAR T cells in older patients. Blood, 2020, 135, 2020-2021.	0.6	4
376	Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells. Frontiers in Molecular Biosciences, 2020, 7, 84.	1.6	26
377	Treating central nervous system lymphoma in the era of precision medicine. Expert Review of Precision Medicine and Drug Development, 2020, 5, 275-281.	0.4	1
378	Exhausted and outnumbered: CD4+ T cells in the myeloma battlefield. Leukemia and Lymphoma, 2020, 61, 1777-1779.	0.6	1

#	Article	IF	Citations
379	Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies. Stem Cell Research and Therapy, 2020, 11, 234.	2.4	55
380	Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma. Blood, 2020, 136, 1632-1644.	0.6	119
381	Emerging therapies in mantle cell lymphoma. Journal of Hematology and Oncology, 2020, 13, 79.	6.9	33
382	Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Leukemia and Lymphoma, 2020, 61, 2103-2112.	0.6	55
383	Developing anti-CD19 antibody-based combinations in lymphoma. Lancet Oncology, The, 2020, 21, 870-872.	5.1	2
384	CAR T Cells for Mantle Cell Lymphoma: Is it Time to Reshuffle the Deck?. Cancer Cell, 2020, 37, 761-763.	7.7	0
385	Circular RNA and tumor microenvironment. Cancer Cell International, 2020, 20, 211.	1.8	22
386	Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia. Frontiers in Oncology, 2020, 10, 685.	1.3	29
387	Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma. Frontiers in Oncology, 2020, 10, 777.	1.3	6
388	Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cellÂtherapy for the treatment of diffuse large B-cell lymphoma. Immunotherapy, 2020, 12, 725-732.	1.0	11
389	Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2020, 26, 1581-1588.	2.0	40
390	Cardiovascular Effects of CAR T CellÂTherapy. JACC: CardioOncology, 2020, 2, 193-203.	1.7	84
391	CAR T Cell Therapyâ€"Related Cardiovascular Outcomes andÂManagement. JACC: CardioOncology, 2020, 2, 97-109.	1.7	73
392	Chimeric antigen receptor Tâ€cell therapies: Optimising the dose. British Journal of Clinical Pharmacology, 2020, 86, 1678-1689.	1.1	25
393	Advances in targeted therapy for malignant lymphoma. Signal Transduction and Targeted Therapy, 2020, 5, 15.	7.1	66
394	Tuning the Antigen Density Requirement for CAR T-cell Activity. Cancer Discovery, 2020, 10, 702-723.	7.7	296
395	A ray of hope in a dire situation: Radiotherapy for progression after chimeric antigen receptor Tâ€cell therapy. British Journal of Haematology, 2020, 190, 18-19.	1.2	0
396	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 635, xix-xxxviii.	0.4	0

#	Article	IF	Citations
397	Early experience using salvage radiotherapy for relapsed/refractory nonâ€Hodgkin lymphomas after CD19 chimericÂantigen receptor (CAR)ÂT cell therapy. British Journal of Haematology, 2020, 190, 45-51.	1.2	51
398	Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas. Acta OncolÃ³gica, 2020, 59, 766-774.	0.8	9
399	You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy. Cancers, 2020, 12, 706.	1.7	73
400	Immunomodulators in Lymphoma. Current Treatment Options in Oncology, 2020, 21, 28.	1.3	4
401	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 636, xvii-xxxvi.	0.4	0
402	Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells. Molecular Therapy, 2020, 28, 1392-1416.	3.7	44
403	The Many Facets of CD38 in Lymphoma: From Tumorâ€“Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy. Cells, 2020, 9, 802.	1.8	23
404	T cell-engaging therapies â€" BiTEs and beyond. Nature Reviews Clinical Oncology, 2020, 17, 418-434.	12.5	296
405	KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. New England Journal of Medicine, 2020, 382, 1331-1342.	13.9	1,067
406	Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer. Cancers, 2020, 12, 842.	1.7	21
407	Ten things the hematologist wants you to know about CAR-T cells. Intensive Care Medicine, 2020, 46, 1243-1245.	3.9	5
408	Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies. Blood, 2020, 135, 17-27.	0.6	191
409	Tisagenlecleucel in Non-Hodgkin Lymphoma: The Restricted Mean Survival Time as a Tool for Estimating Progression-Free Life Expectancy Better than the Median. Acta Haematologica, 2020, 143, 598-599.	0.7	6
410	Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy. Molecular Carcinogenesis, 2020, 59, 775-782.	1.3	36
411	Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. Clinical Immunology, 2020, 214, 108382.	1.4	40
412	T lymphocyte-targeted immune checkpoint modulation in glioma. , 2020, 8, e000379.		28
413	Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation. Frontiers in Immunology, 2020, 11, 147.	2.2	39
414	Next-generation CAR T cells to overcome current drawbacks. International Journal of Hematology, 2020, 114, 532-543.	0.7	7

#	Article	IF	Citations
415	Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective. Frontiers in Oncology, 2020, 10, 885.	1.3	20
416	Clinical Features and Prognostic Impact of Coexpression Modules Constructed by WGCNA for Diffuse Large B-Cell Lymphoma. BioMed Research International, 2020, 2020, 1-14.	0.9	5
417	Phase II trial of coâ€administration of CD19â€and CD20â€targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer Medicine, 2020, 9, 5827-5838.	1.3	36
418	Neurological Complications of CAR T Cell Therapy. Current Oncology Reports, 2020, 22, 83.	1.8	16
419	Treatment of Histologic Transformation. Hematology/Oncology Clinics of North America, 2020, 34, 785-794.	0.9	4
420	Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma. Cancer Journal (Sudbury, Mass), 2020, 26, 195-205.	1.0	24
421	Immune and Cell Therapy in Non-Hodgkin Lymphoma. Cancer Journal (Sudbury, Mass), 2020, 26, 269-277.	1.0	4
422	DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Advances, 2020, 4, 3024-3033.	2.5	75
423	Recent advances in CAR-T cell engineering. Journal of Hematology and Oncology, 2020, 13, 86.	6.9	192
425	Cellular Therapy in Follicular Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 701-714.	0.9	1
426	Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy. OncoImmunology, 2020, 9, 1785608.	2.1	35
427	How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood, 2020, 136, 925-935.	0.6	158
428	Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Advances, 2020, 4, 2871-2883.	2.5	134
429	CD19 / CD22 Dualâ€Targeted CARâ€T Therapy Active in Relapsed/Refractory DLBCL. Oncologist, 2020, 25, S12-S13.	1.9	1
430	Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas. Leukemia and Lymphoma, 2020, 61, 2561-2567.	0.6	16
431	Advances in Treatment of Follicular Lymphoma. Cancer Journal (Sudbury, Mass), 2020, 26, 231-240.	1.0	5
432	Radiotherapy for Non-Hodgkin Lymphomas. Cancer Journal (Sudbury, Mass), 2020, 26, 217-230.	1.0	11
433	A rational relationship: Oncolytic virus vaccines as functional partners for adoptive T cell therapy. Cytokine and Growth Factor Reviews, 2020, 56, 149-159.	3.2	3

#	Article	IF	Citations
434	Chimeric antigen receptor Tâ€cell therapy in patients with neurologic comorbidities. Pediatric Blood and Cancer, 2020, 67, e28199.	0.8	12
435	Toxicities of novel therapies for hematologic malignancies. Expert Review of Hematology, 2020, 13, 241-257.	1.0	2
436	Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceutics, 2020, 12, 194.	2.0	40
437	Identification of hurdles in the development of cell-based therapies. Cytotherapy, 2020, 22, 53-56.	0.3	1
438	Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Cytotherapy, 2020, 22, 166-171.	0.3	27
439	The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-Tâ€™s come into focus. Bone Marrow Transplantation, 2020, 55, 1604-1613.	1.3	147
440	Combination therapy with oncolytic viruses and immune checkpoint inhibitors. Expert Opinion on Biological Therapy, 2020, 20, 635-652.	1.4	36
441	Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert Opinion on Biological Therapy, 2020, 20, 653-664.	1.4	39
442	CAR-T Treatment: Determining the Survival Gain in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 490-491.	0.2	5
443	Perspectives on chemotherapy for the management of double-hit lymphoma. Expert Opinion on Pharmacotherapy, 2020, 21, 653-661.	0.9	8
444	Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents. Annals of Pharmacotherapy, 2020, 54, 879-898.	0.9	4
445	Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplants for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Is More Actually Less?. Biology of Blood and Marrow Transplantation, 2020, 26, e75-e76.	2.0	1
446	Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome. Journal of Critical Care, 2020, 57, 124-129.	1.0	25
447	The clinical potential of gene editing as a tool to engineer cellâ€based therapeutics. Clinical and Translational Medicine, 2020, 9, 15.	1.7	56
448	Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. Biology of Blood and Marrow Transplantation, 2020, 26, 1071-1076.	2.0	63
449	The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia. Expert Opinion on Biological Therapy, 2020, 20, 799-812.	1.4	5
450	CAR T-Cell-Associated Neurotoxicity. Critical Care Nursing Quarterly, 2020, 43, 191-204.	0.4	28
451	CAR T cells: continuation in a revolution of immunotherapy. Lancet Oncology, The, 2020, 21, e168-e178.	5.1	204

#	Article	IF	Citations
452	Cellular Immunotherapy in Lymphoma: Beyond CART Cells. Current Treatment Options in Oncology, 2020, 21, 21.	1.3	6
453	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 631, xxiii-xlii.	0.4	1
454	A review of cancer immunotherapy toxicity. Ca-A Cancer Journal for Clinicians, 2020, 70, 86-104.	157.7	753
455	Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. American Journal of Kidney Diseases, 2020, 76, 63-71.	2.1	74
456	Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy. Briefings in Functional Genomics, 2020, 19, 175-182.	1.3	59
457	Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction. Cancer Discovery, 2020, 10, 552-567.	7.7	184
458	Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly. International Journal of Molecular Sciences, 2020, 21, 883.	1.8	24
459	The role of clinical pharmacology across novel treatment modalities. Clinical Pharmacology and Therapeutics, 2020, 108, 413-415.	2.3	2
460	Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment. Cancers, 2020, 12, 125.	1.7	50
461	Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies. International Journal of Molecular Sciences, 2020, 21, 515.	1.8	49
462	Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. Hematological Oncology, 2020, 38, 137-145.	0.8	3
463	Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nature Medicine, 2020, 26, 270-280.	15.2	182
464	Disseminated toxoplasmosis and haemophagocytic lymphohistiocytosis following chimeric antigen receptor Tâ€cell therapy. British Journal of Haematology, 2020, 189, e4-e6.	1.2	5
465	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 632, xxiii-xlii.	0.4	0
466	The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy, 2020, 22, 57-69.	0.3	70
467	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. New England Journal of Medicine, 2020, 382, 545-553.	13.9	1,252
468	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. Bone Marrow Transplantation, 2020, 55, 1525-1532.	1.3	17
469	Development of CAR-T cell therapy for B-ALL using a point-of-care approach. OncoImmunology, 2020, 9, 1752592.	2.1	23

#	Article	IF	Citations
470	Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica, 2020, 105, 1907-1913.	1.7	23
471	The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptorâ€“T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. Cytotherapy, 2020, 22, 214-226.	0.3	29
472	Expanding Access to Chimeric Antigen Receptor T-Cell Therapies: Challenges and Opportunities. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e27-e34.	1.8	25
473	Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells. Frontiers in Genetics, 2020, 11, 312.	1.1	27
474	Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. Blood Advances, 2020, 4, 629-637.	2.5	48
475	A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models. Clinical Cancer Research, 2020, 26, 3694-3706.	3.2	18
476	Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. JAMA Network Open, 2020, 3, e202072.	2.8	74
477	A phase <scp>II</scp> trial evaluating the efficacy of <scp>highâ€dose</scp> Radioiodinated Tositumomab (<scp>Antiâ€CD20</scp>) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for <scp>highâ€risk</scp> relapsed or refractory <scp>nonâ€hodgkin</scp> lymphoma. American Journal of Hematology, 2020, 95, 775-783.	2.0	7
478	Bâ€cell maturation antigenâ€specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives. International Journal of Cancer, 2020, 147, 2029-2041.	2.3	10
479	CAR T-cell therapy in diffuse large B-cell lymphoma. Memo - Magazine of European Medical Oncology, 2020, 13, 32-35.	0.3	2
481	The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy. Leukemia and Lymphoma, 2020, 61, 1601-1609.	0.6	12
482	Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy. Leukemia and Lymphoma, 2020, 61, 1784-1796.	0.6	16
483	EHA evaluation of the ESMOâ€”Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO Open, 2020, 5, e000611.	2.0	10
484	Car-T Treatment for Hematological Malignancies. Journal of Investigative Medicine, 2020, 68, 956-964.	0.7	20
485	Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients. , 2020, 8, e000148.		42
486	Excellent proliferation and persistence of allogeneic donor-derived 41-BB based CAR-T cells despite immunosuppression with cyclosporine A. Haematologica, 2020, 105, 322-324.	1.7	14
487	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. International Journal of Molecular Sciences, 2020, 21, 2856.	1.8	31
488	Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer. Clinical and Experimental Medicine, 2020, 20, 469-480.	1.9	8

#	Article	IF	Citations
489	Implantable Therapeutic Reservoir Systems for Diverse Clinical Applications in Large Animal Models. Advanced Healthcare Materials, 2020, 9, e2000305.	3.9	13
490	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. Journal of Critical Care, 2020, 58, 58-64.	1.0	31
491	Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder. Blood, 2020, 135, 1344-1352.	0.6	69
492	Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?. Biology of Blood and Marrow Transplantation, 2020, 26, e183-e191.	2.0	25
493	Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. Biology of Blood and Marrow Transplantation, 2020, 26, 1239-1246.	2.0	56
494	Genome and base editing for genetic hearing loss. Hearing Research, 2020, 394, 107958.	0.9	18
495	Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). BMJ Open, 2020, 10, e034629.	0.8	26
496	Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies. Cell Transplantation, 2020, 29, 096368972091943.	1.2	16
497	Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy. Blood, 2020, 135, 668-679.	0.6	7
498	Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2020, 38, 2862-2871.	0.8	102
499	The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood, 2020, 135, 523-533.	0.6	134
500	Long-term outcomes of Sleeping Beautyâ€“generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood, 2020, 135, 862-865.	0.6	27
501	A CAR against CAR for unintended consequences. Blood, 2020, 135, 460-462.	0.6	0
502	Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Advances, 2020, 4, 560-572.	2.5	88
503	Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Advances, 2020, 4, 676-686.	2.5	101
504	Chimeric antigen receptorâ€“T cells with cytokine neutralizing capacity. Blood Advances, 2020, 4, 1419-1431.	2.5	27
505	Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Advances, 2020, 4, 1432-1439.	2.5	54
506	Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. Blood Advances, 2020, 4, 1440-1447.	2.5	29

#	Article	IF	Citations
507	LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Advances, 2020, 4, 1367-1377.	2.5	66
508	Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. Journal of Hematology and Oncology, 2020, 13, 29.	6.9	146
509	Chimeric antigen receptor Tâ€cell therapy toxicities. British Journal of Clinical Pharmacology, 2021, 87, 2414-2424.	1.1	19
510	Revving the CAR â€“ Combination strategies to enhance CAR T cell effectiveness. Blood Reviews, 2021, 45, 100695.	2.8	22
511	Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 33-40.	0.6	17
512	Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia, 2021, 35, 752-763.	3.3	52
513	Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy. Immunological Medicine, 2021, 44, 10-15.	1.4	14
514	Developing cell therapies as drug products. British Journal of Pharmacology, 2021, 178, 262-279.	2.7	6
515	Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. Transplantation and Cellular Therapy, 2021, 27, 46-52.	0.6	28
516	Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. Molecular Therapy, 2021, 29, 505-520.	3.7	48
517	Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies. Molecular Therapy, 2021, 29, 433-441.	3.7	22
518	Real-world adverse events associated with CAR T-cell therapy among adults ageâ€‰â‰¥â€‰65â€‰years. Journal of Geriatric Oncology, 2021, 12, 239-242.	0.5	16
519	Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia. Bone Marrow Transplantation, 2021, 56, 376-386.	1.3	11
520	Infection profiles of different chemotherapy regimens and the clinical feasibility of antimicrobial prophylaxis in patients with DLBCL. Blood Reviews, 2021, 46, 100738.	2.8	9
521	Immune effector cellâ€“associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro-Oncology, 2021, 23, 112-121.	0.6	53
522	Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations. Bone Marrow Transplantation, 2021, 56, 679-682.	1.3	14
523	Toward Better Understanding and Management of CAR-T Cellâ€“Associated Toxicity. Annual Review of Medicine, 2021, 72, 365-382.	5.0	34
524	Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. Bone Marrow Transplantation, 2021, 56, 683-685.	1.3	7

#	Article	IF	Citations
525	Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma. Annals of Pharmacotherapy, 2021, 55, 390-405.	0.9	13
526	Ibrutinib for improved chimeric antigen receptor Tâ€cell production for chronic lymphocytic leukemia patients. International Journal of Cancer, 2021, 148, 419-428.	2.3	42
527	Modelâ€Based Cellular Kinetic Analysis of Chimeric Antigen Receptorâ€T Cells in Humans. Clinical Pharmacology and Therapeutics, 2021, 109, 716-727.	2.3	49
528	Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy. Transplantation and Cellular Therapy, 2021, 27, 55.e1-55.e7.	0.6	7
529	Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 57.e1-57.e8.	0.6	7
530	Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. Critical Reviews in Oncology/Hematology, 2021, 157, 103096.	2.0	10
531	Clinical development of CAR T cell therapy in China: 2020 update. Cellular and Molecular Immunology, 2021, 18, 792-804.	4.8	50
532	CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1â€“positive B-Cell Lymphoma. Clinical Cancer Research, 2021, 27, 473-484.	3.2	68
533	Relapse of Hodgkin lymphoma after autologous hematopoietic cell transplantation: A current management perspective. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 95-103.	0.6	0
534	Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma. Expert Opinion on Pharmacotherapy, 2021, 22, 93-107.	0.9	12
535	Pharmacology of Chimeric Antigen Receptorâ€“Modified T Cells. Annual Review of Pharmacology and Toxicology, 2021, 61, 805-829.	4.2	7
536	Hematopoietic stem cell transplantation for diffuse large Bâ€cell lymphoma having 8q24/MYC rearrangement in Japan. Hematological Oncology, 2021, 39, 66-74.	0.8	2
537	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood, 2021, 137, 323-335.	0.6	111
538	Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection, 2021, 49, 215-231.	2.3	63
539	Joining Forces: Improving Clinical Response to Cellular Immunotherapies with Small-Molecule Inhibitors. Trends in Molecular Medicine, 2021, 27, 75-90.	3.5	5
540	Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. Transplantation and Cellular Therapy, 2021, 27, 58-66.	0.6	21
541	Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial. Annals of Oncology, 2021, 32, 120-121.	0.6	43
542	A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. Leukemia, 2021, 35, 1586-1596.	3.3	57

#	Article	IF	Citations
543	CAR T cell therapy in B-cell acute lymphoblastic leukaemia: Insights from mathematical models. Communications in Nonlinear Science and Numerical Simulation, 2021, 94, 105570.	1.7	20
544	Acute Leukemias. Hematologic Malignancies, 2021, , .	0.2	2
545	CD28 Costimulatory Domainâ€“Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function. Cancer Immunology Research, 2021, 9, 62-74.	1.6	29
546	Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy â€“ what are we doing; where are we going?. Expert Opinion on Biological Therapy, 2021, 21, 627-637.	1.4	25
547	Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy. Biomaterials, 2021, 268, 120584.	5.7	40
548	Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 176-181.	0.2	8
549	CAR-T cell therapy and infection: a review. Expert Review of Anti-Infective Therapy, 2021, 19, 749-758.	2.0	47
550	Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity. Neuro-Oncology Practice, 2021, 8, 259-265.	1.0	3
551	Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet, The, 2021, 397, 1010-1022.	6.3	196
552	Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy. Leukemia and Lymphoma, 2021, 62, 828-836.	0.6	11
553	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood, 2021, 137, 2634-2645.	0.6	111
554	CARâ€T TREK through the lymphoma universe, to boldly go where no other therapy has gone before. British Journal of Haematology, 2021, 193, 449-465.	1.2	17
555	Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients. Oncologist, 2021, 26, 120-132.	1.9	37
556	Combinatorial CAR design improves target restriction. Journal of Biological Chemistry, 2021, 296, 100116.	1.6	7
557	Melanoma cells can be eliminated by sialylated CD43 Ã— CD3 bispecific T cell engager formats in vitro and in vivo. Cancer Immunology, Immunotherapy, 2021, 70, 1569-1581.	2.0	7
558	Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management. Clinical Cancer Research, 2021, 27, 1242-1246.	3.2	62
559	Chimeric antigen receptor (CAR) natural killer (NK)â€cell therapy: leveraging the power of innate immunity. British Journal of Haematology, 2021, 193, 216-230.	1.2	61
560	Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?. Bone Marrow Transplantation, 2021, 56, 974-977.	1.3	39

#	Article	IF	Citations
561	Chimeric antigen receptor Tâ€cell therapy after allogeneic stem cell transplant for relapsed/refractory large Bâ€cell lymphoma. British Journal of Haematology, 2021, 192, 212-216.	1.2	14
562	Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Leukemia and Lymphoma, 2021, 62, 590-597.	0.6	2
563	Firstâ€line treatment of doubleâ€hit and tripleâ€hit lymphomas: Survival and tolerance data from a retrospective multicenter French study. American Journal of Hematology, 2021, 96, 302-311.	2.0	32
564	Late Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid Malignancies. Transplantation and Cellular Therapy, 2021, 27, 222-229.	0.6	27
565	A Question of Beneficence: Comorbidity Assessment to Ascertain Potential Benefit of CD19 Chimeric Antigen Receptor T Cells for Patients with Diffuse Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 2-3.	0.6	0
566	CXCR4 in WaldenstrÃ¶mâ€™s Macroglobulinema: chances and challenges. Leukemia, 2021, 35, 333-345.	3.3	53
567	Investigational drugs for the treatment of diffuse large B-cell lymphoma. Expert Opinion on Investigational Drugs, 2021, 30, 25-38.	1.9	24
568	Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transplantation, 2021, 56, 1134-1143.	1.3	17
569	Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains. Human Gene Therapy, 2021, 32, 730-743.	1.4	9
570	Polatuzumab vedotin, an anti-CD79b antibodyâ€“drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma. Future Oncology, 2021, 17, 127-135.	1.1	6
571	Prolonged neurotoxicity in a lymphoma patient after CD19â€directed CAR Tâ€cell therapy: A case report and brief review of the literature. Advances in Cell and Gene Therapy, 2021, 4, e104.	0.6	1
572	CAR T Cell and BiTE Therapyâ€”New Therapies, New Risks?. Current Cardiovascular Risk Reports, 2021, 15, 1.	0.8	1
573	Engineering precision therapies: lessons and motivations from the clinic. Synthetic Biology, 2021, 6, ysaa024.	1.2	5
574	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CARâ€refractory large B-cell lymphoma. Blood, 2021, 137, 2321-2325.	0.6	51
575	Safety of CAR T-cell therapy in kidney transplant recipients. Blood, 2021, 137, 2558-2562.	0.6	33
576	Liquid biopsy for disease monitoring after antiâ€CD19 chimeric antigen receptor T cell in diffuse large Bâ€cell lymphoma. EJHaem, 2021, 2, 112-114.	0.4	1
577	Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Annals of Oncology, 2021, 32, 34-48.	0.6	231
578	Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies. Journal of Geriatric Oncology, 2021, 12, 235-238.	0.5	9

#	Article	IF	Citations
579	CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder. American Journal of Transplantation, 2021, 21, 809-814.	2.6	44
580	Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 73-79.	0.2	14
581	Palliative, Ethics, and End-of-Life Care Issues in the Cancer Patient. Critical Care Clinics, 2021, 37, 105-115.	1.0	9
582	Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy. Bone Marrow Transplantation, 2021, 56, 570-580.	1.3	25
583	Cytokine syndromes associated with hematopoietic cellular therapy. Advances in Cell and Gene Therapy, 2021, 4, .	0.6	1
584	Humanized antiâ€CD19 chimeric antigen receptorâ€T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection. Hematological Oncology, 2021, 39, 75-86.	0.8	15
585	Exploring the NK cell platform for cancer immunotherapy. Nature Reviews Clinical Oncology, 2021, 18, 85-100.	12.5	605
586	Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma. Clinical Hematology International, 2021, 3, 21.	0.7	8
587	CAR T Toxicity Management: Cytokine Release Syndrome and Neurotoxicity. , 2021, , 915-928.		0
588	Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. Journal of Medical Economics, 2021, 24, 458-468.	1.0	23
589	Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110180.	1.4	21
590	Toxicities of Novel Antineoplastic Therapies. , 2021, , 711-738.		1
591	CAR19/22 T cell therapy in adult refractory Burkittâ€™s lymphoma. Cancer Immunology, Immunotherapy, 2021, 70, 2379-2384.	2.0	17
592	New Approaches to Allogeneic Haematopoietic Cell Transplantation. Touch Reviews in Oncology & Haematology, 2021, 17, 28.	0.1	0
593	Allogeneic CAR Cell Therapyâ€"More Than a Pipe Dream. Frontiers in Immunology, 2020, 11, 618427.	2.2	64
594	Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes. Journal of Clinical Investigation, 2021, 131, .	3.9	54
595	Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma. Clinical Cancer Research, 2021, 27, 1912-1922.	3.2	26
596	Cancer Immunology. , 2021, , .		0

#	Article	IF	Citations
598	Relapse After Hematopoietic Cell Transplantation. , 2021, , 711-721.		0
599	Perspectives in immunotherapy: meeting report from the â€œImmunotherapy Bridgeâ€•(December 4thâ€“5th,) Tj ETQq1 1 0.784314 rg	1.8	3
600	Outcomes in refractory diffuse large Bâ€cell lymphoma: results from a multicenter realâ€world study in China. Cancer Communications, 2021, 41, 229-239.	3.7	15
601	Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies. Current Cardiology Reports, 2021, 23, 11.	1.3	35
602	Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML. OncoImmunology, 2021, 10, 1945804.	2.1	16
603	Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singaporeâ€™s private insurance payerâ€™s perspective. Journal of Medical Economics, 2021, 24, 637-653.	1.0	9
604	Current treatment options for aggressive non-Hodgkin lymphoma in elderly and frail patients: practical considerations for the hematologist. Therapeutic Advances in Hematology, 2021, 12, 204062072199648.	1.1	7
605	Antibodies Against Vaccine-preventable Infections After CD19 or BCMA CAR T-cell Therapy. , 2021, 18, .		0
606	Treatment and resistance of glioblastoma to CAR T-cell immunotherapies. , 2021, , 453-471.		0
607	Schwere Candida-glabrata-Pankolitis und letale Aspergillus-fumigatus-Lungeninfektion vor dem Hintergrund einer Knochenmarkaplasie nach CD19-spezifischer CAR T-Zell-Therapie â€“ ein Fallbericht. Karger Kompass Onkologie, 2021, 8, 159-165.	0.0	0
608	Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy â€“ a case report. BMC Infectious Diseases, 2021, 21, 121.	1.3	33
609	Biological bases of cancer immunotherapy. Expert Reviews in Molecular Medicine, 2021, 23, e3.	1.6	14
610	Industrial Perspective on Immunotherapy. Advances in Experimental Medicine and Biology, 2021, 1295, 327-347.	0.8	0
611	The dual role of Natural Killer cells during tumor progression and angiogenesis: Implications for tumor microenvironment-targeted immunotherapies. , 2021, , 305-347.		0
612	CARâ€NK cells: the next wave of cellular therapy for cancer. Clinical and Translational Immunology, 2021, 10, e1274.	1.7	66
613	BiTEs better than CAR T cells. Blood Advances, 2021, 5, 607-612.	2.5	59
614	Challenges of Cellular Therapy During the COVID-19 Pandemic. Advances in Experimental Medicine and Biology, 2021, 1318, 657-672.	0.8	4
615	The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma. Therapeutic Advances in Hematology, 2021, 12, 204062072110177.	1.1	3

#	Article	IF	Citations
616	AYA Considerations for Aggressive Lymphomas. Current Hematologic Malignancy Reports, 2021, 16, 61-71.	1.2	1
617	Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early- Phase Cellular Therapy Clinical Trials. Transplantation and Cellular Therapy, 2021, 27, 105-107.	0.6	1
618	Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies. Current Hematologic Malignancy Reports, 2021, 16, 32-39.	1.2	6
619	Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy. Cancers, 2021, 13, 840.	1.7	17
620	Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models. Cancer Immunology, Immunotherapy, 2021, 70, 2503-2515.	2.0	28
621	Autologous Stem Cell Transplantation in the Management of Relapsed Non-Hodgkin Lymphoma. Journal of Clinical Oncology, 2021, 39, 467-475.	0.8	13
622	Antiâ€tumor efficacy of human antiâ€câ€met CARâ€T cells against papillary renal cell carcinoma in an orthotopic model. Cancer Science, 2021, 112, 1417-1428.	1.7	21
623	Cure rate in the elderly patients with diffuse large B cell lymphoma deteriorates after the age of 80â€"results from a single-center survey. Annals of Hematology, 2021, 100, 1013-1021.	0.8	3
625	Recent advances in cellular therapy for malignant lymphoma. Cytotherapy, 2021, 23, 662-671.	0.3	5
626	CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department. Clinical Toxicology, 2021, 59, 376-385.	0.8	4
628	Utility of a safety switch to abrogate CD19.CAR T-cellâ€"associated neurotoxicity. Blood, 2021, 137, 3306-3309.	0.6	26
629	Emerging Immunotherapy for Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2021, 22, 1944.	1.8	39
630	How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies. Journal of Clinical Oncology, 2021, 39, 456-466.	0.8	21
631	Novel Therapy Approaches to Follicular Lymphoma. Drugs, 2021, 81, 453-469.	4.9	4
632	Sex as decisive variable in lymphoid neoplasmsâ€"an update. ESMO Open, 2021, 6, 100001.	2.0	3
633	Hematologic Rescue of CAR T-cellâ€"mediated Prolonged Pancytopenia Using Autologous Peripheral Blood Hematopoietic Stem Cells in a Lymphoma Patient. HemaSphere, 2021, 5, e545.	1.2	16
634	CRISPR Takes the Front Seat in CART-Cell Development. BioDrugs, 2021, 35, 113-124.	2.2	10
635	Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. Leukemia and Lymphoma, 2021, 62, 1629-1638.	0.6	1

#	Article	IF	Citations
636	Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice. European Journal of Clinical Pharmacology, 2021, 77, 1225-1234.	0.8	8
637	Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?. Journal of Clinical Oncology, 2021, 39, 487-498.	0.8	27
638	Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. New England Journal of Medicine, 2021, 384, 673-674.	13.9	178
639	Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells. Leukemia and Lymphoma, 2021, 62, 1692-1701.	0.6	22
641	Targeted Therapies for Follicular Lymphoma. Current Hematologic Malignancy Reports, 2021, 16, 25-31.	1.2	2
642	Understanding the Feasibility of Implementing Car T-Cell Therapies from a Canadian Perspective. Healthcare Policy, 2021, 16, 89-105.	0.3	0
643	Targeted Treatment of Follicular Lymphoma. Journal of Personalized Medicine, 2021, 11, 152.	1.1	3
644	Regulatory challenges and considerations for the clinical application of CAR T cell therapy. Expert Opinion on Biological Therapy, 2021, 21, 549-552.	1.4	1
645	CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial. Bone Marrow Transplantation, 2021, 56, 1642-1650.	1.3	14
646	Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplantation, 2021, 56, 1651-1664.	1.3	221
647	Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. American Journal of Hematology, 2021, 96, 455-461.	2.0	35
648	Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovahâ€™s Witnesses. Leukemia and Lymphoma, 2021, 62, 1497-1501.	0.6	1
649	Biology in Practice: Harnessing the Curative Potential of the Immune System in Lymphoid Cancers. Journal of Clinical Oncology, 2021, 39, 346-360.	0.8	3
650	Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation. Annals of Hematology, 2021, 100, 865-878.	0.8	6
651	Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies. Cancers, 2021, 13, 650.	1.7	4
652	Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies. Biomarkers in Medicine, 2021, 15, 201-217.	0.6	1
653	The best matrix for the brain: advances in secondary CNS lymphoma. Lancet Haematology,the, 2021, 8, e96-e97.	2.2	2
654	CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies. Journal of Hematology and Oncology, 2021, 14, 26.	6.9	26

#	Article	IF	Citations
655	CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases. Molecular Therapy, 2021, 29, 571-586.	3.7	124
656	Chimeric Antigen Receptor T-Cell Therapy in the Management of Relapsed Non-Hodgkin Lymphoma. Journal of Clinical Oncology, 2021, 39, 476-486.	0.8	8
657	Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood, 2021, 137, 3272-3276.	0.6	95
658	Genetic engineering of T cells for immunotherapy. Nature Reviews Genetics, 2021, 22, 427-447.	7.7	63
659	New CAR Designs: Highlights From SOHO 2020. Journal of the Advanced Practitioner in Oncology, 2021, 12, 30-32.	0.2	0
660	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. Hemato, 2021, 2, 79-88.	0.2	0
661	Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma. Current Hematologic Malignancy Reports, 2021, 16, 72-81.	1.2	7
662	Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies. Journal of Clinical Oncology, 2021, 39, 534-544.	0.8	6
663	Novel Therapies in the Treatment of Hodgkin Lymphoma. Current Treatment Options in Oncology, 2021, 22, 42.	1.3	5
664	Realâ€life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive Bâ€cell lymphomas. Hematological Oncology, 2021, 39, 336-348.	0.8	25
665	Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. Leukemia, 2021, 35, 3268-3271.	3.3	21
666	Monitoring of tisagenlecleucel transgene DNA using a quantitative polymerase chain reaction assay. Molecular Therapy - Methods and Clinical Development, 2021, 20, 535-541.	1.8	5
667	Chimeric Antigen Receptor T-Cell Therapy. Indian Journal of Medical and Paediatric Oncology, 2021, 42, 089-092.	0.1	0
668	Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals?. Cancers, 2021, 13, 1106.	1.7	16
669	Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 170-175.	0.2	17
670	Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy. Clinical and Experimental Immunology, 2021, 205, 1-11.	1.1	11
671	Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapy. Cellular Immunology, 2021, 361, 104277.	1.4	4
672	Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia. Cancers, 2021, 13, 1568.	1.7	21

#	Article	IF	Citations
673	Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)â€"T Cells. Cancers, 2021, 13, 1229.	1.7	12
674	Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management. Diseases (Basel, Switzerland), 2021, 9, 20.	1.0	19
675	The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2021, 27, 233-240.	0.6	24
676	Incorporating Novel Targeted and Immunotherapeutic Agents in the Treatment of B-Cell Lymphomas. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 310-327.	1.8	1
677	Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. Journal of Clinical Oncology, 2021, 39, 920-930.	0.8	110
678	Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. Frontiers in Oncology, 2021, 11, 648655.	1.3	19
679	Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy. Frontiers in Oncology, 2021, 11, 626818.	1.3	13
680	Adoptive TÂcell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4. Molecular Therapy - Oncolytics, 2021, 20, 387-398.	2.0	20
681	Predicting Outcomes following Anti-CD19 CAR T Cell Therapy in Aggressive B Cell Lymphomas. Transplantation and Cellular Therapy, 2021, 27, 195-196.	0.6	2
682	Post-CAR-T cell therapy presenting as proteinaceous lymphadenopathy. Human Pathology: Case Reports, 2021, 23, 200475.	0.2	0
683	T cell circuits that sense antigen density with an ultrasensitive threshold. Science, 2021, 371, 1166-1171.	6.0	99
684	The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28. Frontiers in Immunology, 2021, 12, 639818.	2.2	60
685	Cytokine release syndrome and neurological event costs in lisocabtagene maraleucelâ€"treated patients in the TRANSCEND NHL 001 trial. Blood Advances, 2021, 5, 1695-1705.	2.5	18
686	Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 2021, 384, 842-858.	13.9	388
687	Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies. Leukemia and Lymphoma, 2021, 62, 2052-2063.	0.6	16
688	2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. American Journal of Hematology, 2021, 96, 617-629.	2.0	145
689	Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: aÂsystematic review and meta-analysis. Immunotherapy, 2021, 13, 345-357.	1.0	6
690	Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?. Lancet Haematology,the, 2021, 8, e216-e228.	2.2	41

#	Article	IF	Citations
691	Cellular Therapy in Pediatric Hematologic Malignancies. Clinics in Laboratory Medicine, 2021, 41, 121-132.	0.7	2
692	Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. Bone Marrow Transplantation, 2021, 56, 1919-1928.	1.3	13
693	Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma. Expert Opinion on Biological Therapy, 2021, 21, 435-441.	1.4	43
694	Research advances in chimeric antigen receptor-modified T-cell therapy (Review). Experimental and Therapeutic Medicine, 2021, 21, 484.	0.8	1
696	Targeting loss of heterozygosity for cancer-specific immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	39
697	Phase I Clinical Trials in Adoptive T-Cell Therapies. Journal of the Royal Statistical Society Series C: Applied Statistics, 2021, 70, 815-834.	0.5	4
698	Novel immunotherapy in follicular lymphoma: a narrative review. Annals of Lymphoma, 0, 5, 9-9.	4.5	1
699	A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma. OncoTargets and Therapy, 2021, Volume 14, 2185-2201.	1.0	9
700	Narrative review: secondary central nervous system lymphoma. Annals of Lymphoma, 0, 5, 5-5.	4.5	2
701	Chimeric Antigen Receptorâ€“Modified Immune Effector Cell Therapies. Cancer Journal (Sudbury, Mass), 2021, 27, 90-91.	1.0	0
702	Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy. Journal of Immunology, 2021, 206, 1561-1568.	0.4	36
703	Chimeric antigen receptor T cell therapy in oncology â€“ Pipeline at a glance: Analysis of the ClinicalTrials.gov database. Critical Reviews in Oncology/Hematology, 2021, 159, 103239.	2.0	21
704	Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy. Seminars in Ophthalmology, 2021, 36, 329-334.	0.8	4
705	The Current Status of Gene Therapy for the Treatment of Cancer. Biologics: Targets and Therapy, 2021, Volume 15, 67-77.	3.0	55
706	Targeting a neoantigen derived from a common TP53 mutation. Science, 2021, 371, .	6.0	194
707	Relapsed/Refractory International Prognostic Index (R/<scp>Râ€IPI</scp>): An international prognostic calculator for relapsed/refractory diffuse large Bâ€cell lymphoma. American Journal of Hematology, 2021, 96, 599-605.	2.0	8
708	Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 242.e1-242.e6.	0.6	5
709	Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma. Therapeutics and Clinical Risk Management, 2021, Volume 17, 183-192.	0.9	1

#	Article	IF	Citations
710	A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Science Immunology, 2021, 6, .	5.6	105
711	Chimeric Antigen Receptor T Cells for B-Cell Lymphoma. Cancer Journal (Sudbury, Mass), 2021, 27, 107-111.	1.0	3
712	Is Adoptive Cellular Therapy With Nonâ€“T-Cell Immune Effectors the Future?. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10	1.0	1
713	Neurotoxicity Biology and Management. Cancer Journal (Sudbury, Mass), 2021, 27, 126-133.	1.0	7
714	Improving and Maintaining Responses in Pediatric Bâ€“Cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptorâ€“T Cell Therapy. Cancer Journal (Sudbury, Mass), 2021, 27, 151-158.	1.0	0
715	CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus. Cancers, 2021, 13, 1050.	1.7	17
716	Post-Transplant Cyclophosphamide and Tacrolimusâ€”Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. Journal of Clinical Medicine, 2021, 10, 1173.	1.0	10
717	Detection of <scp>CARâ€T19</scp> cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories. Cytometry Part B - Clinical Cytometry, 2021, 100, 622-631.	0.7	6
718	Perspectives in membranous nephropathy. Cell and Tissue Research, 2021, 385, 405-422.	1.5	16
719	What is CAR T-cell therapy?. Drug and Therapeutics Bulletin, 2021, 59, 73-76.	0.3	2
720	Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia. Clinical Cancer Research, 2021, 27, 3549-3555.	3.2	51
721	Vector engineering, strategies and targets in cancer gene therapy. Cancer Gene Therapy, 2022, 29, 402-417.	2.2	18
723	CAR-T cell persistence in the treatment of leukemia and lymphoma. Leukemia and Lymphoma, 2021, 62, 2587-2599.	0.6	13
724	Antibodies to vaccine-preventable infections after CAR-T-cell therapy for B-cell malignancies. JCI Insight, 2021, 6, .	2.3	18
725	Industrializing engineered autologous T cells as medicines for solid tumours. Nature Reviews Drug Discovery, 2021, 20, 476-488.	21.5	12
726	Personalized patient care with aggressive hematological malignancies in non-responders to first-line treatment. Expert Review of Precision Medicine and Drug Development, 2021, 6, 203-215.	0.4	2
727	CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells. Clinical Cancer Research, 2021, 27, 5951-5960.	3.2	12
728	Recent progress in the treatment of cancer in children. Ca-A Cancer Journal for Clinicians, 2021, 71, 315-332.	157.7	43

#	Article	IF	Citations
729	Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas. Blood Research, 2021, 56, S1-S4.	0.5	4
730	Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. Cancers, 2021, 13, 1781.	1.7	17
731	Chimeric Antigen Receptorâ€"Modified T Cells and T Cellâ€"Engaging Bispecific Antibodies: Different Tools for the Same Job. Current Hematologic Malignancy Reports, 2021, 16, 218-233.	1.2	4
732	Reactions Related to CAR-T Cell Therapy. Frontiers in Immunology, 2021, 12, 663201.	2.2	54
733	Therapeutic cancer vaccines. Nature Reviews Cancer, 2021, 21, 360-378.	12.8	630
734	Immunotherapy to get on point with base editing. Drug Discovery Today, 2021, 26, 2350-2357.	3.2	4
735	A Systematic Review of the Role of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in the Treatment of Solid Tumors. Cureus, 2021, 13, e14494.	0.2	6
736	Mechanisms of response and resistance to CAR T cell therapies. Current Opinion in Immunology, 2021, 69, 56-64.	2.4	18
737	Quality of life in caregivers of patients receiving chimeric antigen receptor Tâ€cell therapy. Psycho-Oncology, 2021, 30, 1294-1301.	1.0	6
738	Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. Journal of Hematology and Oncology, 2021, 14, 66.	6.9	35
739	Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study. Neuro-Oncology, 2021, 23, 1569-1575.	0.6	20
740	Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies. Frontiers in Immunology, 2021, 12, 609762.	2.2	23
741	Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia. , 2021, 9, e002056.		52
742	The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor Tâ€cell therapy. British Journal of Haematology, 2021, 193, 1060-1075.	1.2	13
743	Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center. Leukemia and Lymphoma, 2021, 62, 2288-2291.	0.6	1
744	Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy. Biologics: Targets and Therapy, 2021, Volume 15, 95-105.	3.0	33
745	Diffuse large B-cell lymphoma: new targets and novel therapies. Blood Cancer Journal, 2021, 11, 68.	2.8	41
746	Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma. Blood Advances, 2021, 5, 2245-2255.	2.5	16

#	Article	IF	Citations
749	Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients. ACS Synthetic Biology, 2021, 10, 1184-1198.	1.9	9
750	Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma. Cancers, 2021, 13, 1684.	1.7	17
751	Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. Future Oncology, 2021, 17, 1269-1283.	1.1	20
752	Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences, 2021, 22, 5536.	1.8	17
753	Design of TCR Structural Variants That Retain or Invert the Normal Activation Signal. ImmunoHorizons, 2021, 5, 349-359.	0.8	3
754	Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications. Frontiers in Immunology, 2021, 12, 658314.	2.2	28
755	Cardiovascular Toxicities of CAR T-cell Therapy. Current Oncology Reports, 2021, 23, 78.	1.8	10
756	Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy. Frontiers in Oncology, 2021, 11, 664688.	1.3	10
757	Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. Cancers, 2021, 13, 2712.	1.7	13
758	T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. Journal of Clinical Oncology, 2021, 39, 1415-1425.	0.8	30
759	Current Treatment Options in CLL. Cancers, 2021, 13, 2468.	1.7	20
760	T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia, 2021, 35, 1843-1863.	3.3	123
761	The era of CD19-directed therapy in diffuse large B-cell lymphoma. Lancet Oncology, The, 2021, 22, 741-742.	5.1	3
762	Emerging biological therapies for the treatment of malignant pleural mesothelioma. Expert Opinion on Emerging Drugs, 2021, 26, 179-192.	1.0	3
764	CAR-T failure: beyond antigen loss and T cells. Blood, 2021, 137, 2567-2568.	0.6	12
765	Realâ€world evidence of tisagenlecleucel for the treatment of relapsed or refractory large Bâ€cell lymphoma. Cancer Medicine, 2021, 10, 3214-3223.	1.3	73
767	A new warhead in lymphoma therapy?. Blood, 2021, 137, 2568-2570.	0.6	1
768	Proven and unproven cell therapies â€“ what we have learned so far?. ISBT Science Series, 2021, 16, 213-218.	1.1	2

#	Article	IF	Citations
769	Heart Failure With Targeted Cancer Therapies. Circulation Research, 2021, 128, 1576-1593.	2.0	33
770	IQGAP2 acts as an independent prognostic factor and is related to immunosuppression in DLBCL. BMC Cancer, 2021, 21, 603.	1.1	7
771	CAR T-Cells for CNS Lymphoma: Driving into New Terrain?. Cancers, 2021, 13, 2503.	1.7	15
772	Two Cases of Pancytopenia with Coombs-Negative Hemolytic Anemia after Chimeric Antigen Receptor T-Cell Therapy. International Journal of Molecular Sciences, 2021, 22, 5449.	1.8	3
774	CAR T cells â€“ the future for cancer therapy. Medicine, 2021, 49, 322-324.	0.2	0
775	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. Circulation Research, 2021, 128, 1780-1801.	2.0	48
776	CAR T cells for T-cell leukemias: Insights from mathematical models. Communications in Nonlinear Science and Numerical Simulation, 2021, 96, 105684.	1.7	16
777	Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. Journal of Hematology and Oncology, 2021, 14, 73.	6.9	135
778	The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome. BMC Cancer, 2021, 21, 500.	1.1	5
779	A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells. Cellular Immunology, 2021, 363, 104342.	1.4	11
780	Advances in Cellular Immunotherapy in Hematologic Malignancies. Advances in Oncology, 2021, 1, 223-236.	0.1	0
781	Treatment resistance in diffuse large B-cell lymphoma. Leukemia, 2021, 35, 2151-2165.	3.3	44
782	An unmet need: Harmonization of IL-7 and IL-15 combination for the ex vivo generation of minimally differentiated T cells. Cellular Immunology, 2021, 363, 104314.	1.4	5
783	From VAD to VRD. Cancer Journal (Sudbury, Mass), 2021, 27, 190-195.	1.0	1
784	Advances in Management for Older Adults With Hematologic Malignancies. Journal of Clinical Oncology, 2021, 39, 2102-2114.	0.8	24
785	Ibrutinib improves the efficacy of antiâ€CD19â€CAR Tâ€cell therapy in patients with refractory nonâ€Hodgkin lymphoma. Cancer Science, 2021, 112, 2642-2651.	1.7	23
786	Graftâ€versusâ€host disease risk after chimeric antigen receptor Tâ€cell therapy: the diametric opposition of T cells. British Journal of Haematology, 2021, 195, 660-668.	1.2	37
787	Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Reviews Immunology, 2022, 22, 85-96.	10.6	315

#	Article	IF	Citations
788	Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood, 2021, 137, 2621-2633.	0.6	137
789	Are chimeric antigen receptor T cells (CAR-T cells) the future in immunotherapy for autoimmune diseases?. Inflammation Research, 2021, 70, 651-663.	1.6	7
790	Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 295-308.	0.2	0
791	How Can We Engineer CAR T Cells to Overcome Resistance?. Biologics: Targets and Therapy, 2021, Volume 15, 175-198.	3.0	8
792	PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report. Frontiers in Immunology, 2021, 12, 599493.	2.2	8
793	A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma. Frontiers in Oncology, 2021, 11, 664421.	1.3	20
794	Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland. Advances in Therapy, 2021, 38, 3427-3443.	1.3	14
795	Liquid biopsy in lymphoma: Is it primed for clinical translation?. EJHaem, 2021, 2, 616-627.	0.4	6
796	Prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy: A cross-sectional study. Journal of Affective Disorders, 2021, 286, 33-39.	2.0	6
797	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncology, The, 2021, 22, 790-800.	5.1	211
798	The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy. Frontiers in Immunology, 2021, 12, 670286.	2.2	16
799	New drugs and pharmacological interactions in real life. Hematological Oncology, 2021, 39, 78-82.	0.8	0
800	Adverse events reported to the U.S. Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel. American Journal of Hematology, 2021, 96, 1087-1100.	2.0	3
801	Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health. JCO Clinical Cancer Informatics, 2021, 5, 668-678.	1.0	20
803	Taking a BiTE out of the CAR T space race. British Journal of Haematology, 2021, 195, 689-697.	1.2	5
804	Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success. Cancers, 2021, 13, 2816.	1.7	8
805	CAR-HEMATOTOX: a model for CAR T-cellâ€“related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood, 2021, 138, 2499-2513.	0.6	160
806	Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments. Current Hematologic Malignancy Reports, 2021, 16, 345-356.	1.2	21

#	Article	IF	Citations
807	Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions. International Journal of Hematologic Oncology, 2021, 10, IJH33.	0.7	11
808	Engineered Cytokine Signaling to Improve CAR T Cell Effector Function. Frontiers in Immunology, 2021, 12, 684642.	2.2	57
809	FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Oncologist, 2021, 26, 879-886.	1.9	20
810	CAR T-Cell Therapy: An Update for Radiologists. American Journal of Roentgenology, 2021, 217, 1461-1474.	1.0	20
811	Barriers to antibody therapy in solid tumors, and their solutions. Cancer Science, 2021, 112, 2939-2947.	1.7	13
812	Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma. Clinical Pharmacokinetics, 2021, 60, 1621-1633.	1.6	25
813	Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood, 2021, 137, 3454-3459.	0.6	4
814	CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e246-e265.	1.8	27
815	Spacer Length Modification Facilitates Discrimination between Normal and Neoplastic Cells and Provides Clinically Relevant CD37 CAR T Cells. Journal of Immunology, 2021, 206, 2862-2874.	0.4	4
817	MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy. , 2021, 9, e002029.		4
818	Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches. Journal of Medicinal Chemistry, 2021, 64, 9577-9591.	2.9	19
819	Engineering Gene Therapy: Advances and Barriers. Advanced Therapeutics, 2021, 4, 2100040.	1.6	23
820	Glofitamab, a Novel, Bivalent CD20-Targeting T-Cellâ€“Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. Journal of Clinical Oncology, 2021, 39, 1959-1970.	0.8	228
821	Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. Cancers, 2021, 13, 2782.	1.7	21
822	Lisocabtagene Maraleucel for the treatment of B-cell lymphoma. Expert Opinion on Biological Therapy, 2021, 21, 1151-1156.	1.4	4
823	The â€œMagic Bulletâ€• Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. Cells, 2021, 10, 1511.	1.8	3
824	Multidisciplinary Management of Adolescent and Young Adult Patients with Hodgkin Lymphoma. Current Treatment Options in Oncology, 2021, 22, 64.	1.3	3
825	T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. Journal of Hematology and Oncology, 2021, 14, 102.	6.9	64

#	Article	IF	Citations
826	Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells inÂvivo. Molecular Therapy - Methods and Clinical Development, 2021, 21, 237-246.	1.8	20
827	Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells. Clinical Nuclear Medicine, 2021, 46, 627-634.	0.7	25
828	Multifaceted Role of the Transforming Growth Factor Î² on Effector T Cells and the Implication for CAR-T Cell Therapy. Immuno, 2021, 1, 160-173.	0.6	4
829	MRI Guided Focused Ultrasound-Mediated Delivery of Therapeutic Cells to the Brain: A Review of the State-of-the-Art Methodology and Future Applications. Frontiers in Neurology, 2021, 12, 669449.	1.1	12
830	Chimeric antigen receptor <scp>T</scp>â€cells safety: A pharmacovigilance and metaâ€analysis study. American Journal of Hematology, 2021, 96, 1101-1111.	2.0	14
831	Immunotherapy in the treatment of lymphoma. World Journal of Stem Cells, 2021, 13, 503-520.	1.3	3
832	CAR-based cell therapy: evaluation with bibliometrics and patent analysis. Human Vaccines and Immunotherapeutics, 2021, 17, 4374-4382.	1.4	2
833	Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4Âyears. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	1.2	0
834	Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma. Leukemia, 2021, 35, 3581-3584.	3.3	13
835	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2ndâ€“3rd,) Tj ETQq1 1 0.784314 rgBT /Ov	1.8	1
836	New targets for CAR T therapy in hematologic malignancies. Best Practice and Research in Clinical Haematology, 2021, 34, 101277.	0.7	9
837	A Mathematical Description of the Bone Marrow Dynamics during CAR T-Cell Therapy in B-Cell Childhood Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, 2021, 22, 6371.	1.8	8
838	CAR T-Cell Therapy: Updates in Nursing Management. Clinical Journal of Oncology Nursing, 2021, 25, 255-258.	0.3	6
839	A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. Frontiers in Immunology, 2021, 12, 681984.	2.2	32
840	Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting. Blood Advances, 2021, 5, 2523-2527.	2.5	19
841	Avoiding Stops and Overcoming Roadblocks: Considerations for Improving Patient Access to CAR-Based Cell Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e100-e104.	1.8	17
842	Optimizing CAR T cell therapy in lymphoma. Hematological Oncology, 2021, 39, 104-112.	0.8	10
843	Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge. , 2022, 229, 107924.		7

#	Article	IF	Citations
844	Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome. Leukemia and Lymphoma, 2021, 62, 2600-2611.	0.6	9
845	CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities. Frontiers in Immunology, 2021, 12, 693016.	2.2	45
846	Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. Blood, 2021, 137, 3145-3148.	0.6	70
847	Inmunoterapia en oncologÃa de las vÃas aerodigestivas superiores. EMC - OtorrinolaringologÃa, 2021, 50, 1-20.	0.0	0
848	Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review. Frontiers in Immunology, 2021, 12, 693200.	2.2	8
849	The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy. Biologics: Targets and Therapy, 2021, Volume 15, 265-277.	3.0	10
850	Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. Annals of Hematology, 2021, 100, 2303-2310.	0.8	32
851	Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1145-1154.	0.4	29
852	Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors. Bone Marrow Transplantation, 2021, 56, 2630-2636.	1.3	11
853	Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient. Kidney Medicine, 2021, 3, 665-668.	1.0	10
854	Glofitamab CD20-TCB bispecific antibody. Leukemia and Lymphoma, 2021, 62, 1-11.	0.6	11
855	Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder. Frontiers in Oncology, 2021, 11, 709370.	1.3	11
856	Non-viral transfection technologies for next-generation therapeutic T cell engineering. Biotechnology Advances, 2021, 49, 107760.	6.0	33
857	Optimization of lymphapheresis for manufacturing autologous CAR-T cells. International Journal of Hematology, 2021, 114, 449-458.	0.7	6
858	Immunotherapies in Non-Hodgkinâ€™s Lymphoma. Cancers, 2021, 13, 3625.	1.7	5
859	Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Biomarker Research, 2021, 9, 58.	2.8	22
860	Advances in Immunotherapy for Diffuse Large B Cell Lymphoma. BioDrugs, 2021, 35, 517-528.	2.2	1
861	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 2021, 27, 1419-1431.	15.2	273

#	Article	IF	Citations
863	A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nature Reviews Clinical Oncology, 2021, 18, 715-727.	12.5	136
865	Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 698607.	1.3	25
866	Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1â€“2 trial. Leukemia, 2022, 36, 189-196.	3.3	45
867	The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. Blood Cancer Journal, 2021, 11, 124.	2.8	9
868	Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Advances, 2021, 5, 2707-2716.	2.5	55
869	Access to Chimeric Antigen Receptor TÂCell Therapy for Diffuse Large BÂCell Lymphoma. Advances in Therapy, 2021, 38, 4659-4674.	1.3	10
870	Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. , 2021, 9, e002723.		92
871	Chimeric antigen receptor Tâ€'cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges. Voprosy Onkologii, 2021, 67, 350-360.	0.1	2
872	A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma. Translational Oncology, 2021, 14, 101085.	1.7	21
873	CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. Cancer Immunology Research, 2021, 9, 1061-1070.	1.6	37
874	Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients â€“ a matched control multicenter cohort study. Haematologica, 2022, 107, 1111-1118.	1.7	25
875	CAR T and other Adoptive Cell Therapies for B-cell Malignancies. Journal of the National Cancer Center, 2021, , .	3.0	4
876	Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 861-872.	0.2	13
877	Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration. Transplantation and Cellular Therapy, 2021, 27, 558-570.	0.6	36
878	Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica, 2021, 106, 2417-2426.	1.7	81
879	Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. Cancer Immunology Research, 2021, 9, 1035-1046.	1.6	14
880	Outcomes of Richterâ€™s transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database. Annals of Hematology, 2021, 100, 2513-2519.	0.8	23
881	Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy. Journal of Hematology and Oncology, 2021, 14, 106.	6.9	22

#	Article	IF	Citations
882	Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*. Critical Care Medicine, 2022, 50, 81-92.	0.4	13
883	Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment. Frontiers in Oncology, 2021, 11, 702642.	1.3	21
884	Travel-Related Economic Burden of Chimeric Antigen Receptor TÂCell Therapy Administration by Site of Care. Advances in Therapy, 2021, 38, 4541-4555.	1.3	10
885	Toxicity of Immunotherapeutic Agents. Critical Care Clinics, 2021, 37, 605-624.	1.0	2
886	Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk. Frontiers in Oncology, 2021, 11, 706087.	1.3	8
887	Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma. Blood Cancer Journal, 2021, 11, 131.	2.8	28
888	Toxicities associated with adoptive cellular therapies. Best Practice and Research in Clinical Haematology, 2021, 34, 101287.	0.7	9
889	18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Molecular Imaging and Biology, 2021, 23, 818-826.	1.3	8
890	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet, The, 2021, 398, 314-324.	6.3	711
891	Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma. Journal of Blood Medicine, 2021, Volume 12, 775-783.	0.7	12
892	T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances. Cancers, 2021, 13, 4274.	1.7	0
895	Tisagenlecleucel Therapy: Nursing Considerations for the Outpatient Setting. Seminars in Oncology Nursing, 2021, 37, 151178.	0.7	7
896	Chimeric antigen receptor T-cells (CARs) in cancer treatment. Current Molecular Pharmacology, 2021, 14, .	0.7	1
897	Immunomodulatory Drugs for the Treatment of B Cell Malignancies. International Journal of Molecular Sciences, 2021, 22, 8572.	1.8	22
898	Engineering-enhanced CAR T cells for improved cancer therapy. Nature Cancer, 2021, 2, 780-793.	5.7	60
899	Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?. Journal of Immunotherapy and Precision Oncology, 2021, 4, 150-159.	0.6	11
900	Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma. Frontiers in Oncology, 2021, 11, 713577.	1.3	27
901	A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. Leukemia and Lymphoma, 2022, 63, 117-123.	0.6	5

#	Article	IF	Citations
902	The Current and Future Role of Radiation Therapy in the Era of CAR T-cell Salvage. British Journal of Radiology, 2021, 94, 20210098.	1.0	10
903	Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. , 2021, 9, e002303.		16
904	Advances in CAR design. Best Practice and Research in Clinical Haematology, 2021, 34, 101304.	0.7	4
905	Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997â€“2020). Healthcare (Switzerland), 2021, 9, 1062.	1.0	22
906	The role of the hospital pharmacist in immunocellular therapy with chimeric antigen receptor (CAR) T cells. Drugs and Therapy Perspectives, 2021, 37, 433-438.	0.3	1
907	Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults. Leukemia and Lymphoma, 2021, 62, 3333-3347.	0.6	2
908	Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 928-934.	2.3	14
909	RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2021, 27, 6124-6134.	3.2	24
910	Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Advances, 2021, 5, 3397-3406.	2.5	59
911	TGF-Î²/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma. International Journal of Molecular Sciences, 2021, 22, 8706.	1.8	16
912	Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope. Frontiers in Pharmacology, 2021, 12, 720692.	1.6	20
913	Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy. Cancers, 2021, 13, 4279.	1.7	20
914	Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Blood Advances, 2021, 5, 4980-4991.	2.5	12
915	A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients. Value in Health, 2022, 25, 47-58.	0.1	6
917	A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2022, 63, 74-83.	0.6	4
918	Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T). Cmaj, 2021, 193, E1300-E1302.	0.9	2
919	Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy. Blood Cancer Discovery, 2021, 2, 408-422.	2.6	84
920	Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Advances, 2021, 5, 2982-2986.	2.5	45

#	Article	IF	Citations
921	Collapsing Focal Segmental Glomerulosclerosis and Acute Kidney Injury Associated With Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Case Report. Kidney Medicine, 2021, 3, 1086-1090.	1.0	8
923	Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States. Clinical Therapeutics, 2021, 43, 1300-1319.e8.	1.1	18
924	Drug interaction (51. New oral anticancer drugs in hematological malignancies and drug) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 662 Td (	0.0	0
925	Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities. Journal of Hematology and Oncology, 2021, 14, 125.	6.9	42
926	Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses. Current Hematologic Malignancy Reports, 2021, 16, 384-393.	1.2	4
927	Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-Î´ and â€“Î³. Frontiers in Immunology, 2021, 12, 718621.	2.2	16
928	Salvage radiotherapy for primary refractory and relapsed diffuse large B-Cell lymphoma. British Journal of Radiology, 2021, 94, 20210360.	1.0	2
929	CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas. Transplantation and Cellular Therapy, 2021, 27, 910.e1-910.e11.	0.6	26
930	Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report. Anti-Cancer Drugs, 2022, 33, e769-e775.	0.7	5
931	CAR T cells: Building on the CD19 paradigm. European Journal of Immunology, 2021, 51, 2151-2163.	1.6	43
932	Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving â‰¥3 therapy lines in post-CAR-T era. Current Medical Research and Opinion, 2021, 37, 1789-1798.	0.9	3
933	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. , 2021, 9, e002287.		24
934	Targeted immunotherapies to consider for B Cell non-hodgkin lymphoma. Expert Review of Precision Medicine and Drug Development, 2021, 6, 317-332.	0.4	0
935	On the road to eliminating longâ€lived plasma cellsâ€”â€œare we there yet?â€• Immunological Reviews, 2021, 303, 154-167.	2.8	13
936	Advances in treatment of elderly primary central nervous system lymphoma. British Journal of Haematology, 2022, 196, 473-487.	1.2	10
937	Engineering the next generation of CAR-NK immunotherapies. International Journal of Hematology, 2021, 114, 554-571.	0.7	37
938	Production and Application of CAR T Cells: Current and Future Role of Europe. Frontiers in Medicine, 2021, 8, 713401.	1.2	15
939	Efficacy and safety of <scp>CD19</scp>â€directed <scp>CARâ€T</scp> cell therapies in patients with relapsed/refractory aggressive Bâ€cell lymphomas: Observations from the <scp>JULIET</scp>, <scp>ZUMA</scp>â€1, and <scp>TRANSCEND</scp> trials. American Journal of Hematology, 2021, 96, 1295-1312.	2.0	107

#	Article	IF	Citations
940	Janus Kinase Inhibitors and Cell Therapy. Frontiers in Immunology, 2021, 12, 740847.	2.2	4
941	The Agony of Choiceâ€"Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond. Cancers, 2021, 13, 4701.	1.7	6
942	CAR T-cell Therapy in Indolent Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S178-S179.	0.2	0
943	Monitoring and safety of CAR-T therapy in clinical practice. Expert Opinion on Drug Safety, 2022, 21, 363-371.	1.0	0
944	Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Advances, 2021, 5, 4149-4155.	2.5	42
945	[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 953-962.	3.3	27
946	Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. Nature Communications, 2021, 12, 5271.	5.8	17
947	Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy. Cell Discovery, 2021, 7, 84.	3.1	16
948	Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells. Blood Reviews, 2021, 51, 100884.	2.8	1
949	The impact of bridging therapy prior to CD19â€directed chimeric antigen receptor Tâ€cell therapy in patients with large Bâ€cell lymphoma. British Journal of Haematology, 2021, 195, 405-412.	1.2	10
950	The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas. Cancers, 2021, 13, 4683.	1.7	9
951	The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group. Current Oncology, 2021, 28, 3649-3658.	0.9	0
952	Defining and treating high-grade B-cell lymphoma, NOS. Blood, 2022, 140, 943-954.	0.6	19
953	Willingness to Travel for Cellular Therapy: The Influence of Follow-Up Care Location, Oncologist Continuity, and Race. JCO Oncology Practice, 2022, 18, e193-e203.	1.4	0
955	HIV-associated lymphomaâ€"advances in clinical management. Annals of Lymphoma, 0, 5, 26-26.	4.5	4
956	Characteristics and recognition of early infections in patients treated with commercial antiâ€CD19 CARâ€T cells. European Journal of Haematology, 2022, 108, 52-60.	1.1	10
957	CAR T-cell therapy for secondary CNS DLBCL. Blood Advances, 2021, 5, 5626-5630.	2.5	41
958	Establishing a robust chimeric antigen receptor T-cell therapy program in Australia: the Royal Prince Alfred Hospital experience. Cytotherapy, 2022, 24, 45-48.	0.3	2

#	Article	IF	Citations
959	Refractory DLBCL: Challenges and Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 140-148.	0.2	8
960	CD3xCD20 bispecific T-cell redirectors for relapsed or refractory B-cell lymphoma. Lancet, The, 2021, 398, 1109-1110.	6.3	2
961	Immunotherapy of Multiple Myeloma: Promise and Challenges. ImmunoTargets and Therapy, 2021, Volume 10, 343-371.	2.7	11
962	The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies. HemaSphere, 2021, 5, e642.	1.2	2
963	Optimizing outcomes in primary mediastinal B-Cell lymphoma: is R-CHOP enough?. Blood Advances, 2021, 5, 3873-3875.	2.5	1
964	Hematopathologic Correlates of CAR T-Cell Therapy. Clinics in Laboratory Medicine, 2021, 41, 325-339.	0.7	3
965	The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL â€“ Results From the Phase-II STORM Trial. HemaSphere, 2021, 5, e636.	1.2	7
966	Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review. Frontiers in Oncology, 2021, 11, 726134.	1.3	9
967	Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Advances, 2021, 5, 4465-4475.	2.5	28
968	Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 768.e1-768.e6.	0.6	4
969	Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. Journal of Hematology and Oncology, 2021, 14, 140.	6.9	24
970	Advances in mRNA-based drug discovery in cancer immunotherapy. Expert Opinion on Drug Discovery, 2022, 17, 41-53.	2.5	17
971	State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses. Transplantation and Cellular Therapy, 2021, 27, 973-987.	0.6	25
972	Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. Cancers, 2021, 13, 4797.	1.7	12
973	Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience. Cancers, 2021, 13, 4789.	1.7	18
974	Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy. Clinical Lung Cancer, 2022, 23, 14-20.	1.1	4
975	Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cellsâ€"Report on Two Cases. Frontiers in Oncology, 2021, 11, 737645.	1.3	4
976	The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell, 2021, 39, 1422-1437.e10.	7.7	102

#	Article	IF	Citations
977	Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. The Cochrane Library, 2021, 2021, CD013365.	1.5	18
978	CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Advances, 2021, 5, 4059-4063.	2.5	62
979	Is Prophylaxis the Only Way Out for Cytokine Release Syndrome Associated With Chimeric Antigen T-cell Therapy?. Cureus, 2021, 13, e17709.	0.2	2
980	Impact of Radiation Therapy After High Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Lymphomas: A Single Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e149-e160.	0.2	3
981	Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma. Expert Opinion on Biological Therapy, 2021, 21, 1373-1381.	1.4	4
982	Clinical translation of immunomodulatory therapeutics. Advanced Drug Delivery Reviews, 2021, 176, 113896.	6.6	8
983	Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study. Immunotherapy, 2021, 13, 1261-1269.	1.0	3
984	The promise and perils of immunotherapy. Blood Advances, 2021, 5, 3709-3725.	2.5	23
985	NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity. Blood Cancer Discovery, 2021, 2, 648-665.	2.6	37
986	CAR T-Cell Therapies in Mantle Cell Lymphoma, Hints of Cure. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S189-S191.	0.2	2
987	Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. Cell Stem Cell, 2021, 28, 2062-2075.e5.	5.2	80
988	Sequential different B-cell antigenâ€“targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma. Blood Advances, 2022, 6, 717-730.	2.5	22
989	Identifying and managing CAR T-cellâ€“mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team. Expert Opinion on Biological Therapy, 2022, 22, 407-421.	1.4	1
990	Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.6	2
991	An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies. Blood Advances, 2021, 5, 5060-5071.	2.5	9
992	Tumor microenvironment of follicular lymphoma. Annals of Lymphoma, 0, 5, 28-28.	4.5	2
993	Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors. Human Gene Therapy, 2021, 32, 1011-1028.	1.4	14
994	Diffuse large Bâ€cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal, 2022, 52, 1609-1623.	0.5	6

#	Article	IF	Citations
995	CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?. Cancers, 2021, 13, 4664.	1.7	10
996	The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis. Annals of Hematology, 2021, 100, 2733-2744.	0.8	7
997	Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?. Cytotherapy, 2021, 23, 985-990.	0.3	12
998	Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood, 2022, 139, 1026-1038.	0.6	67
999	â€˜Le Roi est mort, vive le Roiâ€™: new roles of radiotherapy in the treatment of lymphomas in combination with immunotherapy.. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	5
1000	CAR T cells for the long run in aggressive B-cell lymphoma. Lancet Oncology, The, 2021, 22, 1347-1348.	5.1	0
1001	Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncology, The, 2021, 22, 1403-1415.	5.1	222
1002	Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma. International Journal of Clinical Oncology, 2022, 27, 213-223.	1.0	10
1003	Genome editing in large animal models. Molecular Therapy, 2021, 29, 3140-3152.	3.7	18
1004	Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives. Cancer Treatment Reviews, 2021, 100, 102288.	3.4	9
1005	Comparison of therapeutic strategies for immuno-oncology. , 2022, , 439-461.		0
1006	Cellular Therapy. Organ and Tissue Transplantation, 2021, , 741-761.	0.0	0
1007	Safety and Efficacy of Polatuzumab Vedotin + Obinutuzumab for Relapsed/Refractory NHL: A Phase 1b/2 Study. SSRN Electronic Journal, 0, , .	0.4	0
1008	Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome. Molecular Cancer, 2021, 20, 5.	7.9	12
1009	Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis. Cancers, 2021, 13, 197.	1.7	20
1010	In vitro OP9-DL1 co-culture and subsequent maturation in the presence of IL-21 generates tumor antigen-specific T cells with a favorable less-differentiated phenotype and enhanced functionality. OncoImmunology, 2021, 10, 1954800.	2.1	3
1011	High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy. Clinical Hematology International, 2021, 3, 96.	0.7	7
1012	Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. Cancers, 2021, 13, 271.	1.7	39

#	Article	IF	Citations
1013	CAR T Cells for Hematologic Malignancies. , 2021, , 829-846.		0
1015	Future Developments: Immunotherapy in AML. Hematologic Malignancies, 2021, , 339-347.	0.2	0
1016	Beyond the storm â€" subacute toxicities and late effects in children receiving CAR T cells. Nature Reviews Clinical Oncology, 2021, 18, 363-378.	12.5	37
1017	Infectious complications of CAR T-cell therapy: a clinical update. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110367.	1.1	28
1018	Engineering T Cells Using CRISPR/Cas9 for Cancer Therapy. Methods in Molecular Biology, 2020, 2115, 419-433.	0.4	8
1019	Chimeric Antigen Receptor (CAR) T Cell Therapy for Cancer. Challenges and Opportunities: An Overview. Methods in Molecular Biology, 2021, 2174, 219-244.	0.4	7
1021	CAR T-Cells. Advances in Experimental Medicine and Biology, 2020, 1244, 215-233.	0.8	24
1022	Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. Journal of Gastroenterology, 2020, 55, 369-382.	2.3	48
1023	Response to Letter to Editor Regarding â€œComparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphomaâ€• Biology of Blood and Marrow Transplantation, 2020, 26, e335-e336.	2.0	4
1025	Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 108, 178-188.	0.4	60
1026	CAR T-cell product performance in haematological malignancies before and after marketing authorisation. Lancet Oncology, The, 2020, 21, e104-e116.	5.1	57
1027	Building better CAR-T therapies. Nature, 2020, 585, S4-S6.	13.7	3
1028	Identification of gene modules associated with survival of diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. Pharmacogenomics Journal, 2020, 20, 705-716.	0.9	11
1029	Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. Leukemia and Lymphoma, 2021, 62, 1344-1352.	0.6	7
1030	Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospitalâ€™s perspective. Journal of Medical Economics, 2020, 23, 1016-1024.	1.0	9
1031	Immunotherapies and immunomodulatory approaches in clinical trials - a mini review. Human Vaccines and Immunotherapeutics, 2021, 17, 1897-1909.	1.4	23
1033	Boosting engineered T cells. Science, 2019, 365, 119-120.	6.0	10
1034	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11

#	Article	IF	Citations
1035	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
1036	Optimized Doxorubicin Chemotherapy for Diffuse Large B-cell Lymphoma Exploits Nanocarrier Delivery to Transferrin Receptors. Cancer Research, 2021, 81, 763-775.	0.4	13
1037	A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy. Cancer Discovery, 2021, 11, 599-613.	7.7	90
1038	Comparison of CAR-T19 and autologous stem cell transplantation for refractory/relapsed non-Hodgkinâ€™s lymphoma. JCI Insight, 2019, 4, .	2.3	14
1039	Heme oxygenase-1 orchestrates the immunosuppressive program of tumor-associated macrophages. JCI Insight, 2020, 5, .	2.3	32
1040	Immunotherapy of lymphomas. Journal of Clinical Investigation, 2020, 130, 1576-1585.	3.9	32
1041	State of the art in CAR T cell therapy for CD19+ B cell malignancies. Journal of Clinical Investigation, 2020, 130, 1586-1594.	3.9	74
1042	Killers 2.0: NK cell therapies at the forefront of cancer control. Journal of Clinical Investigation, 2019, 129, 3499-3510.	3.9	166
1043	Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability. Journal of Clinical Investigation, 2020, 130, 3087-3097.	3.9	110
1044	Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease. Journal of Clinical Investigation, 2020, 130, 4652-4662.	3.9	27
1045	Replacing CAR-T cell resistance with persistence by changing a single residue. Journal of Clinical Investigation, 2020, 130, 2806-2808.	3.9	10
1046	Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. Journal of Clinical Investigation, 2020, 130, 6317-6324.	3.9	66
1047	Sleeping Beautyâ€“engineered CAR T cells achieve antileukemic activity without severe toxicities. Journal of Clinical Investigation, 2020, 130, 6021-6033.	3.9	102
1048	Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas. Therapeutic Advances in Hematology, 2020, 11, 204062072090289.	1.1	13
1049	Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy. Blood, 2020, 136, 516-519.	0.6	25
1050	Indolent lymphomas: pushing the pace with novel agents. Hematology American Society of Hematology Education Program, 2019, 2019, 279-286.	0.9	1
1051	Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma. Hematology American Society of Hematology Education Program, 2020, 2020, 487-493.	0.9	6
1052	PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. European Radiology Experimental, 2020, 4, 63.	1.7	38

#	Article	IF	Citations
1053	New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies. F1000Research, 2019, 8, 1202.	0.8	3
1054	A multivariate, quantitative assay that disentangles key kinetic parameters of primary human T cell function in vitro. PLoS ONE, 2020, 15, e0241421.	1.1	3
1055	Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine. Oncotarget, 2020, 11, 4045-4073.	0.8	12
1056	Gene Therapy in the Management of Parkinsonâ€™s Disease: Potential of GDNF as a Promising Therapeutic Strategy. Current Gene Therapy, 2020, 20, 207-222.	0.9	9
1057	A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma. Immunotherapy, 2020, 12, 681-696.	1.0	14
1058	Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies. Immunotherapy, 2020, 12, 1341-1357.	1.0	3
1059	Complete response to pixantrone as a salvage therapy in a relapsed/refractory diffuse large B-cell lymphoma. OnCOReview, 2020, 10, 62-68.	0.1	2
1060	A brief history of CAR-T cells: from laboratory to the bedside. Acta Haematologica Polonica, 2020, 51, 2-5.	0.1	32
1061	CAR-T cell therapy â€“ toxicity and its management. Acta Haematologica Polonica, 2020, 51, 6-10.	0.1	4
1062	Road to clinical implementation of CAR-T technology in PoznaÅ„. Acta Haematologica Polonica, 2020, 51, 24-28.	0.1	4
1063	Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies. Clinical Hematology International, 2019, 1, 79.	0.7	15
1064	Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia. Clinical Hematology International, 2019, 1, 94-100.	0.7	5
1065	CART Cell Toxicities: New Insight into Mechanisms and Management. Clinical Hematology International, 2020, 2, 149.	0.7	19
1066	A prognostic index predicting survival in transformed WaldenstrÃ¶m macroglobulinemia. Haematologica, 2021, 106, 2940-2946.	1.7	11
1067	The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities. Cancers, 2021, 13, 38.	1.7	17
1068	Why Immunotherapy Fails in Multiple Myeloma. Hemato, 2021, 2, 1-42.	0.2	5
1069	Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias. Journal of Immunotherapy and Precision Oncology, 2020, 3, 113-120.	0.6	10
1070	Efficacy and safety of secondâ€‘generation CAR Tâ€‘cell therapy in diffuse large Bâ€‘cell lymphoma: A metaâ€‘analysis. Molecular and Clinical Oncology, 2020, 13, 33.	0.4	23

#	Article	IF	Citations
1071	Cardiovascular Complications of Novel Anti-Cancer Immunotherapy: Old Problems from New Agents?. Korean Circulation Journal, 2020, 50, 743.	0.7	6
1072	The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Cytokine Release Syndrome From CAR T-Cell Therapy. Journal of the Advanced Practitioner in Oncology, 2019, 10, 833-843.	0.2	1
1073	NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 650-661.	2.3	116
1074	Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1125-1134.	2.3	15
1075	Drug therapy for double-hit lymphoma. Drugs in Context, 2019, 8, 1-13.	1.0	11
1076	Cardiovascular Risk Profile of Chimeric Antigen Receptor T-cell Therapy. Cureus, 2020, 12, e7436.	0.2	2
1077	Severe Motor Weakness Due to Disturbance in Peripheral Nerves Following Tisagenlecleucel Treatment. In Vivo, 2021, 35, 3407-3411.	0.6	3
1078	Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucel: Case Report and Literature Review. In Vivo, 2021, 35, 3401-3406.	0.6	4
1079	New actionable targets and investigational drugs in chronic lymphocytic leukemia. Memo - Magazine of European Medical Oncology, 0, , 1.	0.3	1
1080	Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma. Frontiers in Immunology, 2021, 12, 745320.	2.2	41
1081	An overview of multiplexed analyses of CAR T-cell therapies: insights and potential. Expert Review of Proteomics, 2021, 18, 767-780.	1.3	2
1082	Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges. Annals of Oncology, 2022, 33, 6-12.	0.6	7
1084	Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Expert Review of Anticancer Therapy, 2021, 21, 1313-1320.	1.1	2
1085	FDG-PET/CT in Lymphoma: Where Do We Go Now?. Cancers, 2021, 13, 5222.	1.7	14
1086	Safety of the Anti-CD19 antibody Tafasitamab in Long Term Responders from A Phase II Trial for Relapsed Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 270-275.	0.2	4
1087	Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T. Cancers, 2021, 13, 5181.	1.7	13
1088	Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma. Blood Advances, 2022, 6, 321-326.	2.5	37
1089	Advances in Universal CAR-T Cell Therapy. Frontiers in Immunology, 2021, 12, 744823.	2.2	78

#	Article	IF	Citations
1090	Driving Out Chronic Lymphocytic Leukemia With CAR T Cells. Transplantation and Cellular Therapy, 2022, 28, 5-17.	0.6	4
1091	Emerging Landscape of Immunotherapy for Primary Central Nervous System Lymphoma. Cancers, 2021, 13, 5061.	1.7	9
1092	CRISPR-derived genome editing therapies: Progress from bench to bedside. Molecular Therapy, 2021, 29, 3125-3139.	3.7	14
1093	Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19. Molecular Cancer Therapeutics, 2022, 21, 138-148.	1.9	9
1094	CAR T-cell therapy and critical care. Wiener Klinische Wochenschrift, 2021, 133, 1318-1325.	1.0	18
1095	Advances in immune therapies in hematological malignancies. Journal of Internal Medicine, 2022, 292, 205-220.	2.7	5
1097	Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. Signal Transduction and Targeted Therapy, 2021, 6, 367.	7.1	31
1098	Novel Redirected Tâ€“Cell Immunotherapies for Advanced Prostate Cancer. Clinical Cancer Research, 2022, 28, 576-584.	3.2	26
1099	Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: What is the evidence?. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.6	5
1100	The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy. Seminars in Oncology Nursing, 2021, 37, 151216.	0.7	13
1101	CAR-T in B-cell lymphomas: the past, present and future. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	2
1103	Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma. Expert Opinion on Therapeutic Targets, 2021, 25, 749-760.	1.5	1
1104	Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma. Blood Advances, 2022, 6, 37-45.	2.5	3
1105	Current Status of CAR-T Cell Therapy in Multiple Myeloma. Hemato, 2021, 2, 660-671.	0.2	2
1106	Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. British Journal of Haematology, 2022, 197, 28-40.	1.2	9
1107	How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure. Current Treatment Options in Oncology, 2021, 22, 112.	1.3	10
1108	Gene editing to enhance the efficacy of cancer cell therapies. Molecular Therapy, 2021, 29, 3153-3162.	3.7	5
1109	Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper. British Journal of Haematology, 2022, 196, 864-870.	1.2	10

#	Article	IF	Citations
1110	Assessing CAR T-cell therapy response using genome-wide sequencing of cell-free DNA in patients with B-cell lymphomas. Transplantation and Cellular Therapy, 2021, 28, 30.e1-30.e1.	0.6	11
1111	PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR TÂcells. Molecular Therapy, 2022, 30, 579-592.	3.7	29
1112	Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. Journal of the American College of Cardiology, 2021, 78, 1800-1813.	1.2	55
1113	Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. Lancet Haematology,the, 2021, 8, e818-e827.	2.2	14
1114	Resistance to Chimeric Antigen Receptor T-Cell Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 193-203.	0.1	0
1115	Neue Arzneimittel 2018. , 2019, , 61-175.		1
1116	Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma. Korean Journal of Medicine, 2019, 94, 152-158.	0.1	0
1117	Anti-CD19 CAR T-Cell Therapy for Adult Patients With Refractory Large B-Cell Lymphoma. Journal of the Advanced Practitioner in Oncology, 2019, 10, 11-20.	0.2	0
1119	III. Chimeric Antigen Receptor T-cell Immure Therapy. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1375-1383.	0.0	0
1121	The CAR T Cell Story. Healthbook TIMES Oncology Hematology, 2019, , 22-27.	0.1	0
1122	CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement. Healthbook TIMES Oncology Hematology, 2019, , 16-21.	0.1	0
1124	BASICS OF CAR-T CELL THERAPY AND ITS FUTURE DEVELOPMENT. Japanese Journal of Transfusion and Cell Therapy, 2019, 65, 851-857.	0.1	0
1125	New drug: Tisagenlecleucel for B-cell cancers. Australian Prescriber, 2020, 43, 30-31.	0.5	2
1126	Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care. Hematology American Society of Hematology Education Program, 2019, 2019, 63-70.	0.9	4
1127	CAR Design, Independent of Costimulatory Domain, Impacts Safety and Immunogenicity of CAR T-cell Therapy. , 2020, 17, .		1
1128	Immunotherapy for Hematological Malignancies â€“ Now and Future â€“.. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 301-307.	0.0	0
1129	Chimeric antigen receptor (CAR)-T cell therapy. Okayama Igakkai Zasshi, 2020, 132, 34-36.	0.0	0
1130	Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?. International Journal of Particle Therapy, 2020, 7, 13-20.	0.9	3

#	Article	IF	Citations
1131	Hematopoietic Progenitor Cell Transplantation in Children, Adolescents, and Young Adults With Relapsed Mature B-Cell NHL. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1135-1142.	2.3	0
1132	SÃndrome de neurotoxicidad asociada a cÃ©lulas inmunoefectoras: un enfoque terapÃ©utico en el paciente crÃtico. Medicina Intensiva, 2022, 46, 201-212.	0.4	2
1134	Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 460-466.	2.0	24
1135	Facing CAR T Cell Challenges on the Deadliest Paediatric Brain Tumours. Cells, 2021, 10, 2940.	1.8	5
1136	The Inpatient Unit in a Cancer Center. , 2022, , 15-20.		0
1137	Quantification of cell-free DNA for the analysis of CD19-CAR-T cells during lymphoma treatment. Molecular Therapy - Methods and Clinical Development, 2021, 23, 539-550.	1.8	6
1138	Systematic review of nutrition support interventions in adult haematology and oncology patients receiving CAR T cell therapy. Clinical Nutrition ESPEN, 2021, 46, 60-65.	0.5	3
1140	Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways. Journal of Investigative Dermatology, 2022, 142, 907-914.	0.3	21
1141	Immune targeted therapy for diffuse large B cell lymphoma. Blood Science, 2021, 3, 136-148.	0.4	4
1142	Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges. Frontiers in Immunology, 2021, 12, 782775.	2.2	23
1143	CAR-NK Cells from Engineered Pluripotent Stem Cells: Off-the-shelf Therapeutics for all Patients. Stem Cells Translational Medicine, 2021, 10, S10-S17.	1.6	11
1144	Introduction of Chimeric Antigen Receptor T-cell therapy, Tisagenlecleucel in Japan. Drug Delivery System, 2020, 35, 71-75.	0.0	1
1145	Saudi lymphoma group's clinical practice guidelines for diagnosis, management and follow-up of patients with various types of lymphoma during the Coronavirus Disease 2019 pandemic. Saudi Journal of Medicine and Medical Sciences, 2020, 8, 227.	0.3	1
1146	Novel Combination Strategies to Enhance Immune Checkpoint Inhibition in Cancer Immunotherapy: A Narrative Review. International Journal of Medical Students, 2020, 8, 273-280.	0.2	1
1148	N-quinoline-benzenesulfonamide derivatives exert potent anti-lymphoma effect by targeting NF-ÎºB. IScience, 2020, 23, 101884.	1.9	1
1150	Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma: Is It Time to Consider CAR-T for All?. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1764-1766.	2.3	0
1151	Cancer T-cell therapy: building the foundation for a cure. F1000Research, 2020, 9, 1295.	0.8	2
1152	Lanthanide-semiconductor probes for precise imaging-guided phototherapy and immunotherapy. Journal of Bio-X Research, 2020, 3, 193-204.	0.3	0

#	Article	IF	Citations
1153	Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma. Therapeutic Advances in Hematology, 2021, 12, 204062072110531.	1.1	4
1154	Nonclinical drug development. , 2022, , 573-588.		0
1155	CHAPTER 14. Cell and Immune Therapy. RSC Detection Science, 2020, , 303-344.	0.0	0
1156	Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment. Recent Patents on Anti-Cancer Drug Discovery, 2020, 14, 312-323.	0.8	2
1157	ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0
1159	Lymphomes. , 2020, , 241-255.e3.		0
1160	Masquerade Syndromes. , 2020, , 395-407.		0
1161	Aggressive (hoch maligne) Non-Hodgkin-Lymphome. , 2020, , 513-540.		0
1162	Biofabrication of 3D tumor models in cancer research. , 2020, , 67-90.		1
1163	CD19 Chimeric Antigen Receptor Natural Killer Cells Can Safely Induce Remission in Lymphoid Malignancies. , 2020, 17, .		0
1164	Maligne aandoeningen van het lymfatische systeem. , 2020, , 615-641.		0
1165	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
1166	Antibodyâ€“drug conjugates, cancer immunotherapy, and metronomic chemotherapy as novel approaches in cancer management. Indian Journal of Pharmacology, 2020, 52, 402.	0.4	2
1167	5. Recent Progress and Pitfall in Malignant Lymphoma. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 574-578.	0.0	0
1168	Barriers to achieving a cure in lymphoma. , 2021, 4, 965-983.		0
1169	Infections following CAR-T cells therapy: current state-of-the-art review and recommendations. Acta Haematologica Polonica, 2020, 51, 11-16.	0.1	7
1170	Addressing the Challenges of Aggressive Lymphomas. Journal of the Advanced Practitioner in Oncology, 2020, 11, 316-320.	0.2	0
1171	Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Advances, 2022, 6, 2055-2068.	2.5	60

#	Article	IF	Citations
1172	Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma. Blood Advances, 2022, 6, 1255-1263.	2.5	26
1173	Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients. Frontiers of Medicine, 2021, , 1.	1.5	1
1174	Synthetic control arms in studies of multiple myeloma and diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2022, 196, 1274-1277.	1.2	9
1175	Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13RÎ±2 and Suppress Malignant Glioma: A Preclinical Study. Frontiers in Immunology, 2021, 12, 715000.	2.2	10
1176	Hematopoietic Stem Cells and Regeneration. Cold Spring Harbor Perspectives in Biology, 2022, 14, a040774.	2.3	3
1177	Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies. International Journal of Molecular Sciences, 2021, 22, 12015.	1.8	9
1180	Cancer T-cell therapy: building the foundation for a cure. F1000Research, 2020, 9, 1295.	0.8	0
1181	A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy. Aging, 2020, 12, 18741-18753.	1.4	19
1183	CAR T-cells: hot news in cancer therapy. Vnitrni Lekarstvi, 2020, 66, 420-424.	0.1	0
1185	Single agent oral selinexor as a key to potential cure in refractory diffuse large B-cell lymphoma: case report and literature review. American Journal of Blood Research, 2021, 11, 111-117.	0.6	1
1187	High Prevalence of PNH-phenotype Cells in Patients Who Received CD19-targeted CAR T-cell Therapy. HemaSphere, 2021, 5, e628.	1.2	0
1189	Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations. Current Research in Translational Medicine, 2022, 70, 103320.	1.2	9
1190	Immuntherapie. , 2022, , 53-58.		0
1191	Non-Hodgkin-Lymphome. , 2022, , 195-203.		0
1192	Artificial Intelligence in Lymphoma PET Imaging. PET Clinics, 2022, 17, 145-174.	1.5	23
1193	Update on CAR T-Cell Therapies for Relapsed/Refractory B-Cell Lymphomas. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 622-624.	2.3	1
1194	Epsteinâ€“Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes. Current Opinion in Infectious Diseases, 2021, 34, 635-645.	1.3	18
1196	Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma. Haematologica, 2022, 107, 1555-1566.	1.7	15

#	Article	IF	Citations
1197	Polatuzumab vedotinâ€“based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience. Annals of Hematology, 2022, 101, 349-358.	0.8	12
1198	The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 362-372.	0.2	9
1199	Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. Cancers, 2021, 13, 5592.	1.7	9
1200	Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy. Radiology, 2022, 302, 438-445.	3.6	9
1201	The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma. HemaSphere, 2021, 5, e666.	1.2	5
1202	Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review. Innovations in Pharmacy, 2021, 12, 18.	0.2	1
1203	NCCN GuidelinesÂ® Insights: B-Cell Lymphomas, Version 5.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1218-1230.	2.3	98
1204	AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia. Hematology, Transfusion and Cell Therapy, 2021, 43, S13-S21.	0.1	0
1206	Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience. Cancer Management and Research, 2021, Volume 13, 8901-8906.	0.9	12
1207	Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?. Leukemia and Lymphoma, 2021, , 1-11.	0.6	1
1208	Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells. , 2021, 9, e003176.		10
1209	Overview of approved CARâ€T therapies, ongoing clinical trials, and its impact on clinical practice. EJHaem, 2022, 3, 6-10.	0.4	63
1210	Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives. Cancers, 2021, 13, 5722.	1.7	17
1211	Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions. Cancers, 2021, 13, 5827.	1.7	18
1212	Commercialization of Investigational Cell Therapy Products. , 2022, , 161-178.		0
1213	Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the preâ€CAR Tâ€cell era. Hematological Oncology, 2022, 40, 292-296.	0.8	6
1214	AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma. Hematology, Transfusion and Cell Therapy, 2021, 43, S22-S29.	0.1	0
1215	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. European Journal of Cancer, 2022, 160, 112-133.	1.3	24

#	Article	IF	Citations
1216	Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy. International Journal of Molecular Sciences, 2021, 22, 12126.	1.8	8
1217	The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e335-e339.	0.2	19
1218	Incidence and prophylaxis of herpes zoster in relapsed or refractory B-cell lymphoma patients after CD19-specific CAR-T cell therapy. Leukemia and Lymphoma, 2022, 63, 1001-1004.	0.6	5
1219	A Reversible Chemogenetic Switch for Chimeric Antigen Receptor Tâ€...Cells**. Angewandte Chemie - International Edition, 2022, 61, .	7.2	8
1220	Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study. Oncology and Therapy, 2022, 10, 123-141.	1.0	8
1221	New indications and platforms for CARâ€T therapy in lymphomas beyond DLBCL. EJHaem, 2022, 3, 11-23.	0.4	2
1222	Chimeric antigen receptor Tâ€cell therapy: Challenges and framework of outpatient administration. EJHaem, 2022, 3, 54-60.	0.4	6
1223	T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. Pharmaceuticals, 2021, 14, 1172.	1.7	13
1224	Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem, 2022, 3, 39-45.	0.4	9
1225	Diffuse Large B-Cell Lymphoma: Optimizing Therapy for Relapsed/Refractory Disease. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1327-1330.	2.3	1
1226	Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation. American Journal of Surgical Pathology, 2022, 46, 742-753.	2.1	9
1227	AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients. Hematology, Transfusion and Cell Therapy, 2021, 43, S3-S12.	0.1	3
1228	A Recurring Chemogenetic Switch for Chimeric Antigen Receptor T Cells. Angewandte Chemie, 0, , .	1.6	0
1229	T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy. Frontiers in Immunology, 2021, 12, 780442.	2.2	42
1230	Sequencing of Novel Therapies for Mantle Cell Lymphoma. Current Treatment Options in Oncology, 2021, 22, 118.	1.3	3
1231	Disease-specific outcomes after chimeric antigen receptor T-cell therapy. European Journal of Cancer, 2021, , .	1.3	2
1232	Current landscape of clinical development and approval of advanced therapies. Molecular Therapy - Methods and Clinical Development, 2021, 23, 606-618.	1.8	21
1233	Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncology, 2022, 18, 277-289.	1.1	20

#	Article	IF	Citations
1234	ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature. Frontiers in Medicine, 2021, 8, 713047.	1.2	3
1235	The EHA Research Roadmap: Infections in Hematology. HemaSphere, 2021, 5, e662.	1.2	5
1236	Terapia con linfocitos T con receptor de antÃgeno quimÃ©rico (CAR-T) en pacientes con linfoma de cÃ©lula B agresivo. Perspectiva actual tras una dÃ©cada de tratamiento. Medicina ClÃnica, 2021, , .	0.3	0
1237	Antigen multimers: Specific, sensitive, precise, and multifunctional high-avidity CAR-staining reagents. Matter, 2021, 4, 3917-3940.	5.0	4
1238	CAR T Cells. Advances in Experimental Medicine and Biology, 2021, 1342, 297-317.	0.8	4
1239	Neurologic Toxicities of Immunotherapy. Advances in Experimental Medicine and Biology, 2021, 1342, 417-429.	0.8	2
1241	Mechanisms of Resistance and Relapse After CAR-T Cell Therapy. Cancer Drug Discovery and Development, 2022, , 207-219.	0.2	1
1242	A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper. Clinical and Translational Oncology, 2022, 24, 968-980.	1.2	3
1243	Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy. Cancers, 2022, 14, 260.	1.7	26
1244	Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives. Journal of Clinical Medicine, 2022, 11, 253.	1.0	10
1245	Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel. Clinical Case Reports (discontinued), 2022, 10, e05209.	0.2	13
1246	Managing Relapsed Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	2
1247	Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). , 2022, 10, e003847.		44
1249	Co-Expression of miR155 or LSD1 shRNA Increases the Anti-Tumor Functions of CD19 CAR-T Cells. Frontiers in Immunology, 2021, 12, 811364.	2.2	11
1251	CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma. Blood Advances, 2022, 6, 2695-2699.	2.5	11
1252	Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. Blood Advances, 2022, 6, 2867-2871.	2.5	24
1253	CAR-T-Zellen in der Praxis: Lebende Onkologika in der â€žRoutineversorgungâ€œ. , 0, , .		0
1254	Advance in the Treatment with Molecular Targeted Drugs for Malignant Lymphoma and Chronic Lymphocytic Leukemia. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 2183-2190.	0.0	0

#	Article	IF	Citations
1255	Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy. Translational Cancer Research, 2020, 9, 7310-7322.	0.4	2
1256	El Plan Profarma y las cÃ©lulas CAR-T. Revista De InvestigaciÃ³n Y EducaciÃ³n En Ciencias De La Salud (RIECS), 2020, 5, 116-121.	0.0	0
1257	CAR-T-Zelltherapie: Konzept â€žOne and Doneâ€œ. , 0, , .		0
1258	High Prevalence of PNH-phenotype Cells in Patients Who Received CD19-targeted CAR T-cell Therapy. HemaSphere, 2021, 5, e628.	1.2	2
1259	CAR-T cells, from principle to clinical applications. Bulletin Du Cancer, 2021, 108, S4-S17.	0.6	15
1263	Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nature Medicine, 2022, 28, 325-332.	15.2	182
1264	Relapsed disease: off-the-shelf immunotherapies vs customized engineered products. Hematology American Society of Hematology Education Program, 2021, 2021, 164-173.	0.9	1
1265	Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL. Blood Advances, 2022, 6, 2920-2926.	2.5	20
1266	CD81 costimulation skews CAR transduction toward naive T cells. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	6
1267	Profile of capillary-leak syndrome in patients received chimeric antigen receptor T cell therapy. Bone Marrow Transplantation, 2022, , .	1.3	2
1268	CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia. Leukemia, 2022, 36, 1015-1024.	3.3	15
1269	Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain. Cancers, 2022, 14, 538.	1.7	4
1270	Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis. BMC Cancer, 2022, 22, 98.	1.1	15
1271	Engineered T Cells: CAR T Cell Therapy and Beyond. Current Oncology Reports, 2022, 24, 23-31.	1.8	23
1272	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. Radiotherapy and Oncology, 2022, 166, 171-179.	0.3	27
1273	Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?. Frontiers in Pediatrics, 2021, 9, 784024.	0.9	13
1274	Therapeutic roles of CAR T cells in infectious diseases: Clinical lessons learnt from cancer. Reviews in Medical Virology, 2022, 32, e2325.	3.9	6
1275	Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies. Cytotherapy, 2022, 24, 405-412.	0.3	6

#	Article	IF	Citations
1276	CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report. Frontiers in Immunology, 2022, 13, 778192.	2.2	6
1277	Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners. Biomedicines, 2022, 10, 307.	1.4	9
1278	Inhibition of Calcium Signaling Prevents Exhaustion and Enhances Antiâ€Leukemia Efficacy of CARâ€T Cells via SOCEâ€Calcineurinâ€NFAT and Glycolysis Pathways. Advanced Science, 2022, 9, e2103508.	5.6	21
1281	The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity. Cancers, 2022, 14, 299.	1.7	11
1282	Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. Blood Advances, 2022, 6, 2536-2547.	2.5	8
1283	Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	3
1284	Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. Neurological Research and Practice, 2022, 4, 1.	1.0	9
1285	The Evolving Role of Allogeneic Stem Cell Transplant in the Era of Molecularly Targeted Agents. Cancer Journal (Sudbury, Mass), 2022, 28, 78-84.	1.0	0
1286	Post-transplant GVHD in the era of molecularly targeted therapy. Journal of Illusion, 2022, 11, 53-63.	0.0	0
1287	Resistance and recurrence of malignancies after CAR-T cell therapy. Experimental Cell Research, 2022, 410, 112971.	1.2	4
1288	Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma. Bone Marrow Transplantation, 2022, 57, 431-439.	1.3	26
1290	Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison. Leukemia and Lymphoma, 2022, 63, 845-854.	0.6	6
1291	Chimeric antigen receptorâ€engineered adoptive cell therapy for AML: Current status and future perspectives. Immunomedicine, 2022, 2, .	0.7	0
1292	Phase Ib study of combinations of avadomide (CCâ€122), CCâ€223, CCâ€292, and rituximab in patients with relapsed/refractory diffuse large Bâ€cell lymphoma. EJHaem, 2022, 3, 139-153.	0.4	4
1293	Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment. Oncologist, 2022, 27, 57-66.	1.9	4
1294	Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas. Cancers, 2022, 14, 626.	1.7	11
1295	HLA-independent T cell receptors for targeting tumors with low antigen density. Nature Medicine, 2022, 28, 345-352.	15.2	73
1296	The current landscape of immunotherapy for pediatric brain tumors. Nature Cancer, 2022, 3, 11-24.	5.7	21

#	Article	IF	Citations
1297	Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies. Frontiers in Cell and Developmental Biology, 2021, 9, 805195.	1.8	7
1298	Roadmap for Starting an Outpatient Cellular Therapy Program. Cancer Drug Discovery and Development, 2022, , 355-368.	0.2	0
1299	Current global trends in the development of CAR-T therapy. Journal of Illusion, 2022, 11, 1-9.	0.0	0
1300	Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCLâ€"a matched cohort analysis. Annals of Hematology, 2022, 101, 755.	0.8	1
1301	Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richterâ€™s Transformation. Frontiers in Oncology, 2022, 12, 828471.	1.3	19
1302	The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma. Journal of Personalized Medicine, 2022, 12, 197.	1.1	4
1303	iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting. Frontiers in Immunology, 2022, 13, 841107.	2.2	42
1304	Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2022, , 1-4.	0.6	0
1305	Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure. OncoImmunology, 2022, 11, 2033528.	2.1	19
1306	Strategies Towards Antigen-Specific Treatments for Membranous Nephropathy. Frontiers in Immunology, 2022, 13, 822508.	2.2	8
1307	Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (rituximab, gemcitabine, cisplatin, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.6	0
1308	Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. Journal of Clinical Oncology, 2022, 40, 369-381.	0.8	60
1309	Anti-CAIX BBÎ¶ CAR4/8 TÂcells exhibit superior efficacy in a ccRCC mouse model. Molecular Therapy - Oncolytics, 2022, 24, 385-399.	2.0	15
1310	Presumptive Recurrence of Intra-ocular Lymphoma Despite Chimeric Antigen Receptor T-cell Therapy. Retinal Cases and Brief Reports, 2022, Publish Ahead of Print, .	0.3	1
1311	Post-CAR-T Cell Therapy (Consolidation and Relapse): Lymphoma. , 2022, , 169-171.		1
1314	Methods to monitor in vivo expansion and efficacy of CAR-T cells in preclinical models. Methods in Cell Biology, 2022, 167, 185-201.	0.5	0
1315	Management of Cytokine Release Syndrome (CRS) and HLH. , 2022, , 135-139.		5
1316	Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma. PharmacoEconomics - Open, 2022, 6, 367-376.	0.9	6

#	Article	IF	Citations
1317	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. Journal of Clinical Oncology, 2022, 40, 481-491.	0.8	160
1318	Emerging drug targets for colon cancer: A preclinical assessment. Expert Opinion on Therapeutic Targets, 2022, 26, 207-216.	1.5	4
1319	Management of haemostatic complications of chimaeric antigen receptor Tâ€cell therapy. British Journal of Haematology, 2022, 197, 250-259.	1.2	0
1320	CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma. Human Gene Therapy, 2022, 33, 318-329.	1.4	10
1321	Prognostic Value of Radiomic Features of 18F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells. Frontiers in Oncology, 2022, 12, 834288.	1.3	12
1322	Cancer Immunotherapies: What the Perioperative Physician Needs to Know. Current Oncology Reports, 2022, 24, 399-414.	1.8	6
1323	Ex Vivo Model to Assess the Exposure of Patients to Plasticizers from Medical Devices during Pre-CAR-T Cellsâ€™ Apheresis. Toxics, 2022, 10, 79.	1.6	1
1324	Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing. Frontiers in Immunology, 2022, 13, 802906.	2.2	18
1325	Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned. Experimental Hematology, 2022, 108, 1-7.	0.2	9
1326	CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection. PLoS Pathogens, 2022, 18, e1009831.	2.1	20
1327	Chimeric antigen receptor Tâ€cell therapy combined with autologous stem cell transplantation improved progressionâ€free survival of relapsed or refractory diffuse large Bâ€cell lymphoma patients: A singleâ€center, retrospective, cohort study. Hematological Oncology, 2022, 40, 637-644.	0.8	12
1328	Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine. Diagnostics, 2022, 12, 409.	1.3	5
1329	CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network. Blood, 2022, 139, 792-796.	0.6	34
1330	Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit. Haematologica, 2022, 107, 1214-1217.	1.7	5
1331	The Past, Present, and Future of Clinically Applied Chimeric Antigen Receptor-T-Cell Therapy. Pharmaceuticals, 2022, 15, 207.	1.7	5
1332	Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications. Journal of Controlled Release, 2022, 343, 703-723.	4.8	25
1333	Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Annals of Oncology, 2022, 33, 259-275.	0.6	139
1334	Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages. International Immunopharmacology, 2022, 106, 108587.	1.7	15

#	Article	IF	Citations
1335	Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. New England Journal of Medicine, 2022, 386, 629-639.	13.9	243
1336	A human orthogonal IL-2 and IL-2RÎ² system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. Science Translational Medicine, 2021, 13, eabg6986.	5.8	64
1337	An orthogonal IL-2 and IL-2RÎ² system drives persistence and activation of CAR T cells and clearance of bulky lymphoma. Science Translational Medicine, 2021, 13, eabg7565.	5.8	37
1338	Modified T cells as therapeutic agents. Hematology American Society of Hematology Education Program, 2021, 2021, 296-302.	0.9	3
1340	The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine. Touch Reviews in Oncology & Haematology, 2021, 17, 95.	0.1	0
1341	2021, 110, 414-419.	0.0	0
1342	Adoptive T-cell Immunotherapy: Perfecting Self-Defenses. Experientia Supplementum (2012), 2022, 113, 253-294.	0.5	1
1343	Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL). Therapeutic Advances in Hematology, 2022, 13, 204062072210807.	1.1	7
1344	Neurologic complications of immune modulatory therapy. , 2022, , 537-551.		0
1345	Global Research Trends on the Treatment of Diffuse Large B-Cell Lymphoma: A Bibliometric and Visualized Study. Journal of Cancer, 2022, 13, 1785-1795.	1.2	1
1346	Mantle cell lymphoma management trends and novel agents: where are we going?. Therapeutic Advances in Hematology, 2022, 13, 204062072210807.	1.1	8
1347	Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas. Current Treatment Options in Oncology, 2022, 23, 89-98.	1.3	3
1348	Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody. Immune Network, 2022, 22, e4.	1.6	12
1349	Multifunctional theranostic nanoparticles for multi-modal imaging-guided CAR-T immunotherapy and chemo-photothermal combinational therapy of non-Hodgkin's lymphoma. Biomaterials Science, 2022, 10, 2577-2589.	2.6	10
1350	Cellular Therapy Advances in Chronic Lymphocytic Leukemia and Richter's Syndrome. Current Problems in Cancer, 2022, 46, 100827.	1.0	1
1351	Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large Bâ€Cell lymphoma â€results of a single center, retrospective cohort in China. Hematological Oncology, 2022, 40, 617-625.	0.8	6
1353	Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies. Haematologica, 2022, 107, 2096-2107.	1.7	17
1354	Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: AÂWork Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. Journal of Allergy and Clinical Immunology, 2022, 149, 1525-1560.	1.5	53

#	Article	IF	Citations
1355	Role of Salvage Radiation Treatment of Relapses in Relapsed/Refractory Diffuse Large B Cell Lymphoma Post Autologous Stem Cell Transplant. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	2
1356	Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplantation, 2022, 57, 742-752.	1.3	45
1357	Phase Ib study of avadomide (CCâ€122) in combination with rituximab in patients with relapsed/refractory diffuse large Bâ€cell lymphoma and follicular lymphoma. EJHaem, 2022, 3, 394-405.	0.4	7
1358	Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. Current Treatment Options in Oncology, 2022, 23, 155-170.	1.3	17
1360	Emerging CAR T Cell Strategies for the Treatment of AML. Cancers, 2022, 14, 1241.	1.7	24
1361	CAR T-Cell Therapy for Large B-Cell Lymphoma â€" Who, When, and How?. New England Journal of Medicine, 2022, 386, 692-696.	13.9	42
1362	Treatment of Classic Hairy Cell Leukemia: Targeting Minimal Residual Disease beyond Cladribine. Cancers, 2022, 14, 956.	1.7	3
1363	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer Journal, 2022, 12, 32.	2.8	73
1364	Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study. Cancers, 2022, 14, 1018.	1.7	7
1365	Immunotherapy in Advanced Prostate Cancerâ€"Light at the End of the Tunnel?. International Journal of Molecular Sciences, 2022, 23, 2569.	1.8	11
1366	CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma. Frontiers in Immunology, 2022, 13, 837457.	2.2	9
1367	Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma. Current Problems in Cancer, 2022, 46, 100825.	1.0	2
1368	Cardiac adverse events associated with chimeric antigen receptor T- cell therapy. American Journal of Emergency Medicine, 2022, 57, 225-226.	0.7	2
1369	Design of experiments as a decision tool for cell therapy manufacturing. Cytotherapy, 2022, 24, 590-596.	0.3	3
1370	The evolving landscape of chimeric antigen receptor T-cell therapy associated cardiotoxicity. American Journal of Emergency Medicine, 2022, 57, 220-221.	0.7	1
1371	Immune effector cell-associated neurotoxicity syndrome: A therapeutic approach in the critically ill. Medicina Intensiva (English Edition), 2022, , .	0.1	2
1372	CAR T-cell therapy for B-cell lymphoma. Current Problems in Cancer, 2022, 46, 100826.	1.0	26
1373	Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma. Transplantation and Cellular Therapy, 2022, 28, 251-257.	0.6	14

#	Article	IF	Citations
1374	Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. Journal of Translational Medicine, 2022, 20, 124.	1.8	21
1375	Cytopenia after CAR-T Cell Therapyâ€"A Brief Review of a Complex Problem. Cancers, 2022, 14, 1501.	1.7	43
1376	A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. Blood Advances, 2022, 6, 2757-2762.	2.5	19
1377	Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors. Cancer Research Communications, 2022, 2, 158-171.	0.7	8
1378	The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). Current Treatment Options in Oncology, 2022, 23, 381-403.	1.3	5
1379	A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021. Frontiers in Immunology, 2022, 13, 840956.	2.2	30
1380	Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review (protocol). Open Research Europe, 0, 2, 38.	2.0	1
1381	Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nature Medicine, 2022, 28, 713-723.	15.2	117
1382	Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy. International Journal of Molecular Sciences, 2022, 23, 3368.	1.8	6
1383	CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?. Blood, 2022, 139, 2737-2746.	0.6	60
1384	Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkinâ€™s Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL). Cancer Research and Treatment, 2023, 55, 304-313.	1.3	1
1385	Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States. Transplantation and Cellular Therapy, 2022, 28, 404.e1-404.e6.	0.6	15
1386	Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic. Genes and Development, 2022, 36, 259-277.	2.7	19
1387	Chimeric antigen receptor T-cell (CAR-T) therapy in patients with aggressive B-cell lymphomas. Current outlook after a decade of treatment. Medicina ClÃnica (English Edition), 2022, , .	0.1	0
1388	A drug profile on selinexor for the treatment of refractory diffuse large B-cell lymphoma. Expert Review of Hematology, 2022, , 1-7.	1.0	0
1389	Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. Transplantation and Cellular Therapy, 2022, 28, 294-302.	0.6	17
1390	Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma. Cancer Research, 2022, 82, 2610-2624.	0.4	24
1391	Value of CT-Textural Features and Volume-Based PET Parameters in Comparison to Serologic Markers for Response Prediction in Patients with Diffuse Large B-Cell Lymphoma Undergoing CD19-CAR-T Cell Therapy. Journal of Clinical Medicine, 2022, 11, 1522.	1.0	5

#	Article	IF	Citations
1392	Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody. Molecular Therapy - Oncolytics, 2022, 24, 719-728.	2.0	12
1393	Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. European Heart Journal, 2022, 43, 1928-1940.	1.0	39
1394	Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021. Frontiers in Immunology, 2022, 13, 822004.	2.2	17
1395	Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel. Experimental Hematology and Oncology, 2022, 11, 17.	2.0	14
1396	Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics. Cancers, 2022, 14, 1469.	1.7	6
1397	In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large Bâ€Cell Lymphoma. Clinical Pharmacology and Therapeutics, 2022, 112, 81-89.	2.3	14
1398	Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy. Expert Review of Hematology, 2022, 15, 215-232.	1.0	2
1399	Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and antiâ€CD19â€chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large Bâ€cell lymphoma and high tumor burden. Hematological Oncology, 2023, 41, 275-284.	0.8	6
1400	A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells. Frontiers in Oncology, 2022, 12, 726985.	1.3	4
1401	Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clinical Microbiology and Infection, 2022, 28, 1321-1327.	2.8	14
1402	CAR T cells and autologous transplantation can coexist for DLBCL. Blood, 2022, 139, 1266-1267.	0.6	2
1403	Comparison of single copy geneâ€based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19â€directed CAR T cells in treated patients. International Journal of Oncology, 2022, 60, .	1.4	5
1404	Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Brutonâ€™s Tyrosine Kinase Inhibitor in Canada. Current Oncology, 2022, 29, 2021-2045.	0.9	6
1405	HLAâ€matched allogeneic antiâ€CD19 CARâ€T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden. Immunomedicine, 2022, 2, .	0.7	0
1406	Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma. Value in Health, 2022, 25, 1344-1351.	0.1	9
1407	Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies. Cells, 2022, 11, 1140.	1.8	8
1408	Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Advances, 2022, 6, 5774-5785.	2.5	43
1409	Improving the Safety of Mesenchymal Stem Cell-Based Ex Vivo Therapy Using Herpes Simplex Virus Thymidine Kinase. Molecules and Cells, 2022, 45, 479-494.	1.0	4

#	Article	IF	Citations
1410	CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. Journal of Experimental and Clinical Cancer Research, 2022, 41, 119.	3.5	167
1411	Case Report: Cardiac Tamponade in Association With Cytokine Release Syndrome Following CAR-T Cell Therapy. Frontiers in Cardiovascular Medicine, 2022, 9, 848091.	1.1	4
1412	Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas. Cancers, 2022, 14, 1276.	1.7	1
1413	Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel. Frontiers in Immunology, 2022, 13, 830773.	2.2	21
1414	Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nature Reviews Clinical Oncology, 2022, 19, 342-355.	12.5	113
1415	Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2022, 28, 342.e1-342.e5.	0.6	5
1416	DLBCL 1Lâ€"What to Expect beyond R-CHOP?. Cancers, 2022, 14, 1453.	1.7	7
1417	Odronextamab, a human CD20Ã—CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematology,the, 2022, 9, e327-e339.	2.2	98
1418	Richterâ€™s Transformation. Current Oncology Reports, 2022, 24, 1081-1090.	1.8	6
1419	Identifying aggressive subsets within diffuse large B-cell lymphoma: implications for treatment approach. Expert Review of Anticancer Therapy, 2022, , .	1.1	0
1420	Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantationâ€ineligible relapsed and refractory diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2022, , .	1.2	1
1421	Specific targeting of cancer stem cells by immunotherapy: A possible stratagem to restrain cancer recurrence and metastasis. Biochemical Pharmacology, 2022, 198, 114955.	2.0	12
1422	Donor T cells for CAR T cell therapy. Biomarker Research, 2022, 10, 14.	2.8	9
1423	Bispecific T-cell engagers non-covalently decorated drug-loaded PEGylated nanocarriers for cancer immunochemotherapy. Journal of Controlled Release, 2022, 344, 235-248.	4.8	6
1424	Chimeric antigen receptor T-cell therapy for relapsed mantle cell lymphoma: real-world experience from a single tertiary care center. Bone Marrow Transplantation, 2022, 57, 1010-1012.	1.3	6
1425	Peak absolute lymphocyte count after <scp>CARâ€T</scp> infusion predicts clinical response in aggressive lymphoma. American Journal of Hematology, 2022, 97, .	2.0	2
1426	Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies. Signal Transduction and Targeted Therapy, 2022, 7, 98.	7.1	19
1427	EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapyâ€"A Cohort Study. Frontiers in Immunology, 2022, 13, 877477.	2.2	17

#	Article	IF	Citations
1428	CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Progressive Muscular Dystrophy: A Case Report. OncoTargets and Therapy, 2022, Volume 15, 361-366.	1.0	0
1430	Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2022, 28, 305.e1-305.e9.	0.6	14
1431	Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms. Leukemia and Lymphoma, 2022, 63, 1849-1860.	0.6	14
1432	CAR-T Cells for the Treatment of Lung Cancer. Life, 2022, 12, 561.	1.1	8
1433	A phase <scp>II</scp> trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre <scp>GOAL</scp> trial. British Journal of Haematology, 2022, 198, 482-491.	1.2	8
1434	CD-19 CART therapy and orthostatic hypotension: a single center retrospective cohort study. Cardio-Oncology, 2022, 8, 6.	0.8	1
1435	CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers. Nature Biomedical Engineering, 2022, 6, 830-841.	11.6	25
1436	Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. Expert Review of Hematology, 2022, 15, 305-320.	1.0	25
1437	Comparing apples and oranges: The ZUMAâ€7, TRANSFORM and BELINDA trials. Hematological Oncology, 2022, 40, 1090-1093.	0.8	7
1438	Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma. Advances in Therapy, 2022, 39, 2630-2640.	1.3	2
1439	A genome-scale gain-of-function CRISPR screen in CD8 TÂcells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metabolism, 2022, 34, 595-614.e14.	7.2	70
1440	Stem cell transplant for mantle cell lymphoma in Taiwan. Scientific Reports, 2022, 12, 5662.	1.6	3
1441	Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 387-405.	2.3	124
1442	Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. Journal of Experimental and Clinical Cancer Research, 2021, 40, 367.	3.5	72
1443	Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma. Medicine (United States), 2021, 100, e27733.	0.4	2
1444	Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021. Internal Medicine Journal, 2021, 51, 67-88.	0.5	36
1445	Immunotherapy-Related Publications in Colorectal Cancer: A Bibliometric Analysis. Healthcare (Switzerland), 2022, 10, 75.	1.0	5
1446	Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	1

#	Article	IF	Citations
1447	Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials. Frontiers in Immunology, 2021, 12, 780145.	2.2	11
1448	Transverse myelitis after antiâ€CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. EJHaem, 2022, 3, 223-227.	0.4	0
1450	Tumor Microenvironment of Lymphomas and Plasma Cell Neoplasms: Broad Overview and Impact on Evaluation for Immune Based Therapies. Frontiers in Oncology, 2021, 11, 719140.	1.3	2
1451	Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nature Communications, 2021, 12, 7200.	5.8	31
1452	Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy. Frontiers in Oncology, 2021, 11, 798352.	1.3	7
1453	Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment. Cancers, 2022, 14, 141.	1.7	8
1454	PATIENTS WITH SECONDARY HYPOGAMMAGLOBULINEMIA APPROPRIATE FOR ADMINISTRATION AND METHODS OF USE OF IMMUNOGLOBULIN REPLACEMENT THERAPY. Japanese Journal of Transfusion and Cell Therapy, 2021, 67, 549-558.	0.1	0
1455	Elevated LDH greater than 400ÂU/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort. Experimental Hematology and Oncology, 2021, 10, 55.	2.0	13
1456	Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies. Journal of Personalized Medicine, 2021, 11, 1345.	1.1	19
1457	CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies. Frontiers of Medicine, 2021, 15, 783-804.	1.5	3
1458	Efficacy and Safety Exposureâ€“Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma. AAPS Journal, 2022, 24, 11.	2.2	4
1459	Understanding neutropenia secondary to intrinsic or iatrogenic immune dysregulation. Hematology American Society of Hematology Education Program, 2021, 2021, 504-513.	0.9	4
1460	Application of CRISPR/Cas9 in Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 803894.	1.4	17
1462	Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large Bâ€Cell Lymphoma: Results from a Phase 1b Study. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e443-e451.	0.2	10
1463	Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study. Annals of Translational Medicine, 2021, 9, 1769-1769.	0.7	2
1464	Potential Role of IFNÎ³ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy. Blood Cancer Discovery, 2022, 3, 90-94.	2.6	23
1465	Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma. Current Treatment Options in Oncology, 2022, 23, 171-187.	1.3	9
1466	RNA delivery for cancer gene therapy. , 2022, , 375-424.		0

#	Article	IF	Citations
1467	Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT. Journal of Hematology and Oncology, 2022, 15, 36.	6.9	17
1468	Chimeric antigen receptor T-cell therapy in adult patients with B-cell lymphoproliferative diseases. Gematologiya I Transfuziologiya, 2022, 67, 8-28.	0.1	1
1469	Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e730-e737.	0.2	6
1470	Chimeric anti-GPC3 sFv-CD3Îµ receptor-modified T cells with IL7 co-expression for the treatment of solid tumors. Molecular Therapy - Oncolytics, 2022, 25, 160-173.	2.0	4
1471	Highly favorable outcomes with salvage radiation therapy and autologous hematopoietic cell transplantation in relapsed and refractory DLBCL patients with minimal to no response to salvage chemotherapy. Bone Marrow Transplantation, 2022, 57, 1038-1041.	1.3	1
1472	Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood, 2022, 139, 2306-2315.	0.6	62
1473	Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access. Transplantation and Cellular Therapy, 2022, 28, 358-364.	0.6	40
1474	No CNS sanctuary for lymphoma from CAR T. Blood, 2022, 139, 2261-2263.	0.6	1
1475	Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR TÂcells. Molecular Therapy - Methods and Clinical Development, 2022, 25, 311-330.	1.8	33
1476	Ultrasound and microbubble-mediated drug delivery and immunotherapy. Journal of Medical Ultrasonics (2001), 2022, , 1.	0.6	6
1477	HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Advances, 2023, 7, 744-755.	2.5	5
1478	Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptorâ€“T Cell Therapy for Hematological Malignant Neoplasms. JAMA Network Open, 2022, 5, e228161.	2.8	22
1479	Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States. Leukemia and Lymphoma, 2022, 63, 2052-2062.	0.6	8
1480	CAR T-Cell Therapy in the Older Person: Indications and Risks. Current Oncology Reports, 2022, 24, 1189-1199.	1.8	11
1481	Development of CAR T Cell Therapy in Childrenâ€”A Comprehensive Overview. Journal of Clinical Medicine, 2022, 11, 2158.	1.0	12
1482	Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center. Bone Marrow Transplantation, 2022, 57, 1025-1027.	1.3	27
1483	Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience. Journal of Immunotherapy, 2022, 45, 254-262.	1.2	6
1484	Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood, 2022, 139, 3722-3731.	0.6	28

#	Article	IF	Citations
1505	Advances in therapeutic strategies for primary CNS B-cell lymphomas. Expert Review of Hematology, 2022, 15, 295-304.	1.0	1
1506	Developments over the last 60Âyears in diffuse large Bâ€cell lymphomas. British Journal of Haematology, 2020, 191, 552-557.	1.2	2
1507	Outcomes of relapsed/refractory diffuse large Bâ€cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second lineâ€"A populationâ€based study of 736 patients. British Journal of Haematology, 2022, 198, 267-277.	1.2	16
1508	Novel treatments in B cell non-Hodgkinâ€™s lymphomas. BMJ, The, 2022, 377, e063439.	3.0	5
1509	New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma. Journal of Oncology Pharmacy Practice, 2022, 28, 1848-1858.	0.5	5
1510	NextGen CARs: the race is on. Blood, 2020, 136, 1570-1571.	0.6	0
1518	Pharmacoeconomic Analysis of CAR-T Cell Therapy in Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemias. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2022, 15, 205-212.	0.1	1
1519	Off-the-Shelf Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells. Cancer Treatment and Research, 2022, 183, 255-274.	0.2	0
1520	Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma. Cancer Treatment and Research, 2022, 183, 161-184.	0.2	2
1521	Review of Hematological and Oncological Emergencies. Advanced Emergency Nursing Journal, 2022, 44, 84-102.	0.2	2
1522	2020â€"2021 Drug Updates in Hematologic Malignancies. Journal of the Advanced Practitioner in Oncology, 2022, 13, 282-285.	0.2	0
1523	Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood, 2022, 140, 491-503.	0.6	32
1524	A national service for delivering <scp>CD19 CARâ€T</scp>in large Bâ€cell lymphoma â€" The <scp>UK</scp> realâ€world experience. British Journal of Haematology, 2022, 198, 492-502.	1.2	40
1525	Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2022, 13, 834113.	1.6	6
1526	Targeting CD19 in diffuse large Bâ€cell lymphoma: An expert opinion paper. Hematological Oncology, 2022, 40, 505-517.	0.8	7
1527	Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation. Leukemia and Lymphoma, 2022, , 1-8.	0.6	0
1528	ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma. Blood Reviews, 2022, 56, 100967.	2.8	2
1529	In-situ scalable manufacturing of Epsteinâ€"Barr virus-specific T-cells using bioreactor with an expandable culture area (BECA). Scientific Reports, 2022, 12, 7045.	1.6	1

#	Article	IF	Citations
1530	Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer. Frontiers in Immunology, 2022, 13, .	2.2	5
1531	A bibliometric analysis of diffuse large B-cell lymphoma research from 2001 to 2020. Computers in Biology and Medicine, 2022, 146, 105565.	3.9	9
1532	Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome. Frontiers in Oncology, 2022, 12, 888109.	1.3	2
1533	Efficacy and safety of CAR-T cell therapy in minorities. Bone Marrow Transplantation, 2022, , .	1.3	0
1534	Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant. Transplantation and Cellular Therapy, 2022, 28, 473-482.	0.6	20
1535	Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors. Molecular Cancer Therapeutics, 2022, 21, 1195-1206.	1.9	18
1536	Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood, 2022, 140, 504-515.	0.6	19
1537	Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy. Communications Medicine, 2022, 2, .	1.9	5
1538	Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia. Blood, 2022, 140, 11-15.	0.6	23
1539	All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma. Frontiers in Oncology, 2022, 12, .	1.3	3
1540	Demographic differences among patients treated with chimeric antigen receptor <scp>Tâ€cell</scp> therapy in the United States. Cancer Medicine, 2022, 11, 4440-4448.	1.3	6
1541	Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nature Medicine, 2022, 28, 1189-1198.	15.2	190
1542	Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor T cell therapy in patients with large B cell lymphoma. Cytotherapy, 2022, 24, 940-953.	0.3	5
1543	Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies. Frontiers in Oncology, 2022, 12, .	1.3	11
1544	Assessment of Hospitalizations and Emergency Department Visits After Chimeric Antigen Receptor T-Cell Therapy Among Commercially Insured Patients. JAMA Oncology, 2022, 8, 1068.	3.4	5
1545	An integrated approach to cardioprotection in lymphomas. Lancet Haematology,the, 2022, 9, e445-e454.	2.2	5
1546	CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights. Blood, 2022, 140, 1461-1469.	0.6	8
1547	gBOINâ€ET: The generalized Bayesian optimal interval design for optimal doseâ€finding accounting for ordinal graded efficacy and toxicity in early clinical trials. Biometrical Journal, 2022, 64, 1178-1191.	0.6	11

#	Article	IF	Citations
1548	Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma. Leukemia and Lymphoma, 2022, 63, 2041-2051.	0.6	1
1549	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discovery, 2022, 3, 385-393.	2.6	29
1550	Bench at Bedside Models Facilitate CAR-T Cell Supply Chain. Transplantation and Cellular Therapy, 2022, 28, 221-222.	0.6	2
1551	Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell, 2022, 185, 1745-1763.e22.	13.5	88
1552	Change in Patientsâ€™ Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. Transplantation and Cellular Therapy, 2022, 28, 401.e1-401.e7.	0.6	10
1553	Novel immunotherapies in multiple myeloma. International Journal of Hematology, 2022, 115, 799-810.	0.7	3
1554	THE ANTIBODY-DRUG CONJUGATE LONCASTUXIMAB TESIRINE FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA. Blood, 2022, , .	0.6	7
1555	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. Cancers, 2022, 14, 2470.	1.7	4
1556	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplantation, 2022, 57, 1217-1239.	1.3	119
1557	Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. , 2022, 10, e003486.		21
1558	The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. , 2022, 10, e004475.		50
1559	Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma. Clinical Cancer Research, 2022, 28, 3378-3386.	3.2	15
1560	Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment. International Review of Cell and Molecular Biology, 2022, , 123-147.	1.6	8
1561	Emerging Concepts in Managing Malignancy in Kidney Transplant Patients. Seminars in Nephrology, 2022, 42, 63-75.	0.6	4
1562	Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 753-759.	0.2	6
1563	CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings. Current Oncology, 2022, 29, 3647-3657.	0.9	18
1564	Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. Cancers, 2022, 14, 2516.	1.7	15
1565	Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies. Translational Oncology, 2022, 22, 101459.	1.7	8

#	Article	IF	Citations
1566	Systematic Review of Available CAR-T Cell Trials around the World. Cancers, 2022, 14, 2667.	1.7	31
1567	CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies. Cells, 2022, 11, 1804.	1.8	1
1568	Overcoming resistance to antiâ€CD19 CAR Tâ€cell therapy in Bâ€cell malignancies. Hematological Oncology, 2022, 40, 821-834.	0.8	3
1569	Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma. Frontiers in Immunology, 2022, 13, .	2.2	8
1570	Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive Bâ€cell ‹scp›nonâ€Hodgkin‹/scp› lymphoma. Cancer Medicine, 2022, 11, 4889-4899.	1.3	8
1571	BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events. Expert Review of Hematology, 2022, 15, 503-517.	1.0	1
1572	Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL. Frontiers in Immunology, 2022, 13, .	2.2	7
1573	Exhaustion of CAR T cells: potential causes and solutions. Journal of Translational Medicine, 2022, 20, .	1.8	32
1574	Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies. Cytotherapy, 2022, 24, 767-773.	0.3	10
1575	CAR-T cells for cancer immunotherapyâ€"the barriers ahead and the pathsÂthrough. International Reviews of Immunology, 2022, 41, 567-581.	1.5	1
1576	Nanodrugs Targeting T Cells in Tumor Therapy. Frontiers in Immunology, 0, 13, .	2.2	13
1577	Binding and Efficacy of Anti-Robo4 CAR-T Cells against Solid Tumors. Biomedicines, 2022, 10, 1273.	1.4	1
1578	Bispecific CAR T-cells for B-cell Malignancies. Expert Opinion on Biological Therapy, 2022, 22, 1005-1015.	1.4	5
1579	New Therapeutic Strategies for Adult Acute Myeloid Leukemia. Cancers, 2022, 14, 2806.	1.7	15
1580	Oncologic emergencies and urgencies: A comprehensive review. Ca-A Cancer Journal for Clinicians, 2022, 72, 570-593.	157.7	18
1581	Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies. Transfusion and Apheresis Science, 2022, 61, 103473.	0.5	1
1583	Cancer therapeutic drug guide. , 2023, , 451-506.		0
1584	Trust Your Gut: Changes in Intestinal Microbiome Are Associated With Outcomes Following CAR-T Therapy. , 2022, 19, .		0

#	Article	IF	Citations
1585	A Brief Introduction to Current Cancer Gene Therapy. Methods in Molecular Biology, 2022, , 1-21.	0.4	3
1587	Malignant Lymphoma:. Journal of the Nihon University Medical Association, 2022, 81, 83-86.	0.0	0
1588	Revising the Treatment Pathways in Lymphoma: New Standards of Careâ€"How Do We Choose?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 629-642.	1.8	2
1589	Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. Blood Advances, 0, , .	2.5	1
1590	Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing. Cytotherapy, 2022, 24, 869-878.	0.3	23
1591	LINC00461 Regulates the Recurrence of Large B Cell Lymphoma through the miR-411-5p/BNIP3 Pathway. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-13.	0.5	0
1592	Sustained Remission of Relapsed Diffuse Large B-cell Lymphoma After Safe Administration of CD19-directed CAR T-cells in a Patient With Chronic Intestinal and Pulmonal GvHD. HemaSphere, 2022, 6, e735.	1.2	1
1594	CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Frontiers in Immunology, 0, 13, .	2.2	55
1595	Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma. Expert Review of Anticancer Therapy, 0, , .	1.1	1
1597	Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy. Current Cardiology Reviews, 2022, 18, .	0.6	1
1598	CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity. International Journal of Molecular Sciences, 2022, 23, 6931.	1.8	3
1599	Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cellsâ€"single-center experience. Annals of Hematology, 2022, 101, 1769-1776.	0.8	13
1600	The Past, Present, and Future of Non-Viral CAR T Cells. Frontiers in Immunology, 0, 13, .	2.2	39
1601	Real-world characteristics of T-cell apheresis and clinical response toÂtisagenlecleucel in B-cell lymphoma. Blood Advances, 2022, 6, 4657-4660.	2.5	11
1602	ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy. Transplantation and Cellular Therapy, 2022, 28, 523-529.	0.6	7
1603	Review: Sustainable Clinical Development of CAR-T Cells â€“ Switching From Viral Transduction Towards CRISPR-Cas Gene Editing. Frontiers in Immunology, 0, 13, .	2.2	20
1604	Systemic Relapse in a Young Adult Patient with Primary CNS Diffuse Large B-Cell Lymphoma. Case Reports in Hematology, 2022, 2022, 1-9.	0.3	1
1605	CAR T-cell Infusion Following Checkpoint Inhibition Can Induce Remission in Chemorefractory Post-transplant Lymphoproliferative Disorder of the CNS. HemaSphere, 2022, 6, e733.	1.2	8

#	Article	IF	Citations
1606	Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	33
1607	Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective. Cancers, 2022, 14, 2912.	1.7	4
1608	Fertility and CAR T-cells: Current practice and future directions. Transplantation and Cellular Therapy, 2022, 28, 605.e1-605.e8.	0.6	5
1609	Prophylaxis and Management of Secondary CNS Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	0
1610	Enhanced systemic antilymphoma immune response by photothermal therapy with CpG deoxynucleotide coated nanoparticles. Blood Advances, 0, , .	2.5	2
1611	Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Annals of Oncology, 2022, 33, 916-928.	0.6	30
1612	A Bridge To CAR. Transplantation and Cellular Therapy, 2022, 28, 282-283.	0.6	1
1613	Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Transplantation and Cellular Therapy, 2022, 28, 610-617.	0.6	6
1614	Second-line CAR T cells for lymphomas. Lancet, The, 2022, 399, 2247-2249.	6.3	2
1615	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a profile of its use in the USA. Drugs and Therapy Perspectives, 0, , .	0.3	0
1616	Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain. Molecular Cancer Therapeutics, 2022, 21, 1171-1183.	1.9	4
1617	Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future. Frontiers in Immunology, 0, 13, .	2.2	69
1618	CD58 loss in tumor cells confers functional impairment of CAR TÂcells. Blood Advances, 2022, 6, 5844-5856.	2.5	20
1619	Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Science Advances, 2022, 8, .	4.7	63
1620	T-cell Immunotherapy and Cardiovascular Disease. Heart Failure Clinics, 2022, 18, 443-454.	1.0	2
1621	Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy. World Journal of Clinical Cases, 2022, 10, 6555-6562.	0.3	2
1622	Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR TÂcells inÂvitro and inÂvivo. Molecular Therapy - Oncolytics, 2022, 26, 120-134.	2.0	4
1623	Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. Therapeutic Advances in Hematology, 2022, 13, 204062072211006.	1.1	4

#	Article	IF	Citations
1624	Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma. Therapeutic Advances in Hematology, 2022, 13, 204062072211033.	1.1	11
1625	Chimeric antigen receptor T cells and management of toxicities: implications of biomarkers. , 2022, , 245-281.		0
1626	NK Cell-Based Immunotherapy in Colorectal Cancer. Vaccines, 2022, 10, 1033.	2.1	10
1627	Resource utilization for chimeric antigen receptor T cell therapy versus autologous hematopoietic cell transplantation in patients with B cell lymphoma. Annals of Hematology, 2022, 101, 1755-1767.	0.8	2
1628	Patterns of utilization and outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 rearrangements. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	0
1629	Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies. Cancers, 2022, 14, 3230.	1.7	23
1631	Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2022, 28, 546-559.	0.6	16
1632	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clinical Cancer Research, 2022, 28, 4003-4017.	3.2	15
1633	Cost-Effectiveness of Chimeric Antigen Receptor TÂCell Therapy in Patients with Relapsed or Refractory Large BÂCell Lymphoma: No Impact of Site of Care. Advances in Therapy, 0, , .	1.3	6
1634	Chimeric antigen receptor Tâ€cell therapy is superior to standard of care as secondâ€line therapy for large Bâ€cell lymphoma: A systematic review and metaâ€analysis. British Journal of Haematology, 2022, 198, 838-846.	1.2	12
1635	Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells. Haematologica, 2023, 108, 171-180.	1.7	11
1636	Retrospective Analysis of the Efficacy and Tolerability of Gemcitabine-based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	1
1637	Real-World Experience and Optimization of Outpatient Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2022, 28, 583-585.	0.6	6
1638	CAR T-cell therapy: which product for which patient?. Blood, 2022, 139, 3673-3674.	0.6	3
1639	Tumor immunotherapy: Mechanisms and clinical applications. , 2022, 1, .		2
1640	Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica, 2023, 108, 110-121.	1.7	39
1641	Antigen glycosylation regulates efficacy of CAR T cells targeting CD19. Nature Communications, 2022, 13, .	5.8	21
1642	Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. Journal of Hematology and Oncology, 2022, 15, .	6.9	23

#	Article	IF	Citations
1643	Case Report: Subtotal Lymphoid and Total Marrow Irradiation as Bridge Therapy to CD19-Directed CAR T Cells in a Chemorefractory DLBCL With Leukemic Involvement. Frontiers in Immunology, 0, 13, .	2.2	2
1644	Targeting the Microenvironment for Treating Multiple Myeloma. International Journal of Molecular Sciences, 2022, 23, 7627.	1.8	9
1645	Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 863-868.	0.2	3
1648	Immunotherapy of sarcomas with modified T cells. Current Opinion in Oncology, 2022, 34, 362-370.	1.1	5
1649	Real world CAR T cell data in diffuse large B-cell lymphoma: hitting a moving target. Leukemia and Lymphoma, 0, , 1-2.	0.6	0
1650	Chimeric antigen receptor T-cell therapy in adults: management of toxicities and implications for critical care. BJA Education, 2022, 22, 330-333.	0.6	1
1651	Radiation Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: What Is the Right Regimen for Palliation?. Advances in Radiation Oncology, 2022, 7, 101016.	0.6	3
1652	Socioeconomic and Racial Disparity in Chimeric antigen receptor T cell (CART)Therapy Access. Transplantation and Cellular Therapy, 2022, 28, 345-346.	0.6	2
1653	Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies. Clinical Cancer Research, 2022, 28, 3940-3949.	3.2	4
1654	Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database. Drug Safety, 2022, 45, 891-908.	1.4	18
1655	Infections in hematologic malignancy patients treated by CD19 chimeric antigen receptor Tâ€cell therapy. Immunomedicine, 0, , .	0.7	1
1656	A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma. Journal of Cancer Research and Clinical Oncology, 2023, 149, 2757-2769.	1.2	4
1657	Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2022, 28, 668.e1-668.e6.	0.6	4
1658	Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany. HemaSphere, 2022, 6, e736.	1.2	4
1659	Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma. Expert Review of Anticancer Therapy, 2022, 22, 903-914.	1.1	1
1660	Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions. Current Opinion in Hematology, 2022, 29, 225-232.	1.2	3
1661	Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. Blood Advances, 2022, 6, 3970-3973.	2.5	6
1662	Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma. Leukemia and Lymphoma, 0, , 1-5.	0.6	0

#	Article	IF	Citations
1663	Patient preferences for treatment in relapsed/refractory diffuse large B-cell lymphoma: a discrete choice experiment. Future Oncology, 2022, 18, 2791-2804.	1.1	1
1664	Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. Clinical Cancer Research, 2022, 28, 3658-3668.	3.2	5
1665	The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose. Expert Review of Anti-Infective Therapy, 2022, 20, 1155-1162.	2.0	3
1666	Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. Blood Advances, 2022, 6, 4821-4830.	2.5	20
1667	Advances and challenges of CARÂTÂtherapy and suitability of animal models (Review). Molecular and Clinical Oncology, 2022, 17, .	0.4	4
1668	Severe acute heart failure during or following cytokine release syndrome after CAR T-cell therapy. Leukemia Research Reports, 2022, , 100338.	0.2	1
1669	Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups. Frontiers in Immunology, 0, 13, .	2.2	13
1670	Pixantrone in patients with relapsed/refractory diffuse large Bâ€cell lymphoma: A realâ€life, retrospective, multicenter trial on behalf of the â€œRTLâ€•(Regional TUSCAN Lymphoma) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 595-596.	1.1	1
1671	Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplantation, 2022, 57, 1477-1488.	1.3	28
1672	Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. Transplantation and Cellular Therapy, 2022, 28, 669-676.	0.6	36
1673	Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica, 2023, 108, 98-109.	1.7	29
1674	Latest developments in the pathobiology of Ewing sarcoma. Journal of Bone Oncology, 2022, 35, 100440.	1.0	0
1675	The Challenges of Novel Therapies in the Care of the Critically Ill Cancer Patient. , 2023, , 448-458.		0
1676	Follicular lymphoma: The long and winding road leading to your cure?. Blood Reviews, 2023, 57, 100992.	2.8	9
1677	Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date. OncoTargets and Therapy, 0, Volume 15, 799-813.	1.0	3
1678	Discovery of a Transferrin Receptor 1-Binding Aptamer and Its Application in Cancer Cell Depletion for Adoptive T-Cell Therapy Manufacturing. Journal of the American Chemical Society, 2022, 144, 13851-13864.	6.6	20
1679	Natural killer cells in antitumour adoptive cell immunotherapy. Nature Reviews Cancer, 2022, 22, 557-575.	12.8	208
1680	Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma. Blood Cancer Journal, 2022, 12, .	2.8	15

#	Article	IF	Citations
1682	Apheresis for chimeric antigen receptor Tâ€cell production in adult lymphoma patients. Transfusion, 2022, 62, 1602-1611.	0.8	7
1683	CAR T-cells in relapsed Burkitt lymphoma â€“ a promising test drive in a rare disease. Leukemia and Lymphoma, 0, , 1-2.	0.6	1
1684	Preclinical In Vitro and In Vivo Models for Adoptive Cell Therapy of Cancer. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.0	2
1685	Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective. Transplantation and Cellular Therapy, 2022, 28, 727-736.	0.6	5
1686	Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells. Scientific Reports, 2022, 12, .	1.6	17
1687	Broadening the MIND: tafasitamab and lenalidomide versus synthetic controls. Clinical Cancer Research, 0, , .	3.2	0
1688	Complete responses to odronextamab in two patients with diffuse large Bâ€cell lymphoma refractory to chimeric antigen receptor Tâ€cell therapy. British Journal of Haematology, 2022, 199, 366-370.	1.2	4
1689	Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era. Frontiers in Immunology, 0, 13, .	2.2	6
1690	Natural killer cells: the next wave in cancer immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	4
1691	Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment. International Journal of Molecular Sciences, 2022, 23, 8242.	1.8	4
1692	Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer. Cancer Discovery, 2022, 12, 2372-2391.	7.7	19
1693	Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas. Current Opinion in Oncology, 2022, 34, 524-530.	1.1	2
1694	Intrathecal Chemotherapy as a Potential Treatment for Steroid-refractory Immune Effector Cell-associated Neurotoxicity Syndrome. Anticancer Research, 2022, 42, 3853-3856.	0.5	6
1695	Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient. Leukemia and Lymphoma, 2022, 63, 3012-3014.	0.6	2
1696	Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas. American Journal of Clinical Dermatology, 2022, 23, 689-706.	3.3	11
1697	Real time experience applying CAR T-cells for B-cell lymphomaâ€"What we have learned so far: Acute toxicity management. Memo - Magazine of European Medical Oncology, 0, , .	0.3	0
1698	CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure. Frontiers in Immunology, 0, 13, .	2.2	8
1699	Chimeric antigen receptor engineered T-cell therapy for central nervous system lymphoma. , 2022, 1, .		0

#	Article	IF	Citations
1700	Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial. PharmacoEconomics - Open, 2023, 7, 37-46.	0.9	1
1701	Acute myeloid leukemia development soon after anti-CD19 chimeric antigen receptor T-cell infusion in a patient with refractory diffuse large B-cell lymphoma and pre-existing clonal hematopoiesis. Haematologica, 2023, 108, 290-294.	1.7	4
1702	German CARs keeping pace. Blood, 2022, 140, 296-298.	0.6	0
1703	Severe infections in recipients of cancer immunotherapy: what intensivists need to know. Current Opinion in Critical Care, 2022, 28, 540-550.	1.6	5
1704	Challenges for Economic Evaluations of Advanced Therapy Medicinal Products: A Systematic Review. Value in Health, 2023, 26, 138-150.	0.1	5
1705	Recent Advances and Challenges in Cancer Immunotherapy. Cancers, 2022, 14, 3972.	1.7	26
1706	Chimeric Antigen Receptor-T Cell Therapy. Korean Journal of Medicine, 2022, 97, 229-237.	0.1	0
1707	Understanding CAR TÂcell-tumor interactions: Paving the way for successful clinical outcomes. Med, 2022, 3, 538-564.	2.2	11
1708	Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies. Frontiers in Immunology, 0, 13, .	2.2	13
1709	Overcoming tumor resistance mechanisms in CAR-NK cell therapy. Frontiers in Immunology, 0, 13, .	2.2	22
1710	Tumor-intrinsic causes of CAR-T failure. Blood, 2022, 140, 414-415.	0.6	0
1711	Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy. Blood Advances, 2022, 6, 4719-4725.	2.5	25
1712	Fitness criteria for Australian patients referred for chimeric antigen receptor Tâ€cell therapy. Internal Medicine Journal, 2022, 52, 1454-1456.	0.5	0
1714	CAR-NK Cells: A Chimeric Hope or a Promising Therapy?. Cancers, 2022, 14, 3839.	1.7	15
1715	The use of ICU resources in CAR-T cell recipients: a hospital-wide study. Annals of Intensive Care, 2022, 12, .	2.2	9
1716	CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives. Biomedicines, 2022, 10, 1960.	1.4	5
1717	The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial. Transplantation and Cellular Therapy, 2022, 28, 750.e1-750.e6.	0.6	10
1718	TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate. Cancer Immunology Research, 2022, 10, 1263-1279.	1.6	0

#	Article	IF	Citations
1719	Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. Blood, 2022, 140, 2024-2036.	0.6	15
1720	Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation. Blood Reviews, 2023, 57, 101002.	2.8	8
1721	Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma. Frontiers in Immunology, 0, 13, .	2.2	3
1722	Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients. Frontiers in Immunology, 0, 13, .	2.2	9
1723	Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy. Haematologica, 2023, 108, 444-456.	1.7	5
1724	Road testing new CAR design strategies in multiple myeloma. Frontiers in Immunology, 0, 13, .	2.2	3
1725	Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Frontiers in Immunology, 0, 13, .	2.2	20
1726	Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma. Transplantation and Cellular Therapy, 2022, 28, 751.e1-751.e7.	0.6	2
1727	Successful provision of CAR-T therapy during a pandemic: low SARS-CoV-2 infection rates and reduction in ICU admissions following modification of patient pathway. Leukemia and Lymphoma, 2022, 63, 3265-3267.	0.6	1
1728	Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments. Cancer Imaging, 2022, 22, .	1.2	9
1729	Land(mark) ahoy: PFS24 in relapsed/refractory diffuse large B-cell lymphoma. Transplantation and Cellular Therapy, 2022, 28, 521-522.	0.6	0
1730	The association of cardiac arrhythmias with chimeric antigen receptor T cell therapy in hospitalised patients: Insights from National Inpatient Sample. European Journal of Cancer, 2022, 174, 131-133.	1.3	2
1731	Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy. Radiotherapy and Oncology, 2022, 175, 65-72.	0.3	13
1732	Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treatment Reviews, 2022, 110, 102443.	3.4	39
1733	Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors. , 2022, 10, e004854.		8
1734	Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma. Leukemia and Lymphoma, 2022, 63, 3052-3062.	0.6	2
1735	Positron emission tomography derived metrics in relapsed or refractory large Bâ€cell lymphoma with residual disease before autologous stem cell transplant. British Journal of Haematology, 0, , .	1.2	3
1736	CAR-T cellsâ€"Real-time experience applying CAR-T cellsâ€"What we have learned so far. Memo - Magazine of European Medical Oncology, 2022, 15, 173-175.	0.3	0

#	Article	IF	Citations
1737	Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor. Pharmacological Research, 2022, 184, 106454.	3.1	11
1738	EXABS-211-CT Building Your CAR-T Program. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, S104-S105.	0.2	0
1739	Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population. European Journal of Cancer, 2022, 175, 246-253.	1.3	5
1740	IP-10 enhances the amplification capacity and antitumor activity of CAR-T cells in vitro and could influence positive outcomes in MM patients treated with CAR-T cell therapy. International Immunopharmacology, 2022, 112, 109253.	1.7	1
1741	Applying a clinical lens to animal models of CAR-T cell therapies. Molecular Therapy - Methods and Clinical Development, 2022, 27, 17-31.	1.8	18
1742	A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy. NMC Case Report Journal, 2022, 9, 275-280.	0.2	0
1743	Preservation and Storage of Cells for Therapy: Current Applications and Protocols. Reference Series in Biomedical Engineering, 2022, , 1-69.	0.1	2
1744	Recent advances in organotypic tissue slice cultures for anticancer drug development. International Journal of Biological Sciences, 2022, 18, 5885-5896.	2.6	16
1745	Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies. Technology in Cancer Research and Treatment, 2022, 21, 153303382211184.	0.8	2
1746	A tractable microscopy- and flow cytometry-based method to measure natural killer cell-mediated killing and infiltration of tumor spheroids. Methods in Cell Biology, 2023, , 43-61.	0.5	1
1747	Intracellular Cardiac Signaling Pathways Altered by Cancer Therapies. , 2022, , 111-173.		0
1748	Acute Kidney Injury in Cancer Patients. Nephrology Self-assessment Program: NephSAP, 2022, 21, 100-107.	3.0	0
1750	Update on diffuse large B-cell lymphoma: highlights from the 2022 ASCO Annual Meeting. Cancer Biology and Medicine, 2022, 19, 1117-1120.	1.4	2
1751	Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations. BMJ, The, 0, , e068956.	3.0	4
1752	High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion. Cancer Gene Therapy, 0, , .	2.2	0
1753	Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. Cancers, 2022, 14, 4192.	1.7	6
1754	Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results. Blood Advances, 2023, 7, 2283-2286.	2.5	6
1755	CAR-T cell potency: from structural elements to vector backbone components. Biomarker Research, 2022, 10, .	2.8	14

#	Article	IF	Citations
1756	Emerging Therapies for the Management of Richter Transformation. Journal of Clinical Oncology, 2023, 41, 395-409.	0.8	10
1757	Chimeric Antigen Receptor (CAR) T-cell Treatment in Renal Cell Carcinoma: Current Clinical Trials and Future Directions. Kidney Cancer, 2022, 6, 159-168.	0.2	1
1758	Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplantation and Cellular Therapy, 2022, 28, 829.e1-829.e8.	0.6	7
1759	Longâ€term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific <scp>LV20</scp>.19 <scp>CAR</scp> Tâ€cells. American Journal of Hematology, 2022, 97, 1580-1588.	2.0	5
1760	CAR Treg cells: prime suspects in therapeutic resistance. Nature Medicine, 2022, 28, 1755-1756.	15.2	4
1761	Comparing Intraperitoneal and Intravenous Personalized ErbB2CAR-T for the Treatment of Epithelial Ovarian Cancer. Biomedicines, 2022, 10, 2216.	1.4	2
1762	Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy. , 2022, 10, e004567.		3
1763	Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis. Expert Review of Anti-Infective Therapy, 2022, 20, 1455-1476.	2.0	8
1764	Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment. Frontiers in Oncology, 0, 12, .	1.3	5
1765	Recent Advances in the Use of Chimeric Antigen Receptorâ€"Expressing T-Cell Therapies for Treatment of Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, 22-27.	0.2	2
1766	Case Analysis in Drug Approval by FDA/EMA Using Real-World Data/Real-World Evidence. , 2022, 14, 133-143.		0
1767	Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	21
1768	Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies. Cancers, 2022, 14, 4452.	1.7	1
1769	Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting. Experimental Hematology and Oncology, 2022, 11, .	2.0	8
1770	Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Advances, 2022, 6, 5969-5979.	2.5	5
1771	Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer. Frontiers in Oncology, 0, 12, .	1.3	0
1772	IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines. Frontiers in Immunology, 0, 13, .	2.2	12
1773	Impact of Cytomegalovirus Replication in Patients with Aggressive B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2022, 28, 851.e1-851.e8.	0.6	10

#	Article	IF	Citations
1774	Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel. Leukemia and Lymphoma, 0, , 1-9.	0.6	4
1775	Paving the road to make chimeric antigen receptorâ€Tâ€cell therapy effective against solid tumors. Cancer Science, 2022, 113, 4020-4029.	1.7	2
1776	Periâ€“CAR-T practice patterns and survival predictors for all CAR-T patients and postâ€“CAR-T failure in aggressive B-NHL. Blood Advances, 2023, 7, 2657-2669.	2.5	11
1777	Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nature Medicine, 2022, 28, 1848-1859.	15.2	79
1778	Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy. Nature Medicine, 2022, 28, 1860-1871.	15.2	80
1779	Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy. Cancers, 2022, 14, 4700.	1.7	6
1780	Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies. Stem Cell Research and Therapy, 2022, 13, .	2.4	11
1781	TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Molecular Cancer, 2022, 21, .	7.9	22
1782	A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nature Medicine, 2022, 28, 2145-2154.	15.2	106
1783	Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis. Leukemia, 2022, 36, 2596-2604.	3.3	17
1784	The correlation factors and prognostic significance of coagulation disorders after chimeric antigen receptor T cell therapy in hematological malignancies: a cohort study. Annals of Translational Medicine, 2022, 10, 975-975.	0.7	2
1785	Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood, 2022, 140, 2584-2593.	0.6	41
1786	Co-Stimulatory Receptor Signaling in CAR-T Cells. Biomolecules, 2022, 12, 1303.	1.8	11
1787	Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing. Frontiers in Immunology, 0, 13, .	2.2	9
1788	Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nature Medicine, 2022, 28, 2124-2132.	15.2	244
1789	Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP. Expert Review of Hematology, 2022, 15, 805-812.	1.0	1
1790	The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy. Frontiers in Oncology, 0, 12, .	1.3	3
1791	CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome. Science Advances, 2022, 8, .	4.7	19

#	Article	IF	Citations
1792	Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma. Frontiers in Immunology, 0, 13, .	2.2	5
1793	Management of prolonged cytopenia following CAR T-cell therapy. Bone Marrow Transplantation, 2022, 57, 1839-1841.	1.3	8
1794	Therapeutic Advances in Immunotherapies for Hematological Malignancies. International Journal of Molecular Sciences, 2022, 23, 11526.	1.8	6
1795	Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, 15-21.	0.2	2
1796	Clinical and Radiographic Predictors of Progression and Survival in Relapsed/Refractory Lymphoma Patients Receiving Anti-CD19 CAR T-cell Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, 49-56.	0.2	3
1797	The forgotten survivor: A comprehensive review on <scp>Nonâ€Hodgkin</scp> lymphoma survivorship. American Journal of Hematology, 2022, 97, 1627-1637.	2.0	3
1798	Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy. Frontiers in Immunology, 0, 13, .	2.2	1
1799	Choosing a CAR for Relapsed/Refractory Large B-cell Lymphoma. Transplantation and Cellular Therapy, 2022, 28, 621-622.	0.6	1
1800	Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, e14-e18.	0.2	1
1801	Treatment Options for Recurrent Primary CNS Lymphoma. Current Treatment Options in Oncology, 2022, 23, 1548-1565.	1.3	1
1802	Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions. Technology in Cancer Research and Treatment, 2022, 21, 153303382211329.	0.8	2
1803	Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo. Technology in Cancer Research and Treatment, 2022, 21, 153303382211332.	0.8	3
1804	Relapsed/refractory diffuse large B-cell lymphoma - advancements in treatment. Medicinski Pregled, 2022, 75, 96-99.	0.1	0
1806	The journey of CAR-T therapy in hematological malignancies. Molecular Cancer, 2022, 21, .	7.9	45
1807	The clinical supply of cell and gene therapy drugs: Challenges ahead. Drug Discovery Today, 2022, , 103421.	3.2	1
1808	Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge. Transplantation and Cellular Therapy, 2023, 29, 34.e1-34.e7.	0.6	3
1809	Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors. , 2022, 10, e004781.		2
1810	Clinical characteristics and prognosis of 16 relapsed/refractory B-cell malignancy patients with CAR T-cell-related hyperferritinaemia. Frontiers in Oncology, 0, 12, .	1.3	0

#	Article	IF	Citations
1812	CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review. Frontiers in Oncology, 0, 12, .	1.3	2
1813	Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2023, 41, 1577-1589.	0.8	12
1814	Whole-process management of complications during CAR-T therapy. , 2022, 1, .		0
1815	Utilization of <scp>realâ€world</scp> data in assessing treatment effectiveness for diffuse large <scp>Bâ€cell</scp> lymphoma. American Journal of Hematology, 2023, 98, 180-192.	2.0	3
1817	Tumor buster - where will the CAR-T cell therapy â€˜missileâ€™ go?. Molecular Cancer, 2022, 21, .	7.9	23
1818	Timely Leukapheresis May Interfere with the â€œFitnessâ€•of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients. Cancers, 2022, 14, 5276.	1.7	3
1819	Comparison of Acoustofluidic and Static Systems for Ultrasound-Mediated Molecular Delivery to T Lymphocytes. Ultrasound in Medicine and Biology, 2023, 49, 90-105.	0.7	1
1820	Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells. Cancer Cell, 2022, 40, 1407-1422.e7.	7.7	27
1822	Next generations of CAR-T cells - new therapeutic opportunities in hematology?. Frontiers in Immunology, 0, 13, .	2.2	24
1823	A novel non-viral PDCD1 site-integrated CAR design: killing 2 birds with 1 stone. Blood Science, 2022, 4, 211-213.	0.4	0
1824	Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study. Acta OncolÃ³gica, 2022, 61, 1332-1338.	0.8	1
1825	Genome-edited allogeneic donor â€œuniversalâ€•chimeric antigen receptor T cells. Blood, 2023, 141, 835-845.	0.6	11
1826	Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Advances, 2023, 7, 32-39.	2.5	32
1827	Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma. Cytotherapy, 2022, , .	0.3	0
1828	Clinical implications of T cell exhaustion for cancer immunotherapy. Nature Reviews Clinical Oncology, 2022, 19, 775-790.	12.5	182
1829	Emerging frontiers in immuno- and gene therapy for cancer. Cytotherapy, 2023, 25, 20-32.	0.3	3
1830	A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy. Transplantation and Cellular Therapy, 2023, 29, 59.e1-59.e6.	0.6	1
1831	The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Frontiers in Pharmacology, 0, 13, .	1.6	7

#	Article	IF	Citations
1832	Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed/refractory aggressive B-cell lymphoma. Radiotherapy and Oncology, 2022, 177, 53-60.	0.3	6
1834	Cross-study safety analysis of risk factors in CAR TÂcell clinical trials: An FDA database pilot project. Molecular Therapy - Oncolytics, 2022, 27, 182-194.	2.0	1
1835	CAPG facilitates diffuse large B-cell lymphoma cell progression through PI3K/AKT signaling pathway. Human Immunology, 2022, 83, 832-842.	1.2	2
1836	<scp>Realâ€world</scp> experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The <scp>SCHOLAR</scp>â€2 retrospective chart review study. British Journal of Haematology, 2023, 202, 749-759.	1.2	10
1837	Exploring the mechanisms of CD19 CAR T-cell failure and salvage strategies in B-cell lymphoma. , 2022, 1, .		0
1838	Transformed WaldenstrÃ¶m Macroglobulinemia: Update on Diagnosis, Prognosis and Treatment. Hemato, 2022, 3, 650-662.	0.2	1
1839	Advances in immunotherapy for glioblastoma multiforme. Frontiers in Immunology, 0, 13, .	2.2	24
1841	Migratory Engineering of T Cells for Cancer Therapy. Vaccines, 2022, 10, 1845.	2.1	8
1842	Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon. International Journal of Molecular Sciences, 2022, 23, 13332.	1.8	10
1843	Development of non-viral site-specific integrated CAR-T technology and its application in clinical treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. Chinese Science Bulletin, 2022, , .	0.4	0
1844	Nanomedicine for advanced cancer immunotherapy. Journal of Controlled Release, 2022, 351, 1017-1037.	4.8	7
1845	Administration of granulocyte-macrophage colony-stimulating factor enhanced chimeric antigen receptor T-cell expansion and cellular immunity recovery without inducing cytokine release syndrome. Frontiers in Medicine, 0, 9, .	1.2	1
1846	Toxicities following CAR-T therapy for hematological malignancies. Cancer Treatment Reviews, 2022, 111, 102479.	3.4	13
1847	A systematic review of contemporary phase I trials in patients with lymphoma. Critical Reviews in Oncology/Hematology, 2022, 180, 103860.	2.0	1
1848	A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy. Blood Advances, 2023, 7, 2479-2493.	2.5	4
1849	Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial. BMJ Open, 2022, 12, e065109.	0.8	3
1850	Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Advances, 2023, 7, 3192-3198.	2.5	9
1851	Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes. Expert Review of Hematology, 2022, 15, 1023-1030.	1.0	4

#	Article	IF	Citations
1852	Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies. Frontiers in Immunology, 0, 13, .	2.2	6
1853	Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma. Leukemia, 2023, 37, 154-163.	3.3	14
1854	Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors. Annals of Medicine, 2022, 54, 2950-2964.	1.5	5
1855	In vivo killing of primary HIV-infected cells by peripheral-injected early memoryâ€“enriched anti-HIV duoCAR T cells. JCI Insight, 2022, 7, .	2.3	10
1856	A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Reports Medicine, 2022, 3, 100720.	3.3	2
1858	Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma. Discover Oncology, 2022, 13, .	0.8	0
1859	Expression levels and patterns of Bâ€cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinent. Cytometry Part B - Clinical Cytometry, 2022, 102, 462-470.	0.7	1
1860	<scp>CAR</scp> T cellâ€driven cerebrospinal fluid cytokine storm with confounding neurological picture in chemorefractory primary cardiac lymphoma. American Journal of Hematology, 2023, 98, 212-219.	2.0	0
1861	T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy. Scientific Reports, 2022, 12, .	1.6	8
1862	Changing the Tune for CAR T-Cell Therapy: A Music City Experience in Remote Patient Monitoring. Oncology Issues, 2022, 37, 20-24.	0.0	1
1863	Evolving Landscape of Antibody Drug Conjugates in Lymphoma. Cancer Journal (Sudbury, Mass), 2022, 28, 479-487.	1.0	2
1864	Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells. Blood, 2023, 141, 673-677.	0.6	3
1865	Gastric adenocarcinoma following CD19-directed chimeric antigen receptor T cell therapy. Annals of Hematology, 0, , .	0.8	1
1866	Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2023, 29, 99-107.	0.6	10
1867	Preclinical models for development of immuneâ€“oncology therapies. Immuno-oncology Insights, 2022, 03, 396-398.	0.0	2
1868	Host metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy. Blood Advances, 2023, 7, 4690-4700.	2.5	1
1869	Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox. Cancers, 2022, 14, 5657.	1.7	4
1870	Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial. International Journal of Hematology, 2023, 117, 251-259.	0.7	2

#	Article	IF	Citations
1871	Gene and Cell Therapy: How to Build a BioDrug. Pediatric Oncology, 2022, , 51-88.	0.5	0
1872	Infection Associated with the Use of CAR T Cells. , 2022, , 315-331.		0
1873	CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma. Therapeutic Advances in Hematology, 2022, 13, 204062072211421.	1.1	5
1874	Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma. Journal of Comparative Effectiveness Research, 2023, 12, .	0.6	1
1875	Polymer- and lipid-based gene delivery technology for CAR T cell therapy. Journal of Controlled Release, 2023, 353, 196-215.	4.8	11
1876	Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR TÂcells are as effective as freshly infused cells. Molecular Therapy - Methods and Clinical Development, 2023, 28, 51-61.	1.8	3
1877	The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma. Therapeutic Advances in Hematology, 2022, 13, 204062072211415.	1.1	3
1878	Immunotherapy of Lymphoma. , 2022, , 1-24.		0
1880	Chimeric antigen receptor T-cell therapy for T-ALL and AML. Frontiers in Oncology, 0, 12, .	1.3	11
1881	Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups. Cancers, 2022, 14, 5670.	1.7	0
1882	A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: Recommendations for service development and implications for palliative care teams. Palliative Medicine, 2023, 37, 215-220.	1.3	6
1883	Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy â€“ a retrospective cohort study using CMS 100% Medicare claims database. Leukemia and Lymphoma, 2023, 64, 339-348.	0.6	3
1884	CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil. Frontiers in Immunology, 0, 13, .	2.2	24
1885	The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma. Journal of Oncology, 2022, 2022, 1-20.	0.6	6
1886	Prognostic impact of peripheral eosinophil counts in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy. Cytotherapy, 2022, , .	0.3	0
1887	Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade. Immuno, 2022, 2, 671-691.	0.6	2
1888	Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment. Current Oncology, 2022, 29, 8975-9005.	0.9	9
1889	Multiplexed engineering and precision gene editing in cellular immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	4

#	Article	IF	Citations
1890	EEG-based grading of immune effector cell-associated neurotoxicity syndrome. Scientific Reports, 2022, 12, .	1.6	0
1891	â€œA.B.C.â€•of Immunotherapy in Hematological Malignanciesâ€¦Promise and Perils. Indian Journal of Medical and Paediatric Oncology, 0, , .	0.1	0
1892	Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy. , 2022, 10, e005459.		4
1893	Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1406-1413.	3.3	7
1894	Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood Advances, 2023, 7, 4765-4772.	2.5	2
1895	Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options. OncoTargets and Therapy, 0, Volume 15, 1481-1501.	1.0	11
1896	Fulminant Cardiotoxicity in a Patient With Cardiac Lymphoma Treated With CAR-T Cells. JACC: CardioOncology, 2022, 4, 708-712.	1.7	2
1897	Current Status of Novel Agents for the Treatment of B Cell Malignancies: Whatâ€™s Coming Next?. Cancers, 2022, 14, 6026.	1.7	4
1898	Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science, 2022, 378, .	6.0	56
1899	Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors. OncoImmunology, 2023, 12, .	2.1	7
1900	A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count. Journal of Translational Medicine, 2022, 20, .	1.8	4
1901	Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 2022, 387, 2220-2231.	13.9	151
1902	Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options. Journal of Clinical Medicine, 2022, 11, 7542.	1.0	7
1903	Cancer Immunotherapy Beyond Checkpoint Blockade. JACC: CardioOncology, 2022, 4, 563-578.	1.7	1
1904	Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR/CXCR5 T cells. Frontiers in Immunology, 0, 13, .	2.2	2
1905	Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy. Cancer Imaging, 2022, 22, .	1.2	5
1906	Chimeric Antigen Receptor T Cells: Toxicity and Management Considerations. AACN Advanced Critical Care, 2022, 33, 301-307.	0.6	1
1907	Doseâ€“response correlation for CAR-T cells: a systematic review of clinical studies. , 2022, 10, e005678.		15

#	Article	IF	Citations
1908	Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkinâ€™s lymphoma: 2-year results of a phase 1 trial. Bone Marrow Transplantation, 2023, 58, 288-294.	1.3	2
1909	Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors. Cancers, 2022, 14, 5983.	1.7	6
1910	Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2023, 116, 999-1007.	0.4	7
1911	Engineered hydrogels for mechanobiology. Nature Reviews Methods Primers, 2022, 2, .	11.8	37
1912	Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. JAMA Network Open, 2022, 5, e2245956.	2.8	13
1913	CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies. Frontiers in Immunology, 0, 13, .	2.2	5
1914	Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?. Journal of Cancer Research and Clinical Oncology, 2023, 149, 2709-2734.	1.2	6
1915	Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma. Cells, 2022, 11, 4085.	1.8	1
1917	Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes. Radiology and Oncology, 2022, 56, 409-419.	0.6	2
1918	Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities. JCO Oncology Practice, 2023, 19, e407-e416.	1.4	2
1919	Acute Kidney Injury in Cancer Immunotherapy Recipients. Cells, 2022, 11, 3991.	1.8	4
1920	Outcomes of Older Adults with Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Mayo Clinic Cohort Analysis. Transplantation and Cellular Therapy, 2023, 29, 176.e1-176.e8.	0.6	0
1921	A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas. Leukemia, 2023, 37, 18-34.	3.3	21
1922	PET/CT in Non-Hodgkin Lymphoma: An Update. Seminars in Nuclear Medicine, 2023, 53, 320-351.	2.5	13
1923	Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T-cell therapy: Results from a comprehensive cancer center. PLoS ONE, 2022, 17, e0278950.	1.1	3
1924	Health economic analysis of third-line interventions in diffuse large B-cell lymphomas in Germany: applying the efficiency frontier. Cost Effectiveness and Resource Allocation, 2022, 20, .	0.6	2
1925	Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes. Biomedicines, 2022, 10, 3196.	1.4	6
1926	Sequencing therapy in relapsed DLBCL. Hematology American Society of Hematology Education Program, 2022, 2022, 146-154.	0.9	8

#	Article	IF	Citations
1927	Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors. Frontiers in Immunology, 0, 13, .	2.2	1
1928	Cardiotoxicity of T-Cell AntineoplasticÂTherapies. JACC: CardioOncology, 2022, 4, 616-623.	1.7	10
1929	The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy. Frontiers in Medicine, 0, 9, .	1.2	0
1930	Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond. International Journal of Molecular Sciences, 2023, 24, 204.	1.8	0
1931	A novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture. Cytotherapy, 2023, 25, 323-329.	0.3	8
1932	Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML). Journal of Translational Medicine, 2022, 20, .	1.8	5
1933	Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR TÂcells. Molecular Therapy, 2023, 31, 676-685.	3.7	4
1934	Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cellâ€“Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. Journal of Clinical Oncology, 2023, 41, 2238-2247.	0.8	107
1935	Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy. Current Treatment Options in Oncology, 2022, 23, 1845-1860.	1.3	2
1936	Do CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms?. International Journal of Molecular Sciences, 2023, 24, 1045.	1.8	2
1937	Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel. Molecular Cancer Therapeutics, 2023, 22, 406-418.	1.9	2
1938	Current state of CAR-T therapy for T-cell malignancies. Therapeutic Advances in Hematology, 2022, 13, 204062072211430.	1.1	11
1939	Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells. International Journal of Nanomedicine, 0, Volume 18, 49-63.	3.3	7
1940	Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR TÂcell immunotherapy. Molecular Therapy, 2023, 31, 686-700.	3.7	7
1941	Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity. Frontiers in Immunology, 0, 13, .	2.2	3
1943	The frequency of differentiated CD3+CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma. Frontiers in Immunology, 0, 13, .	2.2	4
1944	CAR T-cell Therapy: A Major Shift in the Treatment Landscape for Early-Relapse Aggressive B-Cell Lymphomas. , 2023, 20, .		0
1945	Signaling pathways in brain tumors and therapeutic interventions. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	13

#	Article	IF	Citations
1946	Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma. Future Oncology, 2023, 19, 19-28.	1.1	4
1947	Multi-Stakeholder Qualitative Interviews to Inform Measurement of Patient Reported Outcomes After CAR-T. Transplantation and Cellular Therapy, 2023, 29, 254.e1-254.e9.	0.6	3
1948	Molecular and therapeutic effect of CRISPR in treating cancer. , 2023, 40, .		2
1949	CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses. , 2023, 11, e005878.		11
1950	Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation. Annals of Hematology, 0, , .	0.8	0
1951	Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell, 2023, 41, 210-225.e5.	7.7	32
1952	Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare setting. Journal of Market Access & Health Policy, 2023, 11, .	0.8	0
1953	Targeting Positive Cofactor 4 induces autophagic cell death in MYC-expressing diffuse large B cell lymphoma. Experimental Hematology, 2023, , .	0.2	1
1954	Four challenges to CAR T cells breaking the glass ceiling. European Journal of Immunology, 2023, 53, .	1.6	10
1955	Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?. Frontiers in Oncology, 0, 12, .	1.3	2
1956	Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review. Frontiers in Immunology, 0, 13, .	2.2	2
1957	Projecting overall survival in health-economic models: uncertainty and maturity of data. Current Medical Research and Opinion, 2023, 39, 367-374.	0.9	1
1958	The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study. EClinicalMedicine, 2023, 56, 101779.	3.2	8
1959	CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A Single-Center Retrospective Canadian Study. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, 203-210.	0.2	1
1960	It Is in the Eye of the Beholder: Ocular Ultrasound Enhanced Monitoring of Neurotoxicity after CAR-T Cell Therapy. Hematology Reports, 2023, 15, 1-8.	0.3	1
1961	Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2023, 29, 165.e1-165.e7.	0.6	6
1962	Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nature Biotechnology, 2023, 41, 1229-1238.	9.4	22
1963	Relapsed or refractory large Bâ€cell lymphoma after chimeric antigen receptor Tâ€cell therapy: Current challenges and therapeutic options. British Journal of Haematology, 2023, 201, 15-24.	1.2	3

#	Article	IF	Citations
1964	Diabetes insipidus and Guillain-BarrÃ©-like syndrome following CAR-T cell therapy: a case report. , 2023, 11, e006059.		3
1965	Impact of Precision Medicine in Oncology. Cancer Journal (Sudbury, Mass), 2023, 29, 15-19.	1.0	1
1966	CAR T cells: engineered immune cells to treat brain cancers and beyond. Molecular Cancer, 2023, 22, .	7.9	7
1967	Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma. Expert Review of Anticancer Therapy, 2023, 23, 121-126.	1.1	1
1968	Tumor immunology. , 2023, , 245-452.		0
1969	Lymphodepletion and cellular immunotherapy. , 2023, , 181-196.		0
1970	Cellular and Vaccine-Based Immunotherapy for Hematologic Malignancies. , 2023, , .		0
1972	Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659). Oncotarget, 2023, 14, 57-70.	0.8	1
1973	Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol. Systematic Reviews, 2023, 12, .	2.5	0
1974	Novel CD19-specific Î³/Î´ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma. Journal of Hematology and Oncology, 2023, 16, .	6.9	5
1975	Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy. Journal of Cancer Research and Clinical Oncology, 2023, 149, 6131-6138.	1.2	5
1976	High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review. Frontiers in Oncology, 0, 13, .	1.3	1
1977	CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy. International Journal of Molecular Sciences, 2023, 24, 2342.	1.8	3
1978	Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy. HemaSphere, 2023, 7, e817.	1.2	3
1979	Barriers to patient access of CARÂT cell therapies in Austria. Memo - Magazine of European Medical Oncology, 0, , .	0.3	0
1980	Zamtocabtagene Autoleucel (MB-CART2019.1): An Investigational CAR-T Cell Product with Tandem Targeting of CD19 and CD20 as a Potential Treatment Option for Patients with Relapsed/ Refractory B Cell Non-Hodgkin Lymphoma. European Medical Journal Hematology, 0, , 29-31.	0.0	0
1981	Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells. Central-European Journal of Immunology, 0, , .	0.4	0
1982	2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Biology and Medicine, 0, , 129-146.	1.4	0

#	Article	IF	Citations
1983	CAR-T cells for cancer immunotherapy. Chinese Chemical Letters, 2023, 34, 108202.	4.8	3
1984	ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV. Blood Advances, 2023, 7, 2586-2589.	2.5	1
1985	Therapeutic effects of antiâ€GM2 CARâ€T cells expressing ILâ€7 and CCL19 for GM2â€positive solid cancer in xenograft model. Cancer Medicine, 2023, 12, 12569-12580.	1.3	1
1986	Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation. Immunotherapy, 2023, 15, 401-407.	1.0	1
1987	Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Advances, 2023, 7, 4528-4538.	2.5	7
1988	Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naÃ¯ve diffuse large B-cell lymphoma. Experimental Hematology and Oncology, 2023, 12, .	2.0	1
1989	Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data. Pharmacological Research, 2023, 190, 106742.	3.1	4
1990	Highlights into historical and current immune interventions for cancer. International Immunopharmacology, 2023, 117, 109882.	1.7	2
1991	Metabolic challenges and interventions in CAR T cell therapy. Science Immunology, 2023, 8, .	5.6	13
1992	Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study. Cytotherapy, 2023, 25, 521-529.	0.3	1
1993	Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy. Cytotherapy, 2023, 25, 986-992.	0.3	3
1994	Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia. Blood Reviews, 2023, 59, 101042.	2.8	2
1995	Chimeric Antigen Receptor T-cell Therapy in Cancer: A Critical Review. Current Drug Research Reviews, 2023, 15, 241-261.	0.7	2
1996	Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL. HemaSphere, 2023, 7, e858.	1.2	10
1998	Salvage radiotherapy for relapsed/refractory nonâ€Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy. Clinical and Translational Radiation Oncology, 2023, 39, 100587.	0.9	2
1999	Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review. HemaSphere, 2022, 6, e802.	1.2	7
2001	Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. Annals of Allergy, Asthma and Immunology, 2023, 130, 699-712.	0.5	5
2002	SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report. , 2023, 11, e005957.		3

#	Article	IF	Citations
2003	Case report: Cryoablation as a novel bridging strategy prior to CAR-T cell therapy for B cell malignancies with bulky disease. Frontiers in Oncology, 0, 13, .	1.3	3
2004	Monitoring and Modulating Diet and Gut Microbes to Enhance Response and Reduce Toxicity to Cancer Treatment. Cancers, 2023, 15, 777.	1.7	3
2005	Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France. Journal of Medical Economics, 2023, 26, 243-253.	1.0	2
2006	Reprogramming of IL-12 secretion in the PDCD1 locus improves the anti-tumor activity of NY-ESO-1 TCR-T cells. Frontiers in Immunology, 0, 14, .	2.2	3
2007	Management of Marginal Zone Lymphoma: A Canadian Perspective. Current Oncology, 2023, 30, 1745-1759.	0.9	0
2008	Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Advances, 2023, 7, 2872-2883.	2.5	33
2009	Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma. Best Practice and Research in Clinical Haematology, 2023, 36, 101442.	0.7	2
2010	A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. Blood Advances, 2023, 7, 3516-3529.	2.5	14
2011	Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Expert Opinion on Drug Safety, 2023, 22, 5-15.	1.0	1
2012	Immunological Aspects of Richter Syndrome: From Immune Dysfunction to Immunotherapy. Cancers, 2023, 15, 1015.	1.7	2
2013	Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques. Frontiers in Immunology, 0, 14, .	2.2	0
2014	Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor Tâ€cell therapy recipients. Cancer Medicine, 2023, 12, 9228-9235.	1.3	7
2015	FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects. Cancers, 2023, 15, 1063.	1.7	4
2016	CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy. Cancers, 2023, 15, 1052.	1.7	4
2017	Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis. Cells, 2023, 12, 531.	1.8	1
2018	Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma. Leukemia and Lymphoma, 2023, 64, 573-585.	0.6	3
2019	CAR-T Cell Therapy: the Efficacy and Toxicity Balance. Current Hematologic Malignancy Reports, 2023, 18, 9-18.	1.2	15
2020	Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel. Bone Marrow Transplantation, 2023, 58, 590-593.	1.3	1

#	Article	IF	Citations
2021	A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome. Frontiers in Neurology, 0, 14, .	1.1	4
2022	Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development. Clinical and Translational Oncology, 2023, 25, 2204-2223.	1.2	2
2023	Optimizing the manufacturing and antitumour response of CARÂT therapy. , 2023, 1, 271-285.		14
2024	Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkinâ€™s lymphoma patients in England. Leukemia Research, 2023, 127, 107042.	0.4	2
2025	Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy. Haematologica, 0, , .	1.7	1
2026	T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts. Frontiers in Immunology, 0, 14, .	2.2	8
2027	Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome. Biomolecules, 2023, 13, 382.	1.8	8
2028	A Novel Cell-based Luciferase Reporter Platform for the Development and Characterization of T-Cell Redirecting Therapies and Vaccine Development. Journal of Immunotherapy, 2023, 46, 96-106.	1.2	1
2029	Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: A clinical appraisal. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	4
2030	Multidimensional Results and Reflections on CAR-T: The Italian Evidence. International Journal of Environmental Research and Public Health, 2023, 20, 3830.	1.2	2
2031	CAR immune cells: design principles, resistance and the next generation. Nature, 2023, 614, 635-648.	13.7	96
2032	Timing of CAR-T therapy in follicular lymphoma. Expert Review of Anticancer Therapy, 2023, 23, 347-349.	1.1	0
2033	Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL. Cancer Management and Research, 0, Volume 15, 245-255.	0.9	6
2034	Challenges and optimal strategies of CAR T therapy for hematological malignancies. Chinese Medical Journal, 2023, 136, 269-279.	0.9	2
2035	Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy. Trends in Biotechnology, 2023, 41, 907-922.	4.9	11
2036	An Overview of Cytokine Release Syndrome and Other Side Effects of CAR-T Cell Therapy. Praxis, 2023, 112, 189-193.	0.2	2
2037	MIP3Î± as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy. Cancer Immunology, Immunotherapy, 0, , .	2.0	0
2038	Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma. Transplantation and Cellular Therapy, 2023, 29, 349.e1-349.e8.	0.6	4

#	Article	IF	Citations
2039	Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplantation, 2023, 58, 647-658.	1.3	11
2040	Infectious complications of chimeric antigen receptor (CAR) T-cell therapies. Seminars in Hematology, 2023, 60, 52-58.	1.8	2
2041	Novel pathophysiological insights into CAR-T cell associated neurotoxicity. Frontiers in Neurology, 0, 14, .	1.1	4
2042	CAR T-cells and macrophages in large B-cell lymphoma: impact on toxicity and efficacy. Leukemia and Lymphoma, 2023, 64, 808-815.	0.6	3
2043	Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after <scp>CAR</scp> Tâ€cell therapy. British Journal of Haematology, 2023, 202, 294-307.	1.2	7
2044	Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Blood Research, 2023, 58, S20-S28.	0.5	3
2045	A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nature Medicine, 2023, 29, 906-916.	15.2	44
2046	Metabolic reprogramming via an engineered PGC-1Î± improves human chimeric antigen receptor T-cell therapy against solid tumors. , 2023, 11, e006522.		8
2047	LYMPHAPHERESIS FOR CAR-T CELL THERAPY: PREDICTION OF CD3+ CELL COUNTS USING AN AUTOMATED HEMATOLOGY ANALYZER. Japanese Journal of Transfusion and Cell Therapy, 2023, 69, 8-14.	0.1	0
2048	Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis. Cancer Research and Treatment, 2023, 55, 1031-1047.	1.3	1
2049	Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nature Biotechnology, 2023, 41, 1618-1632.	9.4	15
2050	Low-dose administration of prednisone has a good effect on the treatment of prolonged hematologic toxicity post-CD19 CAR-T cell therapy. Frontiers in Immunology, 0, 14, .	2.2	3
2051	How I treat refractory/relapsed diffuse large Bâ€cell lymphomas with <scp>CD19</scp>â€directed <scp>chimeric antigen receptor</scp> T cells. British Journal of Haematology, 2023, 201, 396-410.	1.2	3
2052	Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era. Bone Marrow Transplantation, 2023, 58, 673-679.	1.3	5
2053	Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma. Cancers, 2023, 15, 1747.	1.7	3
2054	Cell-Free DNA Dynamic Concentration and Other Variables Are Predictors of Early Progression after Chimeric Antigen Receptor T Cell Therapy in Patients with Diffuse Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2023, 29, 472.e1-472.e4.	0.6	1
2055	Combining the Target Trial and Estimand Frameworks to Define the Causal Estimand: An Application Using Real-World Data to Contextualize a Single-Arm Trial. Statistics in Biopharmaceutical Research, 2024, 16, 1-10.	0.6	2
2056	Three distinct mechanisms underlying human Î³Î´ T cell-mediated cytotoxicity against malignant pleural mesothelioma. Frontiers in Immunology, 0, 14, .	2.2	1

#	Article	IF	Citations
2057	Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy. JCO Oncology Practice, 0, , .	1.4	0
2058	Role and mechanism of fibroblast-activated protein-Î± expression on the surface of fibroblast-like synoviocytes in rheumatoid arthritis. Frontiers in Immunology, 0, 14, .	2.2	2
2059	Cellular Therapies in Chronic Lymphocytic Leukemia and Richterâ€™s Transformation: Recent Developments in Chimeric Antigen Receptor T-Cells, Natural Killer Cells, and Allogeneic Stem Cell Transplant. Cancers, 2023, 15, 1838.	1.7	3
2060	Case report: CAR-T cell therapy-induced cardiac tamponade. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	1
2061	Treatment of Richter Transformation of Chronic Lymphocytic Leukemia in the Modern Era. Cancers, 2023, 15, 1857.	1.7	3
2062	Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States. Advances in Therapy, 2023, 40, 2355-2374.	1.3	2
2063	Mechanism and Future Application of CAR-T Therapy in DLBCL. , 0, 36, 1505-1510.		0
2064	Remote control of cellular immunotherapy. , 2023, 1, 440-455.		4
2065	Screening and Management of PTLD. Transplantation, 2023, 107, 2316-2328.	0.5	3
2066	Research Progress of Nanomedicine-Based Mild Photothermal Therapy in Tumor. International Journal of Nanomedicine, 0, Volume 18, 1433-1468.	3.3	9
2067	Respiratory Viral Infections in Recipients of Cellular Therapies: A Review of Incidence, Outcomes, Treatment, and Prevention. Open Forum Infectious Diseases, 2023, 10, .	0.4	2
2068	Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma. Transplantation and Cellular Therapy, 2023, 29, 429.e1-429.e6.	0.6	2
2069	Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas. Frontiers in Immunology, 0, 14, .	2.2	1
2070	Fungal Infections Associated with CD19-Targeted Chimeric Antigen Receptor T Cell Therapy. Current Fungal Infection Reports, 0, , .	0.9	0
2071	Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas. Cancers, 2023, 15, 1989.	1.7	2
2072	Bridging the Gap: Early Transition and Hybrid Models of Care to Improve Access to Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2023, 29, 399-402.	0.6	2
2073	Current perspectives on resistance to chimeric antigen receptor Tâ€cell therapy and strategies to improve efficacy in Bâ€cell lymphoma. European Journal of Haematology, 2024, 112, 144-152.	1.1	0
2074	Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after <scp>CD19</scp> â€directed <scp>CAR</scp> Tâ€cell therapy in diffuse large B cell lymphoma. British Journal of Haematology, 0, , .	1.2	2

#	Article	IF	Citations
2075	Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma. Blood Cancer Journal, 2023, 13, .	2.8	6
2076	Positively charged patches: tonic for CAR fitness. Cell Research, 0, , .	5.7	0
2077	CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?. Frontiers in Neurology, 0, 14, .	1.1	6
2078	Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health. Translational Medicine Communications, 2023, 8, .	0.5	3
2079	The Transfer of the Hepatocyte Growth Factor Gene by Macrophages Ameliorates the Progression of Peritoneal Fibrosis in Mice. International Journal of Molecular Sciences, 2023, 24, 6951.	1.8	1
2080	Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy. Cancer Immunology Research, 2023, 11, 707-719.	1.6	7
2081	Long-term outcomes following CAR T cell therapy: what we know so far. Nature Reviews Clinical Oncology, 2023, 20, 359-371.	12.5	119
2082	Novel strategies for cancer immunotherapy: counter-immunoediting therapy. Journal of Hematology and Oncology, 2023, 16, .	6.9	14
2083	BTK Inhibitors and Other Targeted Therapies in WaldenstrÃ¶m Macroglobulinemia. Hemato, 2023, 4, 135-157.	0.2	1
2085	Apoptosis: aJanus bifronsin T-cell immunotherapy. , 2023, 11, e005967.		3
2086	Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome postâ€“CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. Blood Advances, 2023, 7, 2645-2655.	2.5	11
2087	Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies. Frontiers in Immunology, 0, 14, .	2.2	7
2088	Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel)Âfor triple-class exposed relapsed/refractory multiple myeloma patients. BMC Cancer, 2023, 23, .	1.1	13
2089	Hematopoietic stem cell transplantation for malignant lymphoma; shifting positions. Journal of Illusion, 2023, 12, 94-102.	0.0	0
2090	Recent advances in CAR T-cell therapy for lymphoma in China. Clinical and Translational Oncology, 0, , .	1.2	1
2091	Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy. Frontiers of Medicine, 2023, 17, 699-713.	1.5	5
2092	Immunotherapies against human bacterial and fungal infectious diseases: A review. Frontiers in Medicine, 0, 10, .	1.2	6
2093	Cell Therapy, Nursing Implications and Care. , 2023, , 101-122.		0

#	Article	IF	Citations
2094	â€œI just wanted to speak to someone- and there was no oneâ€¦â€• using Burden of Treatment Theory to understand the impact of a novel ATMP on early recipients. Orphanet Journal of Rare Diseases, 2023, 18, .	1.2	1
2095	Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Advances, 2023, 7, 4926-4935.	2.5	12
2096	Early lymphocyte collection for <scp>antiâ€CD19 CART</scp> production improves Tâ€cell fitness in patients with relapsed/refractory diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2023, 202, 74-85.	1.2	4
2097	Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan. International Journal of Clinical Oncology, 2023, 28, 816-826.	1.0	5
2098	Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes. Cancer Management and Research, 0, Volume 15, 367-375.	0.9	1
2099	CAR-T-sejtes kezelÃ©sek a hematolÃ³giai betegsÃ©gekben. Transfusio, 2023, 55, 164-170.	0.0	0
2100	Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome. Pathology and Oncology Research, 0, 29, .	0.9	1
2101	The magic of small-molecule drugs during ex vivo expansion in adoptive cell therapy. Frontiers in Immunology, 0, 14, .	2.2	3
2103	CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement. JACC: Case Reports, 2023, 15, 101840.	0.3	0
2104	<scp>CAR</scp> T in patients with large Bâ€cell lymphoma not fit for autologous transplant. British Journal of Haematology, 2023, 202, 65-73.	1.2	6
2105	Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness. Cytotherapy, 2023, 25, 750-762.	0.3	4
2106	Frontal Intermittent Rhythmic Delta Activity Is a Useful Diagnostic Tool of Neurotoxicity After CAR T-Cell Infusion. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	2
2107	The â€œGreat Debateâ€•at Immunotherapy Bridge 2022, Naples, November 30thâ€“December 1st, 2022. Journal of Translational Medicine, 2023, 21, .	1.8	0
2126	Chimeric Antigen Receptor Therapy in Multiple Myeloma. , 2024, , 309-329.		0
2133	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
2145	CAR T-Cell Therapy and Critical Care Considerations. , 2023, , 427-435.		0
2173	Preparative Regimens Used in Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapies. , 2024, , 125-143.		0
2174	Miscellaneous Complications of Chimeric Antigen Receptor T-Cell Therapy. , 2024, , 537-547.		0

#	Article	IF	Citations
2175	Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy. , 2024, , 509-524.		0
2177	Process and General Management of Patients Undergoing Chimeric Antigen Receptor Therapies. , 2024, , 115-122.		0
2178	Chimeric Antigen Receptor Therapy in Lymphoma. , 2024, , 371-381.		0
2187	Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma. Frontiers in Oncology, 0, 13, .	1.3	2
2228	Myelodysplastic clones arising post chimeric antigen receptor t cell therapy (car-t) procedure: a casuality or a new entity?. Annals of Hematology, 0, , .	0.8	0
2234	Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies. Advances in Experimental Medicine and Biology, 2023, , 85-110.	0.8	0
2241	A Modern-Day Chimera. , 2023, , 139-145.		0
2266	Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	5
2267	Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study. Blood Cancer Journal, 2023, 13, .	2.8	0
2268	Two for one? CAR-T therapy for lymphoma benefits concurrent autoimmune disorders. Bone Marrow Transplantation, 2023, 58, 1175-1176.	1.3	2
2316	Second Chances. , 2023, , 129-144.		0
2322	Therapeutic options for rituximab-resistant patients. , 2024, , 211-230.		0
2344	Case Report: Invasive fungal infection after anti-CD19 CAR-T cell therapy. Implication for antifungal prophylaxis. Frontiers in Immunology, 0, 14, .	2.2	1
2369	Expanding access to CAR T cell therapies through local manufacturing. Nature Biotechnology, 2023, 41, 1698-1708.	9.4	3
2371	T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Nature Reviews Drug Discovery, 2023, 22, 996-1017.	21.5	7
2377	Neurotoxicity of Cancer Immunotherapies Including CAR T Cell Therapy. Current Neurology and Neuroscience Reports, 0, , .	2.0	0
2432	Case Report: CD19 CAR T-cell therapy following autologous stem cell transplantation: a successful treatment for R/R CD20-negative transformed follicular lymphoma with TP53 mutation. Frontiers in Immunology, 0, 14, .	2.2	0
2449	Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy. Bone Marrow Transplantation, 2024, 59, 162-170.	1.3	0

#	Article	IF	Citations
2452	KyoTox-e score; prediction of post-CAR-T prolonged thrombocytopenia using peripheral blood data before apheresis. Bone Marrow Transplantation, 2024, 59, 419-421.	1.3	1
2464	Technologien und LÃ¶sungsansÃtze fÃ¼r die effiziente Herstellung von Zelltherapeutika fÃ¼r die CAR-Immuntherapie. , 2023, , 123-137.		0
2472	Mantle Cell Lymphoma. , 2023, , .		0
2482	A Systematic Literature Review of Health-Related Quality of Life Outcomes and Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma. PharmacoEconomics - Open, 2024, 8, 171-190.	0.9	0
2508	Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives. Blood Cancer Journal, 2024, 14, .	2.8	0
2510	Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplantation, 2024, 59, 569-571.	1.3	0
2530	Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer Journal, 2024, 14, .	2.8	1
2532	The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies. Annals of Hematology, 0, , .	0.8	0
2553	Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Therapy and Coagulopathies. , 2024, , .		0
2559	Case report: Acute HHV6B encephalitis/myelitis post CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma. Frontiers in Neurology, 0, 15, .	1.1	0